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Despite ever-evolving treatment and screening procedures, Colorectal cancer (CRC) remains 
a major cause of cancer-related deaths worldwide. Preoperative chemoradiotherapy (CRT), 
followed by standardized surgical resection of the tumor, represents the standard treatment for 
locally advanced rectal cancers. However, tumor cells can possess or acquire resistance to 
CRT, so that affected patients do not benefit from treatment but are afflicted with potential 
negative side-effects of anti-cancer treatment without any clinical benefit. Therefore, the 
resistance of tumor cells to CRT represents a fundamental problem in oncology and requires 
the elucidation of the molecular mechanisms underlying this issue. It is already known that the 
dysregulation of signalling pathways can cause serious diseases such as cancer and this 
dysregulation is significantly involved in the development of therapy resistance. Inflammatory 
cytokines have a key role in cancer progression by regulating many pathways in both, tumor 
cells and tumor microenvironment. Hence, it is important to understand the tumor intrinsic 
mechanisms by which CRT resistance is controlled. In this thesis the importance of active 
STAT3 signalling in mediating CRT resistance in CRC cell lines was evaluated. The 
requirement of active STAT3 signalling was demonstrated by mutational analysis of STAT3 
and subsequent reconstitution studies in the presence and in the absence of cytokine receptor 
activation. Nevertheless, when combined with chemoradiotherapy, inhibition of STAT3 
signalling using Napabucasin completely abolished tumor growth in a xenograft mouse model. 
Using a RNA-Seq-based screening approach, several STAT3 target genes were identified, 
such as the RBPJ, that are dually influenced by inflammation induced STAT3 activation and 
STAT3 knockdown. Strikingly, genetic inhibition of RBPJ, a key transcriptional regulator of the 
NOTCH cascade, re-sensitized colorectal cancer cells to chemoradiotherapy. Additionally, 
genetic and pharmaceutical inhibition of the entire NOTCH signalling also re-sensitized 
chemoradiotherapy resistant cells. Interestingly, inhibition of NOTCH signalling phenocopied 
the effect of blocking STAT3 signalling. Genetic profiling of rectal cancer patients revealed the 
importance of the NOTCH signalling axis by correlating NOTCH expression with clinical 
outcome. 
This thesis uncovered, that treatment resistance is orchestrated by a poorly understood signal 
axis that combines two classical intracellular pathways, inflammatory cell signalling mediated 
by STAT3, and cell fate decision NOTCH axis controlled by RBPJ. The identification of this 
crosstalk serves the molecular basis for chemoradiotherapy resistance and paves the way for 
a personalized, multimodal treatment of patients with rectal cancers that are positive for 
STAT3/NOTCH-related markers. 
 





Cancer is one of the major public health problems worldwide and an important barrier to 
increasing life expectancy in every country 1-3. In 2020, 19.3 million new cases of cancer raised 
with 9.9 million deaths 1 and cancer burden is expected to increase about 60% from 2018 to 
2040 3. Unfortunately, cancer is a diverse disease, and tumor heterogeneity is a major 
challenge for its diagnosis and the efficacy of treatment 4-6. The Heterogeneity refers to the 
existence of cancer cell subpopulations, with distinct genotypes and phenotypes that harbor 
divergent biological activities, within the tumor and its metastasis 6. Over the past decades, 
significant progress has been achieved in understanding the molecular basis of cancer. 
However, we are far from reaching the point of a cure for all types of cancer. 
2.1.1 Colorectal Cancer 
2.1.1.1 Epidemiology  
Colorectal cancer (CRC) represents a major cause of cancer-related deaths in Europe and 
the United States 2. There has been a dramatic increase in our understanding of the 
epidemiology, molecular mechanisms, and clinical aspects of CRC over the past decades 7 . 
Nevertheless, CRC continues to account for approximately 10% of all annual diagnosed 
cancers worldwide and thus ranks among the third most common malignant tumor entity in the 
Western society, with about 1.88 million cases (1.148,515 cases of colon and 732,210 cases 
of rectal cancer) and 918,880 deaths (576,858 colon cancer and 339,022 rectal cancer) in 
2020 1,3,8-10 (Fig 2.1 A). Importantly, the incidence and mortality rate of CRC are steadily rising 
in developed nations 10,11. It is hypothesized, that the global CRC burden is projected to 
increase by 60% until 2030, reaching more than 2.2 million new CRC cases and 1.1 million 
more deaths 12,13. The distribution of CRC burden varies widely, for colon cancer Southern 
Europe, Australia, New Zealand, and Northern Europe are the regions with the highest 
incidence, while for rectal cancer, these regions are Eastern Europe, Australia, New Zealand 
and Eastern Asian 10.  
Generally, several risk factors are associated with an increased risk of developing CRC 14. 
It is possible to distinguish between (i) modifiable and (ii) non-modifiable risk factors. Modifiable 
factors are dietary factors like low intake of vegetables and fruits but high intake of red and 
processed meat, obesity, smoking, alcohol intake, and lack of physical activity (Fig 2.1 B, left 
panel). Obesity is a worldwide issue and a well-known modifiable cancer risk factor 15. Indexes 
related to obesity like BMI were in a strong correlation with raised CRC risk in males and was 
reported to increase it even by 30-70%. Furthermore, around 11% of CRC cases have been 
related to obesity in Europe 16. Conversely, higher intake of vegetables, fruits, dietary fibre, 
folate, and calcium have been reported to be protective against CRC 14. The probability of 
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being diagnosed with CRC is also related to personal non-modifiable characteristics and habits 
that cannot be changed, such as age, gender, race/ethnicity, chronic disease history and 
familial history (Fig 2.1 B, right panel) 11,17-19. Since cancer is a disease of ageing, the rate of 
CRC development and mortality increase rapidly after the age of 50 7. This corresponds to a 
comparatively high median age of 76 (women) and 72 (men). Relative 5-year survival rates 
with CRC are around 63 % and 62 % for women and men, respectively 20.  
2.1.1.2 CRC development, early detection, and staging 
In simplistic terms, carcinogenesis describes a multistep process caused by a sequence of 
mutations in oncogenes, tumor suppressor genes or by epigenetic changes in DNA for 
instance methylation 21. About 90% of CRC cases are described as adenocarcinomas, that 
develops from epithelia cells of the colon and rectum 22. The distinction between colon and 
rectum is largely anatomical but impacts further treatment and prognosis 3,23. CRCs represents 
a very heterogeneous disease driven by a variety of mutations and mutagens 10  
A| In 2020 19.3 million new cases of cancer raised of which 10% are colorectal cancer (CRC) (left 
panel). This 10% percent corresponds to 1.88 million new cases (38.9% are localized in the rectum and 
61.1% in the colon) and 918,880 deaths in 2020 of which 1 (right panel). B| Several risk factors are 
associated with an increased risk for the development of CRC. In general, a distinction is made between 
modifiable risk factors (left) and non-modifiable risk factors(right). 
Unfortunately, not all CRCs share the same driving mutations, which makes consistent 
treatment almost impossible 10,24. In the majority of cases, CRC occur sporadically (approx. 
95%) and only 2% to 5% of CRC cases are due to hereditary cancer syndromes 25-27. In 
Figure 2.1 Overview of colorectal cancer statistics and risk factors.  
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hereditary cancer, important tumor suppressors or DNA repair genes are inactivated by 
monoallelic gene expression in the germ line. Subsequently, a somatic event “second hit” 
abrogate the functionality of the remaining wild-type allele and lead to tumor formation 26. The 
two most common forms are hereditary nonpolyposis CRC (Lynch syndrome) or familial 
adenomatous polyposis (FAP) 25,26. Lynch syndrome is a consequence of various germline 
mutations in DNA mismatch repair genes 25,28, whereas FAP is characterized by a germline 
mutation in the adenomatous polyposis coli (APC) 25.  
Conventionally, CRC arises as a consequence of changes in the cell morphology of normal 
mucosal epithelium in the colon or rectum, which proliferates uncontrollably to form benign 
polyps. The multistage progression of the most sporadic colorectal adenocarcinomas is 
explained in the adenoma-carcinoma sequence model proposed by Vogelstein et al. 29,30 (Fig 
2.2 A). This model has been used a long time as an example for the development of an 
invasive tumor by multiple genetic alterations. One of the early events in the adenoma-
carcinoma sequence is associated with inactivation of the APC tumor suppressor gene. APC 
acts as a negative regulator of the β‑catenin mediated Wnt signalling, through degradation of 
β‑catenin which thereby limit the transcription of Wnt target genes that are involved in cell cycle 
regulation 31-33. The Wnt pathway is critical to CRC tumorigenesis, and more than 90% of 
patients have alterations, within this pathway 34. Not surprisingly, given the frequency of 
changes, neither APC nor β-catenin is a useful prognostic marker capable of differentiating 
between patients 32. Subsequent malignant transformation is driven by additional mutations 
occurring in later stages, include activation of the oncogene small GTPase Kirsten Rat 
Sarcoma Viral Oncogene Homolog (KRAS) followed by loss of chromosome 18q with SMAD 
Family Member 4 (SMAD4), which is downstream of transforming growth factor-beta (TGFβ), 
and inactivation of the tumor suppressor Tumor Protein p53 (p53) lead to adenocarcinoma 
formation 35. This model predicts that at least 7 distinct mutations are required for CRC 
development 35. Recently, Wood et al. had demonstrated that CRC contains ≤ 80 mutations, 
of which < 15 mutations are the driving force of tumorigenesis 11,36,37. However, Smith et al., 
reported that only 7% of CRCs showed mutations in all three oncogenes (APC, KRAS and 
p53). The most common mutation combination was p53 and APC in 27% of CRC patients 
studied, whereas mutations in p53 and KRAS were exceedingly rare 21. These results 
suggested that tumor mutations arise as heterogeneous pattern and that multiple genetic 
pathways exist, which contribute to CRC development 21. In accordance with that, it has been 
suggested that least three distinct evolutional routes lead to sporadic CRCs 27. The first 
traditional pathway is described above, starting from normal mucosa via tubular adenomas to 
carcinomas (Fig 2.2 A). Another well-described but less frequent (10%-20%) developmental 
pathway of sporadic CRC describes the rise of adenocarcinomas from serrated lesions 27. The 
so-called serrated neoplasia pathway is not characterized by a key mutation, but in early 
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stages by inactivation of various genes via hypermethylation of genomic regions with increase 
CpG islands density and often by activating BRAF mutations 28,38. The third alternative pathway 
led to sporadic CRC with poor prognosis, originates from the normal mucosa via villous, partly 
serrated adenomas (mutations in KRAS, BRAF, and APC) 27.  
Furthermore, the acquisition of genomic instability is a fundamental process in cancer 
development. The most common type of genomic instability occurs in around 85% of sporadic 
CRC which is called chromosomal instability (CIN) 35,39. CIN is a process that generates 
changes in chromosome number and structure, such as somatic copy number alterations 
(SCNA), or loss of chromosome 17p and 18q, leading to aneuploidy 35,39,40. These changes are 
often detectable as a high frequency of SCNA, which are found in 90% of solid tumors and 
which is associated with most of tumors that arise by the adenoma-carcinoma sequence 41,42. 
The second group, occurring in around 13-16% of sporadic CRC are hypermutated and feature 
microsatellite instability (MSI) due to DNA mismatch repair (MMR)defects 40. MSI is observed 
in nearly all CRC tumors that develop in patients with Lynch syndrome by inactivation of 
various DNA mismatch repair genes (hMLH1, hMSH2, hMSH6, and hPMS2) 43,44. Sporadic 
tumors with the MSI phenotype usually show high levels of methylation at regulatory regions 
throughout the genome, including the methylation of CpG-rich promotor sequence of the 
hMLH1 gene 39,44. However, microsatellite-stable (MSS) tumors represent the majority of 
sporadic tumors 23. The CpG island methylator phenotype (CIMP) has also been characterized 
as an epigenetic instability that impacts CRC pathogenesis 45. CIMP influences CRC 
development via promotor hypermethylation and silencing of a range of tumor suppressor 
genes as well as DNA MMR genes, including hMLH1 40,46. Typically, one type of molecular 
signature dominates, suggesting that the three pathways are rarely overlapping 43. In some 
tumors, a complex interplay occurs whereby one signalling pathway is a consequence of 
another 43. However, not all adenomas advance to cancer, the accumulation of specific 
mutations in a particular order is essential for progression towards malignancy. The timeline 
depends upon the specific pathway of tumorigenesis. Tumorigenesis via the CIN pathway can 
take a minimum of 10 years, whereas tumor development via the MSI pathway can occur in a 
few years 44.  
One of the key strategies for reducing the global CRC burden focus on prevention and early 
detection. CRC grows slowly and exposure its symptoms at a late stage 26. The 5-year survival 
for patients, diagnosed with early-stage, localized CRC approach 90%, whereas the survival 
rate of patients diagnosed with late-stage, metastatic CRC, is only 13,1% 14. Therefore, the 
regular screening for CRC allows detection of this disease at an early stage when treatments 
are more successful and the chance for survival is high 3,26. In addition, screening can 
significantly reduce treatment costs, as most screening strategies are less expensive and more 
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important less harmful than chemotherapy for advanced CRC 47. At a size of several 
centimeters, the tumor may block the passage of feces and can lead to cramping, pain, 
bleeding from the rectum 14. Therefore, for the early detection of CRC, a faecal occult blood 
test can be performed, in case of a conspicuous finding, colonoscopy is usually recommended. 
Coloscopy is the preferred screening tool because it allows direct examination of the colorectal 
mucosa and removal of polyps with malignant potential 48-50. From the age of 50 (men) and 55 
(women), the statutory screening program provides for a routinely colonoscopy 20. 
In order to develop the best possible therapy strategy, tumor staging is commonly used to 
classify the extend of cancer spread, the degree of tumor progression and invasion. The 
American Joint Committee on Cancer (AJCC) provides the tumor-node-metastatic (TNM) 
system, which is the current and most used staging system that classify cancer according to 
three characteristics: 1. The local deep infiltration of the primary tumor (T), 2. The extent of 
lymph node metastasis (N), and 3. The presence and number of distant metastasis (M) (Fig 
2.2 B, left panel). Based on these criteria the overall stage of the tumor is assigned ranging 
from 0 to IV according to the Union Internationale Contre le Cancer (UICC) classification 51,52 
(Fig 2.2 B, right panel). However, the TME system also has some limitations. Significantly 
different clinical outcomes were observed in patients with the same histological TME stage. 
Therefore, some attempts have been made to integrate additional parameters to the staging 
of tumors, including immunohistochemistry for tumor biomarkers, molecular signatures, and 
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A| The adenoma-carcinoma sequence in colorectal carcinoma shows typical genetic and morphologic 
alterations (blue) and their effects on the corresponding signalling pathways (black). Modified according 
to 29,32,53. B| Cancer staging according to the American Joint Committee on cancer (AJCC) TNM system 
54 (left) and the Union Internationale Contre le Cancer (UICC) classification (right) . 
 
2.1.1.3 Treatment 
Over the past decades, a growing number of treatment options for CRC raised, which 
strongly depend on the stage of the tumor, its location, the patient’s overall health and various 
other patient characteristics 55. At present, surgery, chemotherapy, radiotherapy, 
antiangiogenic therapy, and novel immunotherapies have been evaluated in clinical trials for 
the treatment of cancers 56. The ideal cancer treatment should achieve complete removal of 
Figure 2.2 Simplified representation of the adenoma-carcinoma sequence in colorectal 
carcinoma and cancer staging according to the AJCC. 
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the tumor and the associated metastasis 57. Therefore, for early-stage and localized CRC 
lesions, surgical approaches that range from locally treatment to more invasive methods are 
used, depending on tumor location and disease invasion 55. The surgical management of rectal 
cancer has evolved over the past 100 years and continues to progress to optimize the 
treatment. Historically, rectal cancer was a not survivable disease, with a lack of standardizes 
surgical techniques 58. The most significant contribution in advancing surgical rectal cancer 
treatment may be the standardization and implementation of a total mesorectal excision (TME) 
58. Nowadays, for early-stage rectal cancers surgical treatment usually involves TME, which is 
the removal of the entire rectum and mesorectum, including mesorectal fascia 59. Adjuvant 
therapy is not indicated for patients with resected (R0 resection) stage I colon cancers 59. 
However, nearly a quarter of CRCs are diagnosed at an advanced stage together with 
metastasis 55,57. Unfortunately, for these patients, surgical resection alone does not provide 
effective treatment 55,57.  
Consequently, chemotherapy was therefore implemented as a neoadjuvant or adjuvant 
treatment approach, to minimize the tumor before surgery and to hamper tumor recurrence 
after surgery, respectively 55. 5-fluorouracil (5-FU) is one of the first chemotherapeutic drugs 
with proven anticancer activity, which was first synthesized by Heidelberger et al. 60. 5-FU is a 
synthetic fluorinated pyrimidine analogue that requires intracellular conversion into active 
metabolites 61. In the early 1990s, neoadjuvant treatment with 5-FU, combined with leucovorin 
became standard of care for patients with stage III and selected stage II colon cancer 62,63. 5-
FU is an essential backbone of chemotherapy treatments for patients with CRC and other 
gastrointestinal cancers, both in neoadjuvant and adjuvant settings 64. 5-FU formed the basis 
for the additional use of oxaliplatin, which has been shown to further improve disease-free 
survival (DFS) and overall survival (OS) in stage III CRC patients 63,65,66. Despite progress in 
novel cancer therapies, 5-FU has been widely used for almost 50 years in treatment of solid 
malignancies and still represents the most effective and most used agent 64. Common 
chemotherapy regimens used in clinics include, FOLFOX (5-FU/leucovorin/oxaliplatin) and 
FOLFIRI (5-FU/leucovorin/irinotecan) 55,67. Regarding cancers of the rectum, locally advanced 
stages of this disease are treated with neoadjuvant chemoradiotherapy (CRT) followed by 
radical surgical resection 68-71. Adjuvant chemotherapy is recommended after curative tumor 
resection for all patients with stage III colon cancer, as well as for patients having stage II colon 
cancer with high-risk features 72. For patients with stage I or low-risk stage II CRC after radical 
surgical resection, adjuvant therapy is not recommended, as it is theoretically possible that 
surgery alone could achieve a complete cure and ensure long-term survival for the patients 73. 
Over the past decades, several strategies including the implementation of 5-FU based 
combination therapies (combination with radiation) and 5-FU pro-drugs have been developed 
to enhance tumor sensitivity 56,74. 
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2.2 Cancer treatment resistance 
A tumor is a heterogenous population of cells, harboring cells with different molecular 
features, that can develop resistance to various therapies including anti-cancer drugs and 
radiation 75. Despite the various treatment options available, the resistance of cancer cells is a 
major clinical challenge and one of the main limiting factors to achieve cure in patients 76.  
The appearance of treatment resistance has been observed since the first treatment of 
patients with chemotherapy 77,78. A large number of patients either did not respond to a 
treatment strategy or initially responded but after a period of time suffered a relapse and 
progression of the disease 55. One essential reason explaining treatment failures is the 
presence of innate or acquired resistance. In the simplest case, treatment can lead to the death 
of a large portion of drug-sensitive cells resulting in a good prognosis for the patient 75,79 (Fig 
2.3 A). Nevertheless, tumor cells may have molecular features that make them resistant to a 
treatment, resulting in a partial response and rapid progression 79. This intrinsic resistance is 
defined as pre-existing resistance without prior exposure to anti-cancer drugs (Fig 2.3 A). 
However, upon exposure to chemotherapy/radiotherapy, the therapeutic pressure combined 
with a range of extracellular signals, can trigger cells to acquired resistance 75,76. This type of 
resistance can emerge after contact with anti-cancer drugs, which changes cancer cells’ 
properties (Fig 2.3 B). Therefore, tumors that initially showed to be sensitive to therapy, later 
become unresponsive due to the development of resistance 80-82. Importantly, many 
descriptions of treatment resistance, especially drug resistance have focused on the 
differences between intrinsic and acquired resistance, however, in practice many tumors are 
becoming resistant owing both intrinsic and acquired resistance 76. 
The initial idea to fight the resistance of cancer cells against single-agent chemotherapies 
was the combined administration of chemotherapeutic agents targeting well-defined cancer-
driving pathways that had no overlapping mechanisms of action 76. This approach showed 
remarkably well results in different types of cancers, including advanced Hodgkin’s lymphoma 
83 and breast cancer 84. These successful results made combined chemotherapy a new 
standard in oncology. Unfortunately, after around 50 years of treating patients with combined 
chemotherapy, its success had also reached a plateau. Conventional methods such as 
surgery, radiotherapy and combined chemotherapy are no longer sufficient to successfully 
treat all tumors 76. Fortunately, the gain of understanding about the molecular mechanisms that 
drive cancer progression has also increased and resulted in more effective therapies against 
tyrosine kinases, nuclear receptors, and other specific molecular targets. More recently, 
oncological therapy has advanced again by using immunological approaches, including 
immune checkpoint inhibitors, to attack cancer 85. In CRC patients with MSI/MMR tumors 
immune checkpoint inhibitors has shown promising efficacy 85. Another strategy to circumvent 
Introduction | Kristin Kördel 
10 
 
therapy resistance is to combine drugs that target different signalling pathways 55. The aim 
here is to inhibit signalling pathways that run in parallel to each other. There are already pre-
clinical studies and clinical trials investigating the safety of such combination approaches. For 
example, EGFR inhibitors are used together with VEGF/MEK/BRAF inhibitors to treat patients 
with RAS wild type metastatic CRC 55,86.Currently, the invention of targeted therapy led to 
significant advances in cancer treatment, because the more specific a drug is, the lower the 
probability to elicit drug resistance 82,87. Nevertheless, acquired resistance to several target 
therapies has already been reported 82.  
A| The tumor is heterogenous, harboring cells with different molecular features, which make them 
sensitive (blue cells) or resistant to different types of treatments 75. After treatment, a complete sensitive 
response to anti-cancer treatment is ideal but rare 79. Pre-existing subpopulations within a tumor can 
mediate intrinsic resistance (orange cells). These subpopulations often harbor resistance mediating 
mutations, which become the predominant populations, resulting in a partial response and rapid 
progression. B| Upon exposure to chemotherapy / radiotherapy, therapeutic pressure combined with 
extracellular signals, malignant cells develop acquired chemoresistance (red cells) leading to a resistant 
response 75,76 (upper panel). Selected molecular mechanisms that directly or indirectly contribute to a 
resistant phenotype in human cancer cells 56,87. 
There are already countless publications dealing with the causes of therapy resistance. 
While some mechanisms of drug resistance are disease-specific, others, such as drug efflux, 
are evolutionarily conserved, as it has already been demonstrated in microbes and human 
resistant cancer 87. In addition, many types of cancer may be initially sensitive to a particular 
chemotherapy and only develop resistance over time due to DNA mutations and metabolic 
changes that promote drug inhibition and degradation 87. Note, that these resistance 
Figure 2.3 Acquired and intrinsic treatment resistance. 
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mechanisms can occur independently or in combination 87. A selection of mechanisms that 
have already been associated with treatment resistance in human cancer cell lines are 
provided in Figure 2.3 B. 
2.2.1 Treatment resistance in CRC 
To date, approximately 50% of all patients with cancer will receive multimodal treatment 
containing radiotherapy of some form, either alone or along with other treatment modalities 
such as surgery or chemotherapy 88,89. About one-third of CRC patients will have no or little 
response to preoperative CRT 68,70,71,90. Furthermore, patients with stage 4 CRC have less than 
a 10% 5-year survival rate owing the ineffectiveness of the current treatment regime 45. Thus, 
patients with resistant tumors fail to show benefit from treatment but face potential acute and 
long-term side effects of chemotherapy and radiation, which include hematologic, 
gastrointestinal, genitourinary, and dermatological toxicity 68,70,71,90-92. In rectal 
adenocarcinoma, approx. 70% of patients do not achieve a pathological complete response 
(pCR) to neoadjuvant therapy 56,93,94. In metastatic diseases a treatment failure was observed 
in approx. 90% of patients. It is hypothesized that in this case the tumor become cross-resistant 
to a range of chemotherapy 95. Since 5-FU is one of the most widely used chemotherapeutic 
agents, it is not surprising that resistance mechanisms have also developed against it. In 5-FU 
resistant SNU-C1 colon cancer cells, mRNA levels of one of the fundamental 5-FU metabolism 
enzymes, thymidylate synthase (TS) were found to be increased, leading to enhanced TS 
catalytic activity 96. Furthermore, high intrinsic levels of TS were related to 5-FU resistance in 
in vitro, in vivo models and in patients 61,97. Therefore, re-sensitization of tumor cells partially 
or even fully refractory to treatment represents an attractive solution to this clinical and 
socioeconomic problem 70,88,98. Despite the many new discoveries, the molecular basis of ever-
evolving treatment resistance remains complex and multifaceted. Consequently, there is an 
emerging need for therapeutic strategies to defeat treatment resistance. 
2.3 Inflammatory gp130 signalling in promoting treatment resistance 
As a hallmark of cancer, inflammation is associated with development and progression of 
tumors 99-101. Inflammation was originally described according to the four cardinal signs: calor 
(heat), pallor/dolor (pain), rubor (redness), and tumor (swelling), as the body’s response to 
tissue damage, caused by multiple different injury’s 101,102. The cardinal signs thereby reflect 
the pro-tumorigenic activity of cytokines and immune cells in the tumor microenvironment 
(TME) 102,103. The inflammatory response causes cellular changes that result in repair of the 
damaged tissue and cellular proliferation at the site of the tumor, which is self-limited in healthy 
individuals 102. Cancer is considered as a “wound that does not heal” and therefore attracts 
similar cell types and mechanisms like wound healing or tissue regeneration 104. Unfortunately, 
the dysregulation of inflammatory processes can lead to chronic inflammation, which in turn 
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leads to the disruption of tissue homeostasis, cell mutations and uncontrolled proliferation 
providing a pro-tumorigenic environment 101,105.  
Already in the 19th century Rudolf Virchow described the role of inflammation in the 
development of cancer 106. During his studies, he observed the presence of leukocytes within 
neoplastic tissue leading to his suggestion that “lymphoreticular inflammation” reflect the origin 
of cancer at sites of chronic inflammation 106-108. In accordance with Virchow’s findings, Jass 
first proposed that infiltration of immune cells represents a novel independent prognostic factor 
in rectal cancer 109. Virchow's hypothesis has been supported in recent decades by a wealth 
of evidence demonstrating that various cancers are triggered by infections and chronic 
inflammatory disease 108. An example for this is the link between inflammatory bowel disease 
(IBD) and development of CRC. Many studies have reported high frequencies of CRC among 
patients with IBD 110. IBD patients with family history of CRC have >2-fold higher risk for colon 
cancer development 111. Furthermore, chronic intestinal inflammation has become a known 
risk factor for developing of CRC 112. Through a multitude of studies, CRC has long been seen 
as one of the best examples of a tumor that is tightly associated with chronic inflammation, 
which is present even in the earliest stages of tumor appearance 113.  
During the past decades, it has become increasingly clear that within the TME, a complex, 
coordinated network of cells communicate to form the local immune response 73. Cytokines, 
chemokines, and other small inflammatory proteins derived from either malignant or host cells 
including stroma, endothelia, and immune cells coordinate the intracellular communication in 
the TME 114 (Fig 2.4 A). According to this, there is recently growing evidence that especially 
inflammatory mediators, including cytokines and their specific receptors are major components 
in regulating CRC growth, angiogenesis, metastasis, and treatment resistance 56,115 (Fig 2.4 
A). Inflammatory cytokines have a key role in cancer progression via many pathways, including 
a direct effect on tumor cells, interaction with the chemokine system, stimulation of epithelial-
to-mesenchymal transition (EMT), and augmentation of metastasis 114,116. Cytokines and 
immune mediators secreted in the TME affect both myeloid progenitors and mature myeloid 
cells by stimulating different signalling pathway, which regulate the activity of several 
transcription factors 117. These transcription factors, in turn, regulate the synthesis of their 
target proteins and thus influence the function of myeloid cells 117. Pro-inflammatory tumor and 
TME-derived soluble factors, including interleukin 1β (IL-1β), interleukin 6 (IL-6), S100A9 and 
transforming growth factor β (TGFβ) and cytokines released by activated T cells, including 
interferon γ (IFNγ), interleukin-4 (IL-4), interleukin 10 (IL-10) and interleukin 13 (IL-13) initiate 
immunosuppressive pathways and further promote myeloid derived suppressor cells (MDSC) 
differentiation into immunosuppressive macrophages and dendritic cells 114. Therefore, the 
TME and its pro-tumoral features emerge increasingly as an attractive therapeutic target 
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because it provides the pro-tumorigenic, chronic inflammatory environment that triggered 
thereby tumor growth, development and may mediate the resistance of cancer cells to 
treatment. Many of the limitations of current treatments, including chemotherapy, radiotherapy, 
and emerging targeted therapies, are that the interaction between the anti-cancer drug and the 
TME is complex and not fully understood. 
2.3.1 Interleukin-6 
A clear pro-tumoral role of IL-6 has already been shown in 1989 by Klein et al. They reported 
about both an autocrine loop of IL-6 production as well as a paracrine loop induced by bone 
marrow stroma cells in multiple melanoma (MM) 118. Accordingly, substantial research has 
focused on IL-6 as a multifunctional pro-inflammatory cytokine which is produced by several 
cells within the TME, including tumor infiltrating immune cells, fibroblasts, endothelial cells, 
keratinocytes and tumor cells themselves 115,119-121 (Fig 2.4 A). The IL‑6 protein is 21-28 kDa 
in size, depending on the extent of glycosylation 119. IL-6 is a major mediator of inflammation 
and is highly expressed in various cancers. In CRC, high IL-6 expression has been suggested 
to be associated with cancer progression and metastasis by inducing signalling cascades and 
thereby triggering proliferation and pro-angiogenetic mechanisms 122-124. Moreover, elevated 
levels of serum IL-6 and sIL-6R were detected in patients with i.e., CRC 125,126 and were 
associated with surgery, chemo- and radiotherapy 127. The IL-6 family consists of various 
cytokines, including, IL-6, interleukin-11 (IL-11), Ciliary neurotrophic factor (CNTF), 
cardiotrophin-1 (CT-1), cardiotrophinlike cytokine (CLC), leukaemia inhibitory factor (LIF), 
onostatin M(OSM), and IL-27 that share the common glycoprotein 130 (gp13) receptor unit 
128,129.  
The IL-6 induced signalling is mediated by two different pathways, the classic signalling and 
the trans-signalling pathway 130. On target cells, IL-6 induces the classic signalling by binding 
to membrane-bound IL-6 receptors (IL-6R), whereas during trans-signalling IL-6 binds to a 
soluble IL-6R (sIL-6R) 130 (Fig 2.4 B). Subsequently, the non-signalling IL-6/IL-6R or IL6/sIL-
6R complexes bind to the signal-transducing membrane protein gp130, thereby promoting its 
homodimerization and subsequent initiation of intracellular signalling 129,131,132. Gp130 is 
ubiquitously expressed, whereas the expression of IL-6R is restricted to hepatocytes, 
neutrophils, monocytes, macrophages, and some lymphocytes 129,133. However, the membrane 
bound IL-6R can be cleaved by the metalloprotease a disintegrin and metalloprotease 17 
(ADAM17) to generate sIL-6R, that in turn promote IL-6 trans-signalling even in cells that are 
not capable of IL-6R 128,134. A major difference regarding the receptor formation of the IL-6 
family members is that the signalling complex of IL-6 and IL-11 contains a gp130 homodimer, 
while other family members need a heterodimeric receptor complex containing gp130 and an 
alternative signalling subunit to activate their signalling cascade 135. IL-6 classic and trans-
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signalling regulate distinct biological effects. The classic signalling is especially important for 
acute-phase immunological response and central homeostatic processes 136,137. In contrast, 
trans-signalling plays a role mainly in the pathophysiology of chronic inflammatory disorders 
and within the TME of some types of cancer 138. IL-6-induced signal initiation leads to multiple 
downstream events that are triggered by activation of receptor-associated cytoplasmic tyrosine 
kinases, including Janus kinase 1 (JAK1), JAK2 and non-receptor tyrosine-protein kinase 2 
(TYK2) 133,135. Activation of these kinases leads to different patterns of tyrosine phosphorylation 
and subsequent activation of transcription factors signal transducer and activator of 
transcription 1,3,5 (STAT1,3,5) 135. IL-6 also induce the following main signalling mechanisms: 
1) The RAS-RAF cascade that regulates several downstream modifiers, including mitogen-
activated protein kinases (MAPKs), 2) The SRC-YAP-NOTCH pathway and 3) The RAC 
serin/threonine-protein kinase (AKT) pathway 135 (Fig 2.4 B).  
A| The communication within a tumor microenvironment (TME) is, besides others, mediated by secreted 
factors (yellow, green, orange, and grey circles), including chemokines, cytokines, and growth factors 
from tumor cells, infiltrating immune cells, and stroma cells. Interleukin-6 (IL-6) is secreted by both tumor 
cells and the tumor surrounding cells and leads to an inflammatory TME which in turn increases 
treatment resistance, invasion and metastasis, angiogenesis, tumor growth and progression as well as 
it mediates tumor induced immunosuppression 114. B| IL-6 cytokine family members have different 
importance within cancer 135. An important feature of the IL-6 family is that they use common cytokine 
receptor units. These receptor complexes consist of the common gp130 domain, together with a ligand-
binding non-signalling receptor (IL-6 family receptor) 135. 
 
There is increasing evidence for a main role of IL-6 in the progression of cancer, particularly 
CRC, and relationships with local and systemic inflammatory responses 110,114. Consistent with 
Figure 2.4 Interleukin-6 within a tumor-promoting tumor microenvironment. 
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this, IL-6 and IL-11 play a prominent role in the progression of sporadic and inflammation-
associated colon and gastric cancer 114. Pharmacologic inhibition of the IL-11/STAT3 axis in 
mouse models of gastrointestinal cancer and human tumor cell line xenografts suppressed cell 
invasion ability and reduced tumor growth 139. 
2.3.2 STAT3  
The link between chronic inflammation and cancer is clearly illustrated by the fact that a 
large portion of CRC tumors and cell lines exhibit a constitutive activity of the key pro-
inflammatory transcription factors nuclear factor -κB (NF-κB) and STAT3 111,140. 
STAT3 belongs to a family of transcription factors that were first discovered in 1994 during 
the evaluation of interferon (IFN)- triggered gene regulation 141. In 1994, Zhong et al., described 
a DNA-binding protein, which becomes activated through phosphorylation on tyrosine in 
response to epidermal growth factor (EGF) and IL-6 142. At the same time Akira et al., 
discovered a protein that gets activated in response to IL-6 in hepatocytes, which they called 
acute phase response factor (APFR) 143. It was subsequently found to be the same protein, 
which was henceforth named STAT3. STAT3 belongs to the STAT family of proteins, 
consisting of seven members (STAT1, STAT2, STAT3, STAT4, STAT6, STAT5a, STAT5b), 
that have similar protein length, slightly varying from 750 to 850 amino acids 141,144. STAT 
proteins comprise of structural and functional conserved domains: 1) amino-terminal domain 
(NTD), 2) coiled-coil domain (CCD), 3) DNA-binding domain (DBD), 4) linker domain (Linker), 
5) Scr-homology 2 domain (SH2), and 6) carboxyl-terminal transactivation domain (TAD) 145 
(Fig 2.5 A). The particular functions of the domains can be found in Fig. 2.5 A (blue). STAT3 
is a protein with dual roles - it transduces signals from growth factors and hormones from the 
cell membrane through the cytoplasm and function as a transcription factor in the nucleus, 
where it regulates gene expression of its target genes 144,146,147. STAT3 is known to regulate 
normal cellular processes, including cell development, differentiation, proliferation, survival, 
angiogenesis, and immune functions 146,147. Moreover, STAT3 is activated by signalling 
induced by the entire IL-6 family of cytokines and growth factors such as EGF, colony 
stimulating factor 1(CSF-1), and platelet derived growth factor (PDGF), IFNγ, IL-10 and IL-2 
148. 
In response to IL-6, STAT3 signalling leads to activation of JAK proteins that activate STAT3 
mainly by direct phosphorylation at tyrosine (705) 119,127,135,149-151. Following activation, 
phosphorylated STATs homo- or hetero-dimerize through reciprocal phosphotyrosine-SH2 
domain interactions and subsequently translocate from the cytosol into the nucleus 141,144. The 
STAT3 dimer can then bind to a 9-base-pair consensus sequence (TTCCGGAA – GAS 
sequence), located in the promotor regions of STAT3 target genes 152 to regulate the 
transcription of specific target genes 141,144 (Fig 2.5 B). An additional phosphorylation site within 
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the TAD region, serin 727, maximizes transcriptional activity of STAT3 153 (Fig. 2.5 B). Under 
physiological conditions, the JAK/STAT3 pathway is transient and tightly regulated, by 
activation of protein phosphatases, by inhibitors of phosphorylation, by nuclear inhibitory 
factors or by negative regulators (suppressors of cytokine signalling -SOCS proteins) 147. 
However, in many cancers, STAT proteins are aberrantly activated 154. 
A| Amino acid sequence of STAT3(α) as an example of the STAT3 protein family. Structurally, STAT3 
comprises the N-terminal domain (NTD), coiled-coil domain (CCD), DNA-binding domain (DBD), linker 
domain (LD), Scr homology (SH2) domain and transcriptional activation domain (TAD) 145. The functions 
of the domains are highlighted in blue, important phosphorylation sites are highlighted in orange. B| 
Highly simplified representation of IL-6 induced STAT3 signalling with the major steps of the intracellular 
signalling cascade. Following receptor ligation, induced by IL-6 binding, JAK2 gets activated to 
phosphorylate STAT3 that in turn dimerizes and translocated into the nucleus to regulated expression 
of STAT3 target genes by binding to specific docking sites called interferon-gamma activated sequences 
(GAS) 119,127,135,149-152. 
 
2.3.2.1 The IL-6/JAK/STAT3 axis in CRC treatment resistance 
Aberrant STAT3 activation is associated with various human cancers and is implicated in 
increased synthesis of key inflammatory mediators, cytokines, and chemokines 146. This results 
in amplification of recruited immune cells and modulation of the function of these cells in the 
TME. Cancer cells harboring increased pSTAT3 activity demonstrate high tumor malignancy 
and its expression is an indicator of poor prognosis 119,145. In addition to STAT3 itself, some of 
Figure 2.5 IL-6 induced STAT3 signalling. 
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its target genes also play a tumorigenic role. IL-6, C-X-C Motif Chemokine Ligand 12 (CXCL12) 
and Mitochondrially Encoded Cytochrome C Oxidase II (COX2) are responsible for 
inflammation while BCL2 Apoptosis Regulator (BCL-2) and BCL2 Like 1 (BCL-XL) are 
important for cell survival. The invasion characteristics of tumor cells can be enhanced by the 
expression of Mucin 1 (MUC1) and the induction of metastasis by proteins such as Matrix 
Metallopeptidase 1,2 and 9 (MMP-1,2 and 9) 145,155. Furthermore, activation of STAT3 by IL-6 
prevents apoptosis and enhances proliferation of malignant cells through upregulation of anti-
apoptotic and proliferative factors 114. STAT3 signalling is frequently activated in both primary 
tumors as well as cell lines and phosphorylated STAT3 can be detected in 25-40% of rectal 
cancers 156. Of note, constitutively activated STAT3 as a result of mutations at the STAT3 
protein or the STAT3 gene is extremely rare. Rather, this protein is abnormally activated by 
autocrine and paracrine mechanisms such as aberrant activity of cell surface receptors by 
TME- associated cytokines, amplified or mutated receptors or by a loss of negative 
endogenous STAT3 regulators such as protein inhibitors of activated STATs (PIAS) 145. Thus, 
it is not surprising that STAT3 has been studied as a tumor therapeutic target excessively, 
owning to its role in tumor formation, metastasis, and drug resistance 157. Direct inhibition of 
the JAK/STAT3 pathway appears to be highly effective and has been approved by the Food 
and Drug Administration (FDA). Unfortunately, clinical studies revealed that direct inhibition of 
STAT3 does not result in satisfactory results due to high sequence similarity with the other 
STAT members 158,159. Moreover, other issues such as high toxicity and poor bioavailability 
have become significant obstacles to the clinical development of direct STAT3 inhibitors 158. 
These findings lead to increased research focused on indirect inhibition of the signalling 
pathway, by targeting its upstream and downstream signalling components 157. Therefore, JAK 
inhibitors, including Ruxolitinib showed positive clinical outcomes and have been approved by 
FDA for cancer therapy 119,127,150.  
Importantly, abundant evidence has indicated that STAT3 is important for mediating 
treatment resistance, such as targeted therapy, chemotherapy, radiotherapy, and 
immunotherapy 160,161. In 2010, my host research group established an in vitro model for testing 
cell lines regarding their sensitivity to CRT. Therefore, 12 human CRC cell lines were pre-
treated with 3 µM 5-FU and subsequently irradiated with 2 Gy. In parallel, pretherapeutic gene 
expression profiles were generated and compared with the corresponding surviving fractions. 
The analysis revealed a significantly STAT3- expression in cell lines with comparatively high 
CRT resistance 162. It has also been demonstrated that the treatment with the STAT3 inhibitor 
STATTIC significant sensitized CRC cells to CRT both in vitro and in vivo 147. In accordance 
with this, a direct contribution of STAT3 inhibition and CRT sensitization was made in CRC 
cells in vitro 163. Furthermore, Ebbing et al. showed that stroma cell-derived IL-6 mediates CRT 
resistance of esophageal adenocarcinomas, which could be reverted by inhibition of IL-6 164.  




2.4 Aims of the thesis 
The aim of the currently work was to further investigate the role of STAT3 as a driver of 
CRT resistance in CRC cells and to uncover possible molecular mechanisms underlying 
STAT3-mediated CRT resistance. Thus, I wanted (i) to get a clear understanding of the 
influence of the JAK/STAT signalling on CRT resistance, testing novel JAK/STAT inhibitors as 
CRT-sensitizer in human CRC cell lines in vitro. (ii) To investigate, whether the use of a 
pharmacological STAT3 inhibitor has an impact on CRC cells in vivo. (iii) To understand the 
STAT3 mediated CRT resistance using an RNA-Sequencing (RNA-Seq) based approach to 
analyze the consequences of STAT3 perturbation on a global transcriptome level. (iv) To 
identify respective STAT3 downstream targets that may functionally mediate the resistance 
phenotype. 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
Table 1 Chemicals 
Substances Company 
2-Mercaptoethanol Carl Roth GmbH & Co. KG 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Carl Roth GmbH & Co. KG  
5-fluorouracil (5-FU) Sigma 
Acetic acid Carl Roth GmbH & Co. KG 
Agarose Sigma 
Ammonium persulfate (APS) AppliChem 
Bovine serum albumin (BSA) Sigma 
Brilliant blue R 250 Carl Roth GmbH & Co. KG 
Bromophenol blue Sigma 
Deoxynucleotide triphosphates (dNTP) Carl Roth GmbH & Co. KG 
Desoxy-ATP (adenosine triphosphate) [33P]-labelled Hartmann Analytic 
Disodium hydrogen phosphate dihydrate (Na2HPO4) Merck 
Dithiothreitol (DTT) AppliChem 
ECL Advance Western Blot detection kit Amersham Bioscience 
Egtazic acid (EGTA) Merck 
Ethanol, 99.8% Carl Roth GmbH & Co. KG 
Ethylenediaminetetraacetic acid (EDTA solution pH 8.0) QualityBiological 
Ficoll Amersham Bioscience 
Formaldehyde solution, 37% AppliChem 
GelRed® Nucleic Acid Gel Stain Biotium 
Glycerol, UltraPure™ Invitrogen 
Glycine AppliChem 
hemalum solution Merck 
Hydrogen chloride (HCL) solution Merck 
IGEPAL-CA-360 Sigma 
Immobilion® Forte western Blot HRP Substrate Millipore Cooperation 
Klenow fragment New England Biolabs 
Magnesium chloride (MgCl) Merck 
Methanol, 99% Carl Roth GmbH & Co. KG 
Milk powder, blotting grade Carl Roth GmbH & Co. KG 
N, N, N’, N’ – Tetramethylethylendiamin (TEMED) AppliChem 
Nonident P-40 (NP-40) AppliChem 
Pefabloc® SC-Protease Inhibitor Carl Roth GmbH & Co. KG 
PhosSTOP Roche 
Potassium chloride (KCL) Merck 
Potassium dihydrogen phosphate trihydrate (KH2PO4) Merck 
Prestained protein ladder (10-180 kDa) BioFroxx 
Proteo Block, Protease inhibitor Fermentas 
Resazurin Solution PromoKine 
Roti®phorese Gel30 solution Carl Roth GmbH & Co. KG 
Roti®Quant Carl Roth GmbH & Co. KG 
Sodium Chloride (NaCl) Carl Roth GmbH & Co. KG 
Sodium Dodecyl Sulfate (SDS) salt Merck 
Sodium Hydroxide (NaOH) Merck 
Sodium orthovanadate (Na3VO4)  Acros Organics 
Sucrose (saccharose) Merck 
Tris ultrapure AppliChem 
Triton X-100 Serva 
Tween20 AppliChem 
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3.1.2 Disposables and laboratory equipment 
Laboratory equipment and solutions that needed to be sterile were sterilized using HST32/3 
autoclave (Zirbus technology GmbH,Bad Grund/Harz,Germany). Pasteur pipets used in cell 
culture or other sensitive settings were sterilized using ST6060 Hot air sterilizer (Thermo Fisher 
Scientific Inc., Waltham, MA, USA). 
Note that only disposables and laboratory equipment that were used in the group of PD Dr. 
Marian Grade and Prof. Dr. Jürgen Wienands were listed in Tab. 2. Other equipment’s and 
solutions that were used in cooperating institutes and departments were not listed. 
3.1.2.1 Disposables 
Table 2 Disposables 
Supplies Company 
12-well plate Sarstedt 
15- and 50-ml tubes  Sarstedt 
175 cm2 Sarstedt 
25 cm2 and 75 cm2 flask Sarstedt 
384-well plate, FrameStar®, skirted PCR plate 4titude 
6-well plate Sarstedt 
96-well plate, black, for photometry Corning 
96-well plate, Cyto One® STARLAB GmbH 
96-well plate, white, for luminescence Thermo Scientific 
Biosphere safe seal tubes 1.5 ml and 2 ml Sarstedt 
Cell scraper M, length 300 mm TPP 
Cell spatula, length 195 mm TPP 
Chromatography paper 3 mm WhatmanTM GE Healthcare UM Limited 
Cryovials Sarstedt 
Disposable reagent reservoirs, PS, white Carl Roth GmbH & Co. KG 
Falcon tubes, 15 ml, 50 ml Sarstedt 
Illustra-MicroSpin-G-25 columns GE Healthcare 
Pasteur pipettes, glas, 150 mm Th. Geyer 
Pasteur pipettes, glas, 230 mm Th. Geyer 
PVDF membrane Hybond-P  Amersham Biosciences 
QIAshredder Qiagen Sciences 
Reaction tubes 1.5 ml Carl Roth GmbH & Co. KG 
Reaction tubes 2 ml and 5 ml STARLAB international GmbH 
Rotilabo®-liquid reservoirs, PVC (unsterile) Carl Roth GmbH & Co. KG 
Serological pipette 2 ml, 5 ml, 10 ml, 25 ml, 50 ml STARLAB international GmbH 
Stericup® Quick Release  Merck Millipore 
Tip One® filtertips sterile,10/20 µl, 100 µl, 200 µl, 1000 µl STARLAB international GmbH 
Tip One® tips 10/20 µl, 200 µl, 300 ml, 1000 µl, 1250 µl STARLAB international GmbH 
 
3.1.2.2 Laboratory equipment 
Table 3 Laboratory equipment 
Equipment Company 
Autoclave, HST32/35 Zirbus technology GmbH 
Biomolecular imager Typhoon FLA900 GE Healthcare 
Caunting chamber Brand GmbH & Co. KG 
Cell culture incubator CO2 Labotect 
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Cell culture incubator O2 Labotect 
Centrifuge 5415 D Eppendorf 
Centrifuge Allegra X-30R Beckman Coulter GmbH 
Centrifuge Heraeus Fresco 17 Thermo Scientific Open Biosystems 
Centrifuge mini Rotilabo® Carl Roth GmbH & Co. KG 
ImageQuant LAS 4000 mini GE Healthcare Life Sciences 
Colony Counter, eCountTM Heathrow Scientific® LLC 
Digital-Control Water Baths, Isotemp® Fisher Scientific 
Elektrophorese plates Ochs Laborbedarf 
Eppendorf® Research®, multichannel pipette (12), 5-100 µl Eppendorf 
Eppendorf® Research®, multichannel pipette (8), 50-1200 µl Eppendorf 
Eppendorf® Research®, multistepper pipette 20-300 µl Eppendorf 
Eppendorf® Research®, single channel pipette, 0.5-10 µl  Eppendorf 
Fluid aspiration system BVC professional Vacuubrand 
Freezer MDF U537 (-20 °C) Sanyo 
Freezer ultra-low (-150 °C) Sanyo 
Freezer VIP Series MDF U74V (-80 °C) Sanyo 
Freezing Container, 5100 Cryo 1°C Thermo Fisher Scientific Inc. 
Fridge (4 °C, - 20 °C) premium Liebherr 
Hera Safe (sterile bench) Heraeus 
Homogeniser in Ultrasonic Technology, BANDELIN 
SONOPULS HD 3100 
BANDELINE electronic GmbH & Co. 
KG 
Hot air sterilizer, Heraeus ST6060 Thermo Fisher Scientific Inc. 
Magnetic stirrer IKA®- Werke GmbH & Co. KG 
Microscope, EC3 Leica AG 
Microscope, Leica DM IL Leica AG 
Microscope, Leica LED2500 Leica AG 
Mini-Transilluminator BioRad 
Mithras LB943 microplate reader Berthold Technologies GmbH 
NucleofectorTM 2b Device Lonza 
pH-meter, PB-11 Sartorius AG 
Phosphoimaging system, Typhoon FLA 9500 GE Healthcare 
Pipette controller, accu-jet® Brand GmbH & Co. KG 
Pipettes, Eppendorf Research® plus, 2,5 µl, 10 µl, 20 µl, 100 
µl, 200 µl, 1000 µl 
Eppendorf 
PowerPac 3000 BioRad 
Real time PCR, C1000 Thermocycler BioRad 
Semi dry blotting aperture Peqlab 
Stainless Steel Beads, 5mm (200) QIAGEN GmbH 
Thermomixe Eppendorf 
Tilting shaker, WS42 A. Hartenstein GmbH 
TissueLyser LT QIAGEN GmbH 
Vaporiser, Vapor 2000 Dräger 
Victor X4 light multilabel reader PerkinElmer 
Vortexer, RS-VA 10 Phoenix Instruments 
Water Purification System, Milli-Q Reference Ultrapure Merck Millipore 
Weight scale, BD ED 100 Sartorius AG 
Weight scale, BP 610 Sartorius AG 
Weight scale, ED224S Sartorius AG 




Most solutions and buffers that referred to this thesis were prepared with double-distilled H2O 
(quality reached using Mili-Q ultrapure Water System, Merck Millipore). For RNA studies 
DNase-, RNAse-, protease-, calcium-, and magnesium-free water was used (Water for 
Molecular Biology, Merck Millipore). 




Table 4 Ready-to-use kits 
Kit Company 
Amaxa™ Cell Line Nucleofector™ Kit V and L Kit (25 RCT) Lonza 
Cignal Reporter Assay Kit STAT3, CCS-9028L QIAGEN GmbH 
Dual-Luciferase Reporter Assay System Promega 
MycoAlertVR, Mycoplasma Detection Kit  Lonza 
Pierce® Bicinchoninic Acid Assay (BSA) protein Assay Kit Thermo Fisher Scientific Inc. 
RNase-Free DNase Set QIAGEN GmbH 
RNeasy Mini Kit QIAGEN GmbH 
SensiFAST™ Probe No-ROX One-Step Kit Bioline 
 
3.1.5 Software 
3.1.5.1 Computer software 
Table 5 Software 
Software Version Company 
EndNote 20 0.1 Cleverbridge AG 
Grapher 8 Apple Inc 
GraphPad Prism 9 GraphPad Software 
ImageJ (Public domain) 1.52a developed at NIH by Wayne Rasband 
ImageQuant™ LAS 4000 mini-1.2  GE Healthcare UK Limited 
ImageQuant™ TL 7.0  GE Healthcare UK Limited 
KaleidaGraph 4.1.0 Synergy Software Systems 
Microsoft Office 2016 2016MSO Microsoft 
ND-1000  PEQLAB Biotechnologie GmbH 
Toolkit for Interactive Network Analysis (TINA)  2 DesignSoft 
Wallac 1420 Workstation 3.00.0.53  PerkinElmer 
 
Note that only software’s that were used in the group of PD Dr. Marian Grade and Prof. Dr. 
Jürgen Wienands were listed in Tab. 6 and 7. Software’s that were used for sequencing and 
analyzing the RNA-Seq experiment were named in section 3.2.6 but originally belongs to the 
corresponding institutes and departments. 
3.1.5.2 Online platforms 
Table 6 Online platforms 





http://bioinformatics.psb.ugent.be/webtools/Venn/ VIB-UGENT Center 
For Plant Systems 
Biology 
COSMIC database https://cancer.sanger.ac.uk/cosmic Sanger institute 
GeneCards, The 
human gene database 
https://www.genecards.org/ Weizmann Institute of 
Science, Life Map 
Science 
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Heatmapper http://www.heatmapper.ca/ Wishart Research 
Group at the 
University of Alberta 
Morpheus https://software.broadinstitute.org/morpheus/ Broad Institute 
NCBI Blast https://blast.ncbi.nlm.nih.gov/Blast.cgi National Centre for 
Biotechnology 
Information 
Cancer Cell Line 
Encyclopedia (CCLE) 
https://portals.broadinstitute.org/ccle Broad Institute 
PrimerBank https://pga.mgh.harvard.edu/primerbank/ The Massachusetts 
General Hospital 
 
3.1.6 Stimulants and Inhibitors / Drugs  
3.1.6.1 Stimulants 
Table 7 Stimulants  
Stimulants Solvent Company 
Hyper-IL-6 Cell culture medium Kindly provided by Prof. Rose John Institute of Biochemistry 
(Kiel)  
IFN-γ Cell culture medium Biomol 
rIL-6 Cell culture medium Merck 
 
3.1.6.2 Inhibitors  
Table 8 Inhibitors 
Inhibitors / inhibitory antibodies Solvent Company 
DAPT DMSO Sigma 
Napabucasin (Napa) DMSO Sellckchem 
Ruxolitinib (Ruxo) DMSO Sellckchem 
Tocilizumab (Toci) PBS Kindly provided by Prof. Rose John 
Institute of Biochemistry (Kiel) 
 
3.1.7 Buffers and solutions 
3.1.7.1 Cell lysis buffer 
NP-40 lysis buffer 
Table 9 NP-40 lysis buffer 
Substances Stock Final concentration For 100 ml 
NaCL 5 M 150 mM 3 ml 
NP-40 100% 1% 1 ml 
Tris 1 M 50 mM 5 ml 
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All components were diluted, add to 100 ml ddH2O and pH adjusted to 7.8. For cell lysis, 
following components (Tab. 10) were added to the required volume of buffer before use. 
Table 10 Freshly added components for NP-40 based cell lysis 
Substances Dilution 
DTT 1:10 (stock: 1 M) 
Phosphatase Inhibitor 1:10 (stock: 1 tablet in 10 ml ddH2O) 
Protease Inhibitor 1:25 (stock: 1 tablet in 10 ml ddH2O) 
 
Ripa buffer 
Table 11 Ripa buffer 
Substances Stock Final concentration For 100 ml 
EDTA 0.5 M 2 mM 400 µl 
NaCL 5 M 150 mM 3 ml 
Na-Deoxycholate  0.5% 500 mg 
NP-40 100% 1% 1 ml 
NP-40  1% 1 ml 
Tris 1 M 50 mM 5 ml 
 
All components were diluted, add to 100 ml ddH2O and pH adjusted to 8. For cell lysis, following 
components (Tab. 12) were added to the required volume of buffer before use. 
Table 12 Freshly added components for Ripa buffer-based cell  
Substances Dilution 
Protease Inhibitor 1:25 (stock: 1 tablet in 10 ml ddH2O) 
Phosphatase Inhibitor 1:10 (stock: 1 tablet in 10 ml ddH2O) 
 
Chromatin fractionation buffer Buffer- A 
Table 13 Chromatin fractionation buffer Buffer- A 
Substances Stock Final concentration For 100 ml 
KCL 250 mM 10 mM 4 ml 
MgCl2 2 M 1,5 mM 75 µl 
Saccharose  0.34 M 11.638 g 
Glycerol  10% 10 ml, 12.6 g 
TritonX-100  0.1% 100 µl 
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Chromatin fractionation buffer Buffer- B 
Table 14 Chromatin fractionation buffer Buffer- B 
Substances Stock Final concentration For 100 ml 
EDTA 0.5 M 3 mM 600 µl 
EGTA 20 mM 0.2 mM 1 ml 
 
All components were diluted, add to 100 ml ddH2O. Before use, components provided in Tab. 
10 were added. 
3.1.7.2 Buffer for EMSA 
Cytoplasmic extraction buffer 
Table 15 Cytoplasmic extraction buffer 
Substances Stock Final concentration For 100 ml pH value 
EDTA 0.5 M 1 mM 200 µl  
Glycerin (v/v)  10% 10 ml  
HEPES 100 mM 20 mM 20 ml 7.4 
KCL 250 mM 10 mM 4 ml  
Na3VO4 1 M 0.1 mM 10 µl  
 
All components were diluted, add to 100 ml ddH2O. Before use, the following components 
(Tab. 16) were added. 
Table 16 Freshly added components for the cytoplasmic extraction buffer 
Substances Dilution/ final concentration 
DTT 3 mM (stock 1 M) 
IGEPAL 0.1% 
Pefabloc 0.4 M 
Protease Inhibitor 1:10 (stock: 1 tablet in 10 ml ddH2O)  
 
Nuclear extraction buffer 
Table 17 Nuclear extraction buffer 
Substances Stock Final concentration For 100 ml pH value 
EDTA 0.5 M 1 mM 200 µl  
Glycerin (v/v)  20% 20 ml  
HEPES 100 mM 20 mM 20 ml 7.4 
KCL 10 M 420 mM 4,2 ml  
Na3VO4 1 M 0.1 mM 10 µl  
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All components were diluted, add to 100 ml ddH2O. Before use, the following components 
(Tab. 18) were added. 
Table 18 Freshly added components for the nuclear extraction buffer 
Substances Dilution/ final concentration 
DTT 3 mM (stock 1 M) 
Pefabloc 0.4 M 
Protease Inhibitor 1:10 (stock: 1 tablet in 10 ml ddH2O) 
 
3.1.7.3 Additional buffers and solutions 
Table 19 Additional Buffers and solutions 
Buffers Substances Final 
concentration 
For 1000 ml pH 
value 
Coomassie decolorizing solution Methanol (v/v) 









Coomassie fixing solution (for gels) Methanol (v/v) 









Coomassie staining solution Methanol (v/v) 
Coomassie Brilliant 
Blue (w/v) 













































Spatula tip  
(for 10 ml 
final volume) 
 
SDS-PAGE loading gel (4x) buffer Tris 1000 nM 121.16 g 6.8 










SDS-PAGE running (1x) buffer SDS-PAGE running 
(10x) buffer 
ddH2O 
1x 100 ml 
900 ml 
 
SDS-PAGE separating gel (4x) 
buffer 
Tris 1500 nM 181.72 g 8.8 
TAE (50 x) Tris 
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EDTA 1 mM 100 ml of 0.5 
M 
8.0 
TAE (1x) TAE (50 x) 
ddH2O 
1x 20 ml 
980 ml 
 










TBE (2.4 x) TBE (10x) 
ddH2O 
2.4 x 416.6 ml 
583,4 ml 
 























Western Blot blocking buffer Milk powder 
TBST (1x) 
5% 50 g 
1000 ml 
 



















All components were diluted, add to 1000 ml ddH2O, and were adjusted to their respective pH 
value. 
3.1.8 Equipment and Substances for SDS- Polyacrylamide gel electrophoresis 
Table 20 Electrophoresis supplies 
 
 
Table 21 Composition of loading and separating gels 
Substances Loading gel (7.5%) Loading gel (10%) Separating gel (5%) 
10% APS 200 µl 200 µl 100 µl 
10% SDS solution 200 µl 200 µl 50 µl 
30% Roti®phorese 5 ml 6.7 ml 0.83 ml 
4x Loading gel buffer (pH 6.8) - - 0.63 ml 
4x Loading gel buffer (pH 8.8) 5 ml 5 ml - 
ddH2O 9.6 ml 7.9 ml 3.4 ml 
TEMED 20 µl 20 µl 10 µl 
 
Equipment Company 
Glass plate, straight cut Biometra GmbH 
Glass plate, fix spacer Biometra GmbH 
Combs for electrophoresis Biometra GmbH 
Silicone seals, 1.0 mm Biometra GmbH 
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Additionally, 75 µl bromphenol-blue solution were added to the gel to make loading easier. The 
listed values are enough for 2 mini gels 
3.1.9 Antibodies for Western Blot analysis 
3.1.9.1 Primary Antibodies 
All primary antibodies (species: rabbit) were diluted according to the manufacturer’s 
recommendations in either 5% Milk-TBST or 5% BSA-TBST and were incubated over night at 
4 °C under gently shaking.  
Table 22 Primary Antibodies used for Western Blot analysis 
Antibodies (clone) Dilution Company 
Actin (Polyclonal) 1: 10,000 Sigma 
ADAM9 (D64B5) 1: 1,000 Cell Signalling 
Cleaved Notch-1 (NICD) (D3B8) 1: 1,000 Cell Signalling 
DLL4 (Polyclonal) 1: 1,000 Cell Signalling 
GP130 (Polyclonal)  1: 1,000 Cell Signalling 
HA-tag (C29F4) 1: 10,000 Cell Signalling 
HDAC1 (Polyclonal) 1: 1,000 Cell Signalling 
HES1 (D6P2U) 1: 1,000 Cell Signalling 
Jagged1 (28H8) 1: 1,000 Cell Signalling 
Jagged2 (C23D2) 1: 1,000 Cell Signalling 
Nicastrin (D38F9) 1: 1,000 Cell Signalling 
NOTCH1 (D1E11) 1: 1,000 Cell Signalling 
NOTCH2 (D76A6) 1: 3,000 Cell Signalling 
NOTCH3 (D11B8) 1:1,000 Cell Signalling 
NUMB (C29G11) 1: 1,000 Cell Signalling 
PEN2 (D6G8) 1: 1,000 Cell Signalling 
Presenilin 1 (D29D1) 1: 2,000 Cell Signalling 
Presenilin 2 (D30G3) 1: 2,000 Cell Signalling 
pSTAT3Ser727 (Polyclonal) 1: 1,000 Cell Signalling 
pSTAT3Tyr705 (D3A7) 1: 1,500 Cell Signalling 
RBPSUH (RBPJ) (D10A4) 1: 2,000 Cell Signalling 
TACE (D22H4) 1: 1,000 Cell Signalling 
 
3.1.9.2 Secondary Antibody 
Secondary antibody (species: goat) was diluted in 5% Milk-TBST and were incubated 2 hours 
at RT under gently shaking.  
Table 23 Secondary Antibody used for Western Blot analysis 
 
 
IgG = immunoglobulin G, HRP = horseradish peroxidase 
 
Protein Dilution Company 
Anti-rabbit IgG-HRP conjugated 1: 30,000 Acris 





siRNA pools were obtained from Dharmacon, the AllStarsNEG as well as the STAT3 siRNAs 
(#7 and #8) were obtained from QIAGEN GmbH. 
Table 24 siRNAS 



























































SERPINB3 (Pool) GAUCUAAGCAUGAUUGUGU NM_006919 



















STAT3 (#7) * CAGCCTCTCTGCAGAATTCAA NM_003150 
STAT3 (#8) * CAGGCTGGTAATTTATATAAT NM_003150 
* siRNA STAT3 (#7) and siSTAT3 (#8) were pooled for RNA-Seq experiments, bp = base pair, n.a. = 
not applicable 
 
3.1.10.2 Primer for semi-quantitative RT-PCR 
For primer design the online platforms PrimerBank and NCBI blast were used. All Primers were 
dissolved in DNase-, RNase-, proteinase-free water and stored at -20°C. HPRT1 was ordered 
from Eurofins all other primers are ordered from IDT (Integrated DNA Technologies). 
Table 25 Primer for semi-quantitative RT-PCR 
Gene Primer sequence (5’ -> 3’) Product size (bp) Accession Number 
BCL-6 CAGCCAACCTGAAAACCCAC 92 NM_001706 
DPYD GGCGGACATCGAGAGTATCCT 78 NM_000110 
DUOX2 AGGATACCGTCCTTTCCTAGAC 194 NM_014080 
ELF3 TCTTCCCCAGCGATGGTTTT 122 NM_004433 
HIF1A TGCTTACACACAGAAATGGCCT 161 NM_001530 
HPRT1 TGACACTGGCAAAACAATGCA 93 NM_000194.2 
MUC1 ACGACGTGGAGACACAGTTC 93 NM_002456 
NAMPT AATGTTCTCTTCACGGTGGAAAA 98 NM_005746 
RBPJ CTGACTCAGACAAGCGAAAGC 79 NM_015874 
S100A9 GGTCATAGAACACATCATGGAGG 155 NM_002965 
SERPINB3 CGCGGTCTCGTGCTATCTG 100 NM_006919 
SERPINB4 ACTCAGTGAAGCCAACACCA 174 NM_175041 
TRIB2 GACTCCGAACTTGTCGCATTG 85 NM_021643 
bp = base pair 
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3.1.9 Vectors and Plasmids 
3.1.9.1 Vectors for dual luciferase assay 
Table 26 Vectors used for dual luciferase assay 
Vector Company 
CignalTM Reporter Assay Kit STAT3 QIAGEN GmbH 
pGL4.14[luc2/Hygro] Vector Promega 
pGL4.47[luc2P/SIE/Hygro] Vector Promega 
pRL_CMV Vector Promega 
 
3.1.9.2 Plasmids used for STAT3 expression 
Table 27 Plasmids used for bacterial HA-tagged fusion protein expression 
Insert Backbone Source 
STAT3 WT pmaxKS Doctoral thesis Florian Krause, CALL, *  
STAT3 Y705F pmaxKS Doctoral thesis Florian Krause, CALL, * 
STAT3 S727A pmaxKS Doctoral thesis Florian Krause, CALL, * 
STAT3 Y705F/S727A pmaxKS Doctoral thesis Florian Krause, CALL, * 
* unpublished data 
 
3.1.10 Probe Sequences for electrophoretic mobility shift assay 
Table 28 Sequences for electrophoretic mobility shift assay 
Probe Probe sequence Company 
M67 5’ -> 3’: CGACATTTCCCGTAAATCTG 
3’ -> 5’: CAGATTTACGGGAAATGTCG 
Sigma 
RBPJ (mutated) 5’ -> 3’: CGGGGGCCCTTGGTAGCAGGCC 
3’ -> 5’: GGCCTGCTACCAAGGGCCCCCG 
Sigma 
RBPJ (native) 5’ -> 3’: CGGGGGCTTCCGGGATCAGGCC 
3’ -> 5’: GGCCTGATCCCGGAAGCCCCCG 
Sigma 
bp = base pair, red = mutation site 
 
3.1.11 Human cell lines and cell culture reagents 
3.1.11.1 Human cell lines 
Human colorectal cancer cell lines, LS411N, SW837 and SW1463, were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA) and cultured in recommended 
medium, supplemented with 10% fetal bovine serum and 2 mM L-glutamine. All additional 
adherent cell lines including culturing details were listed in Tab. 29.  
Materials and Methods | Kristin Kördel 
32 
 
Table 29 Human cell lines and culture conditions 
Cell line Origin Medium Incubator Split 
growth 
ratio 
FLO-1* Human esophagus RMPI + 10% FBS and 1% L-
glutamine 
37 °C, humidified, 
5% CO2 
n.a. 
HeLa* Cervix epithelial 
adenocarcinoma 
EMEM + 10% FBS and 1% L-
glutamine 
37 °C, humidified, 
5% CO2 
n.a. 
LS411N Colorectal carcinoma RMPI + 10% FBS and 1% L-
glutamine 





EMEM + 0.01 mg/ml human 
recombinant Insulin, 10% FBS 
and L-glutamine 



















* This cell lines were not cultivated for this study. We used/ received protein lysates. 
 
3.1.11.2 Cell culture reagents 
Table 30 Cell culture reagents for cultivation of human cell lines. 
Substances Company 
Dimethyl sulfoxide (DMSO) Sigma 
Fetal bovine serum (FBS) Pan 
Leibovitz’s L-15 medium Invitrogen 
L-Glutamine BioWhittaker 
Lipofectamine RNAiMAX  Thermo Fisher Scientific 
Lipofectamin: SiLentFect BioRad 
RPMI-1640 medium Invitrogen 
Lipofectamin: X-tremeGENE™  (Roche) now Merck 
Trypan blue 33.3% Merck 
Phosphate buffered saline PBS pH 7.2 Invitrogen 
0.25% Trypsin-EDTA Invitrogen 
 
3.1.12 Animal Studies 
Athymic nude Naval Medical Research Institute (NMRI) Foxn1nu/Foxn1nu mice were 
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Table 31 Chemicals and Equipment used for animal studies 
Chemicals/ Equipment Company 
Digital caliper, RS PRO, 0-150 mm RS Components GmbH 
Disposable hypodermic needle, 100 Sterican B.Braun Melsungen AG 
Glucose 5% (G-5) B.Braun Melsungen AG 
Hypromellose Sigma 
Injekt®-F Tuberculin, Luer Solo B.Braun Melsungen AG 
Kodan® Tinktur forte Schülke & Mayr GmbH 
Scalpel blade, Bayha 22 C. Bruno Bayha GmbH 
Sevorane (Sevofluran) Abbvie 
Sterofundin® ISO B.Braun Melsungen AG 
Tissue culture dish, 100 * 20 mm Sarstedt 
Tween-80 AppliChem 
Weight scale, Scout Pro Indivumed 
 
Table 32 Substances used for animal studies 
Solution Substances Final 
concentration 
For 100 ml 























Napabucasin for mice 




740 µl (for 1 ml) 
 
Hypromellose solution should be filter-sterilized using Stericup® quick release, Vacuum driven 
disposable filtration system (Millipore). The volume of Napabucasin to be injected was 
determined individually for each mouse depending on weight (weight * 6.666 = µl to be 
injected). The final concentration to be injected is 5 mg/kg. 
  




3.2.1 In vivo experiments 
3.2.1.1 Mice strain, housing conditions and documentation 
Female NMRI-Foxn1nu/Foxn1nu mice used for the experiments were purchased from Janvier 
Breeding Center (Le Genest St. Isle, France). Mice were housed in the animal facility of the 
University Medical Center Göttingen in sterile cages, under standard conditions (22°C, 50% 
relative humidity, 12-h light/dark cycles) and provided with food and water ad libitum. The 
animal experiments were approved by the German Animal Welfare Act (reference number: 
33.9-42502-04-17/2383). 
3.2.1.2 Pharmacokinetics of Napabucasin 
3.2.1.2.1 Determination of Napabucasin concentration 
Firstly, to determine the Napabucasin concentration mice were randomly divided into three 
treatment groups: DMSO, Napabucasin (5 mg/kg) and Napabucasin (20 mg/kg). For xenograft 
transplantation, 2x106 SW1463 cells (logarithmic growth phase), were suspended in 100 µl L-
15 containing 20% FBS, and subcutaneously injected into the right flank of 8 till 10 weeks old 
female nude mice (Figure 3.1 C, upper left picture). When the tumor reached a volume of 
about 150 mm³ (approximately 3 weeks after SW1463 cell injection) the mice were treated like 
indicated in Figure 3.1 A. After 14 days of treatment (oral application of either DMSO or 
Napabucasin once a day), the mice were euthanized and the primary tumors were excised, 
weighed, and frozen at -80 °C for following protein and RNA studies. One portion was fixed by 
formalin (37%) and afterwards embedded in paraffin for immunohistochemical analysis 
(Figure 3.1 C, lower pictures).  
3.2.1.2.2 Testing Napabucasin as a treatment option  
5 mg/kg Napabucasin was chosen to be the best working dose in this mouse model using 
SW1463 to form a tumor. In analogy to section 3.2.1.2.2 experimental tumors were induced by 
subcutaneous injection of 2x106 SW1463 cells in the right flank of 8 till 10 weeks old NMRI-
Foxn1nu/Foxn1nu mice. Mice were randomly assigned into five different treatment groups: 
DMSO (n=15), Napabucasin (n=15), Napabucasin + RT (n=15), Napabucasin + CRT (n=13) 
and DMSO+ CRT groups(n=14). The treatment protocol recapitulates clinical conditions 
described in Spitzner et al.,2014, i.e., fractionated doses of chemotherapy and irradiation, and 
included intraperitoneal injections of 5-FU (50 mg/kg) 147 and oral application of either DMSO 
or Napabucasin (5 mg/kg), each one hour before irradiation (Fig. 3.1 B). Irradiation was 
performed under permanent sevoflurane inhalation narcosis. Non-tumor parts were shielded 
with a lead block for vital organ protection, and tumors were irradiated daily with 1.8 Gy for 14 
days (total dose of 25.2 Gy) using an X-ray irradiator (Tab. 33) (Fig. 3.1 C, upper pictures). 
After irradiation, a depot of G-15 and sterofundin was injected into the left and right flank of the 
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mice. Pictures at day 1, 5, 9 and 14 after start of treatment were taken to document the tumor 
development during the experiment. The treatment phase was followed by an observational 
period in which the re-growth of the tumor was studied.  
Table 33 Parameters for irradiation 
Parameter Settings 




Table high 315 mm 
Irradiation time 1 min, 25 sec 
 
3.2.1.3 Health status, documentation survival and tumor regrowth analysis 
SW1463 tumor-bearing mice were monitored three times a week for health status, tumor 
size, body weight and movement abnormalities (large tumors could restrict the mobility of 
mice). Tumor volume (volume = (width² x length) / 2) was measured thrice weekly after tumor 
cell inoculation. According to the legal termination criterion, mice must be sacrificed when the 
tumor volume reached approximately 1,500 mm³ in size, when the animals show an onset of 
symptoms, including 20% weight loss within three measurements, destruction of the tumor, 
both self-induced and externally caused, general health abnormalities or after 3 months of 
observation period. The complete dissection of each animal was documented in a protocol 
together with representative pictures of different organs. For sample collection, tumors were 
excised, weighed, and stored at -80°C for further analysis. One part of the tumor tissue was 
collected and processed for RNA, DNA, and protein isolation. The other part was fixed by 
formaldehyde and paraffin-embedded for immunohistochemical analyses (Fig. 3.1, lower 
pictures). The Kaplan-Meier method was used to estimate the tumor regrowth and the overall 
survival between the experimental groups. In this study, full tumor regrowth was defined as a 
tripling in tumor size (450 mm3).  
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Figure 3.1 Treatment protocol for testing Napabucasin in a xenograft nude mice model. 
A| and B| Schematic treatment protocol or C| Photographically visualized treatment protocol. SW1463 
cells were injected subcutaneously into NMRI-Foxn1 nude mice. At a tumor volume of approximately 
150 mm³, mice received their treatment which depend on the treatment group: group 1 (control): DMSO; 
group 2 (control): 5 mg/kg Napabucasin; group 3 (CRT): DMSO, 50mg/kg 5-FU, 14x irradiation at 1.8 
Gy; group 4 (CRT): 5 mg/kg Napa, 50mg/kg 5-FU, 14x irradiation at 1.8 Gy; group 5 (RT): 5 mg/kg 
Napabucasin, 14 x irradiation at 1.8 Gy. Mice will be sacrificed when tumor volumes reached 
approximately 1500 mm³, when they show serious physically impairing symptoms or if they reach the 
end of the experiment which is defined as an observation period of 3 months. 
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3.2.2 Human studies 
In this thesis, existing data sets were used and re-analyzed according to the experimental 
approaches. Therefore, biopsy collection, preparation, and gene expression profiling were 
performed as described 165,166. This project was conducted by the Clinical Research Unit 179 
(KFO179). It was approved by the Ethics Committee of the University Medical Center 
Goettingen together with informed consent obtained from all patients. 
Summarized, biopsies (tumor and mucosa) were obtained from 207 patients with locally 
advanced rectal cancer during clinical staging procedure prior to any therapy. These 
pretherapeutic biopsies were collected between 2001 and 2014 at the Department of General, 
Visceral and Pediatric Surgery at the University Medical Center Goettingen as well as in 10 
cooperating hospitals throughout Germany. All patients were treated with preoperative 
chemoradiotherapy, either within or according to the CAO/ARO/AIO-94 and -04 trials 68,90. All 
analysis concerning these data were carried out by the institute of Medical Bioinformatics, 
University Medical Center Goettingen, 37073 Goettingen, Germany. The patients’ 
characteristics were exported from the internal database (SecuTrial, iAS, Berlin, Germany) 
(Tab. 34). Survival rates were conducted using the R package survival, computed using 
Kaplan-Meier analysis and tested with the Cox proportional hazards model.  
Table 34 Clinical characteristics of rectal cancer patients 
Characteristics Cohort (n = 207) 
Age 
Years, median (range) 
 
63 (36 – 82) 
Sex  
Male, n (%) 144 (69.6) 
Female, n (%) 63 (30.4) 
DFS  
Follow-up time, month, median (range) 37 (0 – 188) 
Reported events, n (%) 52 (25.1) 
UICC Staging (2010)  
ypUICC 0, n (%) 35 (16.9) 
ypUICC I, n (%) 56 (27.1) 
ypUICC II, n (%) 48 (23.3) 
ypUICC III, n (%) 49 (23.7) 
ypUICC IV, n (%) 19 (9.2) 
DFS = disease-free survival, UICC = Union International Contre le Cancer, ypUICC refers to 
histopathologic assessment of the resected specimens after completion of preoperative 
chemoradiotherapy. 
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3.2.3 Cell culture 
The Human colorectal cancer cell lines, LS411N, SW837, and SW1463 (ATCC, Manassas, 
VA) were cultured in their recommended medium, supplemented with 10% FBS and 2 mM L-
glutamine. Mycoplasma contamination was routinely tested using MycoAlertVR Mycoplasma 
Detection Kit, and cross-contamination was surveyed by short tandem repeat (STR) profiling 
(Leibniz Institute DSMZ, Braunschweig, Germany). All used cell lines and their conditions are 
listed in Tab. 29. Generally, the recommended cell culture medium and all other substances 
needed for cultivation of the cells should be pre-heated at 37°C prior usage. 
3.2.3.1 Unfreezing 
Frozen cells were thawed at 37°C in a water bath. After defrosting, cells were resuspended 
in 10 ml of their recommended pre-heated cell culture medium and centrifuged for 5 min at 800 
rpm. The supernatant was discarded, the cell pellet was resuspended in fresh medium and 
cells were transferred into a T25 flask. To remove dead and detached cells, the medium was 
exchanged after 24 hours. 
3.2.3.2 Freezing 
To freeze cells, the medium was discarded, and cells were washed with PBS. Afterward, 
cells were harvested using 0.25% Trypsin-EDTA (37 °C, 5 min) to digest cell-cell junctions. 
The detached cells were transferred in 15 ml tubes and centrifuged for 5 min at 800 rpm. The 
supernatant was discarded, the cell pellet was resuspended in the respective freezing medium 
(cell medium with an additional amount of 10% DMSO and 20% FBS) and transferred to 
cryotubes. Afterward, the cryotubes were stored in freezing containers by -80°C to allow 
gradual cooling (1 degree per minute). After at least 100 min, cryotubes were transferred -
150°C for long time storage. 
3.2.3.3 Maintenance, subculture and seeding of adherent cells  
Cells growing in log-phase were subcultured at 70 - 80% confluence by washing with PBS, 
followed by treatment with 0.25% Trypsin-EDTA (37 °C, 5 min). The detached cells were 
resuspended in their respective medium and centrifuged at 800 rpm for 5 min. The cell pellet 
was resuspended in fresh medium, and cells were counted using a counting chamber. Before 
counting, a portion of the cell suspension was diluted with trypan blue solution (1:10) to make 
dead cells visible (dead cells - stained blue, living cells - white/transparent). 10 µl of this 
solution was filled in the counting chamber, and white/transparent cells inside the four large 
corner squares were counted. To calculate the cell number per ml the average of cells in the 
four squares was estimated and multiply with 104 and the dilution factor from trypan blue (1:10 
dilution = 10). After cell counting, cells were seeded in their recommended growth ratio (Tab. 
29) or for experiments in the appropriated cell numbers (Tab. 36). If the cells did not reach 
70% confluence, the used medium was exchanged by new medium.  
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3.2.3.4 Treatment  
Before RNA or protein extraction and during various assays cells were treated with different 
stimuli or inhibitors (Tab. 35). The respective reagent was diluted in pre-heated medium at the 
established concentration for each cell line (Tab. 29).  
Table 35 Established concentrations and incubation times for each reagent 
Substance 



















































*Concentrations and timepoints were previously established167; ** For DLR assay= incubation time 16 h 
 
3.2.4 Transfection methods 
3.2.4.1 Nucleofection (Amaxa) 
Upon nucleofection, cells were temporarily permeabilized by an electric field to absorb 
nucleic acids 168. Cells were transfected using Nucelofactor™ 2b device and respective 
Amaxa™ Cell Line Nucleofector™ kits according to the manufacturer’s recommendation. Briefly, 
cells were washed with PBS, detached using 0.25% Trypsin-EDTA and the cell number was 
calculated using a counting chamber. For one transfection approach, 1* 106 cells were 
resuspended in 100 µl of their appropriate cell-type-specific Nucleofector® solution. 
Afterwards, 1.25 μl siRNA was mixed with this cell solution and the mixture was then 
transferred into a cuvette (each sample should be prepared separately, to avoid storing cells 
longer than 15 min in Nucleofector® solution). The cuvette was inserted into the Nucleofector® 
device and the cell-type-specific program was used to achieve the nucleofection (Tab. 36). 
Immediately after transfection, the cells were removed from the cuvette using a transfer pipette 
and 1 ml of pre-warmed RPMI medium was added. After 15 min incubation at 37°C, cells were 
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centrifuged at 700 rpm for 5 min, the cell pellet was resuspended in recommended medium 
and cell solution was finally transferred into a culture dish or flask. 24 h after transfection 
medium was exchanged.  
3.2.4.2 Lipid-based transfection 
For RNA interference studies the desired siRNA was incorporated into the cells using lipid-
based transfection. This transfection method is based on positively charged liposomes that 
form complexes with the negatively charged phosphate backbone of nucleic acids. These 
Lipid-DNA complexes enter the cells through endocytosis 169. 
One transfection consisted of 100 μl serum-free medium (M0 medium) per well, in which 
first 0.5 μl siRNA (corresponding to 10 ng) was diluted and then 6 μl lipid was pipetted. This 
reaction mix was incubated for 5 min at room temperature to enable the binding of siRNA to 
the liposomes. In the meantime, cells were washed with PBS, detached using 0.25% Trypsin-
EDTA and the cell number was calculated using a counting chamber (for details see Tab. 36) 
The siRNA/lipid solution was pipetted dropwise to the cells. 
Table 36 Transfection details for different assays 
Assay Cell line Cell number Transfection method/ program 






Amaxa, V-Kit, T-30 
RNAiMAX 


















Amaxa, V-Kit; T-30 
X-tremeGENE HP 
 
3.2.5 Molecular biology 
3.2.5.1 Total RNA isolation from human cell lines and animal tissue 
The RNeasy® Mini Kit was used for purification of total RNA from human CRC cell lines and 
animal tissue (mice tumors) according to the manufacturer instructions. Briefly, for cell lysis, 
the medium was discarded, and cells were washed with PBS. Subsequently, 350 µl RLT buffer 
was added to the cell culture flask/dish (< 5*106 cells = 350 µl RLT buffer, 5*106 - 1* 107 cells 
= 600 µl RLT buffer) and cells were harvested using a cell scraper. The resulting lysate was 
pipetted directly into a QIAshredder spin column placed in a 2 ml collection tube, and 
centrifuged for 2 min at full speed and at RT. For animal tissue, the tumor sample was mixed 
with the appropriated amount of RLT buffer (350 µl) put directly into the QIAshredder spin 
column and were centrifuged, too. 
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The homogenized lysate (flow-through into the 2 ml tube) was mixed with 1 volume (350 µl) 
of 70% ethanol by pipetting. This solution was transferred into a RNeasy spin column placed 
in a 2 ml collection tube and centrifuged for 30 s at 10,000 rpm (in this step, the RNA binds to 
the membrane in the column). The flow-through was discarded and 350 µl of RW1 buffer was 
added to the column before re-centrifugation for 20 s at 10,000 rpm. To remove unwanted 
DNA, 80 µl of DNase solution (10 µl DNase mixed with 70 µl buffer) was added to the 
membrane and was incubated for 15 min at RT. Afterwards, 350 µl of RW1 buffer was added 
to the column before centrifugation for 30 sec at 10,000 rpm. The flow-through was discarded 
and the membrane was washed two times using 500 µl of RPE buffer and centrifugation for 30 
sec (first washing step) or 2 min (second washing step) followed by discarding the flow-
through. After the collection tube has replaced the column was centrifuged for 1 min at full 
speed. For elution of the RNA, 25 µl of RNAse-free water was added directly to the membrane. 
The column was centrifuged for 1 min at 10,000 rpm. Note that the RNA was contained in the 
eluate. The total RNA amount was measured using a Nanodrop and RNA stock concentration 
was diluted to 100 ng/µl. For qPCR analysis, the RNA was further diluted to a concentration of 
10 ng/µl. RNA samples were stored at -80 °C. 
3.2.5.2 RT-qPCR 
A RT-qPCR was performed to analyze the relative expression of target genes using the 
SensiFASTTM SYBR® No-ROX One-Step PCR System according to the manufacturer’s 
instructions. All steps were done on ice. RT-qPCR was performed in triplicates in a reaction 
volume of 10 µl as well as a non-template control (NTC) to exclude contaminations. 
For each well a reaction mix of the following reaction components was prepared: 
Table 37 Composition of RT-qPCR reaction mix 
Substances 1 x reaction mix 
PCR water 2.9 µl 
Reverse Transcriptase 0.1 µl 
RiboSafe RNase Inhibitor 0.2 µl 
RNA template (10 ng/µl) 1 µl 
Sensifast (2x) 5 µl 
 
Subsequently, 9.2 µl of the reaction mix was pipetted into each well. For the primer-working 
solution (final concentration: 400 mM) 10 µl of the forward primer and 10 µl of the reverse 
primer were mixed with 80 µl of PCR water. All primers used in this study are listed in Tab. 25. 
The 96-well plate was covered with an adhesive film and was centrifuged for 1 min at 3000 
rpm before placing it into the C100 Thermocycler. 
 
Materials and Methods | Kristin Kördel 
42 
 
Table 38 3-step-cycling for RT-qPCR 
Cycles Temperature Time Notes 
1 45 °C 10 min Reverse transcription 
1 95 °C 2 min Polymerase activation 










The resulting CT values were used to calculate the relative expression of the evaluated 
gene. Therefore, the CT values were normalized to the house-keeping gene Hprt and were 
afterwards analyzed using the ΔΔCt method (Livak and Schmittgen, 2001).  
3.2.5.2.1 Optimization of new primers 
To establish new RT-qPCR primes the model of relative quantification 170 was used. A 
standard RT-qPCR was conducted as described before (see section 3.2.5.2). As RNA 
templates, RNA samples from different CRC cell lines were pooled (SW837, SW1463, 
LS411N, SW480). To generate a standard curve, different RNA template concentrations (100 
ng, 10 ng, 1 ng and 0.1 ng) for each reaction mix were used. For determination of the primer 
efficiencies Cq cycles versus the log of starting quantity were automatically plotted to calculate 
the slope. The corresponding primer efficiencies were calculated according to the equation E= 
10[-1/slope] 171. The optimal primer efficiency was defined between approx. 90 and 110%. 
Melting curve analysis has to result in a single product-specific melting temperature without 
any additional peaks. Additional peaks can be a hint for primer-dimers that were generated 
during amplification cycles. The specificity of the primers was additionally checked using 
agarose gel electrophoresis (see section 3.2.5.2.2). If electrophoresis results in a single 
product (single band) with the desired length, the primes were used for further experiments. 
3.2.5.2.2 Agarose gel electrophoresis 
To separate DNA fragments by size agarose gel electrophoresis was used. For this 1% 
agarose gels were prepared in 1x TAE buffer. The agarose mix was heated to dissolve the 
agarose in the buffer. When the solution has cooled to 50-60 °C it was mixed with 4 µl gelRed® 
(nucleic acid dye) and poured it into the gel tray. Samples were mixed with one fifth of 6x DNA 
loading buffer and loaded onto the gel as well as a 100 bp DNA ladder to determine the size 
of the DNA Fragments. DNA fragments were separated at 120 V for 30 min. Afterwards, the 
dyed nucleic acids were visualized using a transilluminator. 
3.2.6 RNA sequencing analysis of CRC cells with or without Hy-IL-6 stimulation 
To silence the STAT3 expression, SW837 and SW1463 cells were transfected with either 
siRNA targeting STAT3 or a scrambled siRNA as negative control (siCtrl.) (see Tab. 24 for 
siRNA sequences), with three independent biological replicates. To rule out that siRNAs 
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obtained from different companies generate different experimental outcome and to minimize 
the possible variance between the replicate’s siRNAs obtained from two companies 
(Dharmacon and Qiagen) were used. The samples were treated either without further 
stimulation or incubation with 20 ng/ml Hy-IL-6 for 16 hours (for detailed transfection and 
stimulation protocol see section 3.2.4). After incubation, cells were washed with PBS and 
harvested for RNA analysis and Western blot analysis. 
The sequencing of total RNA samples was conducted at the NGS-Integrative Genomics 
Core Unit (NIG), University Medical Center Goettingen. Briefly, the quality and integrity of RNA 
were assessed with the Fragment Analyzer from Advanced Analytical by using the standard 
sensitivity RNA Analysis Kit (DNF-471). All samples selected for sequencing exhibited an RNA 
integrity number > 8. RNA-Seq libraries were generated using the TruSeq RNA library kit. 
Libraries were pooled and sequenced on the Illumina HiSeq 4000 (SE; 1 x 50 bp; 30-35 Mio 
reads/sample).  
RNA-Seq data were analyzed at the Core Facility, Medical Biometry and Statistical 
Bioinformatics, Department of Medical Statistics, University Medical Center Goettingen. 
There initial quality control steps (using FastQC; 172) the alignment of the reads to the human 
reference genome (assembly GRCh38) (using STAR version 2.5.2b; 173) and quality control on 
the input data and the alignment statistics (using Multiqc version v1.6. dev0; 174) were 
performed. In addition, they generated the transcription level quantifications (using ensemble 
annotation release 93 and the software RSEM version 1.2.19; 175) and edgeR (version 3.26.6; 
176) was used to model gene expression with transfection kit and the experimental conditions: 
stimulation, knockdown (KD), combined treatment (stimulation and KD) as factors. 
All results were summarized in tables displaying genes with effect size and significance 
annotation. The resulting P-values were adjusted for multiple testing using Benjamini-
Hochberg to control for the false discovery rate (FDR). 
Differentially expressed genes were identified for three conditions (siCtrl. vs. siCtrl. + Hy-IL-6; 
siCtrl. vs. siSTAT3; siCtrl. + Hy-IL-6 vs. siSTAT3 + Hy-IL-6) according to the FDR cut-off of 
0.01. The number of differentially up- and down-regulated genes was calculated and depicted 
as volcano plots. 
Venn diagram analysis and heatmaps were generated using web-based tools (Tab. 6). The 
sequencing data and abundance measurement files have been submitted to the NCBI Gene 
Expression Omnibus (GEO) under the accession number GSE139455. 
3.2.6.1 Opposite Direction analysis 
To filter the resulting gene lists more stringently a new way to analyze these lists was 
established in this study. The Opposite Direction analysis (ODA) identified genes that were 
significantly upregulated (FDR cut-off 0.01) upon Hy-IL-6 stimulation of cells and, inversely, 
downregulated upon STAT3 silencing or vice versa. 
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3.2.7 Protein biochemistry  
3.2.7.1 Preparation of total cell extracts for Western blot analysis 
Total cell extracts were prepared from CRC cells to investigate the expression of various 
proteins by Western blotting. Before lysis, the medium was discarded, and cells were washed 
once with ice-cold PBS. Afterward, 150 µl of NP-40 lysis buffer (for detailed composition see 
section 3.1.7.1 and Tab. 9 -10) were used per 1 x 106 million cells. For lysis, the cells were 
scraped, and the cell lysate was transferred to a 1.5 ml reaction tube which was incubated for 
45 min on ice. The lysate was centrifuged at 10,000 rpm at 4°C for 10 min to eliminate cell 
debris (cell debris = pellet). The total cell extracts (supernatant) used for Western blot analysis 
were subsequently mixed with one fourth of 5x sample buffer (for detailed composition see 
Tab. 19) and boiled for 5 min at 95 °C. The samples were either stored at -20°C or were directly 
used for SDS-PAGE. 
3.2.7.2 Isolation of purified proteins from three cellular fractions: cytosol, nucleus, and 
chromatin  
Protein extracts from cytosol, nucleus and chromatin were prepared from CRC cells to 
investigate the expression of various proteins in different cellular compartments by western 
blotting. Before lysis, the medium was discarded, and cells were washed once with ice-cold 
PBS. Afterwards, 500 µl per well (6-well plate) of buffer A (for detailed composition see section 
3.1.7.1 and Tab. 13) were added directly to the cells. After 5 min incubation on ice, cells were 
scraped and transferred to a 1.5 ml reaction tube. Cells were subsequently centrifuged at 1,500 
g for 5 min at 4°C. The supernatant (contains the cytoplasmic protein fraction) was transferred 
into a new 1.5 ml reaction tube. The pellet (contains nuclei) was washed with buffer A by light 
tapping. Subsequently, 200 µl of buffer B (for detailed composition see 3.1.7.1 and Tab. 14) 
was added to the pellet, the lysate was incubated for 30 min on ice following centrifugation at 
2,000 g for 5 min at 4º C. The supernatant (containing the soluble nuclear fraction) was 
transferred into a new 1.5 ml reaction tube. The pellet (containing the insoluble chromatin 
fraction) was mixed with additional 200 µl of buffer B and sonicated (time: 10 sec., Amplitude 
42%, pulse 000.5 s/000.5 s). All lysates (cytoplasmic, soluble nuclear and insoluble chromatin 
fraction) used for Western blot analysis were subsequently mixed with one fourth of 5x sample 
buffer (for detailed composition see Tab. 19) and boiled for 5 min at 95 °C. The samples were 
either stored at -20°C or were directly used for SDS-PAGE.  
3.2.7.3 Preparation of total cell extracts for EMSA experiments 
Preparation of total cell extracts was required for EMSA experiments. Before lysis, the 
medium was discarded, and cells were washed once with ice-cold PBS. Afterward, cells were 
incubated with 50 µl cytoplasmic extraction buffer per well (6-well plate) (for detailed 
composition see section 3.1.7.2 and Tab. 15-16) on ice for 5 min. Afterwards, they were 
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harvested using a cell scraper and transferred to a 1.5 reaction tube. The extracts were 
centrifuged at 16,000 g for 15 sec at 4°C. The supernatant (containing the cytosolic protein 
fraction) was transferred into a new 1.5 reaction rube and centrifuged again for 15 sec at 4°C 
and 16,000 g. The resulting supernatant was collected and placed on ice. Subsequently, the 
pellet was incubated with 50 µl nuclear extraction buffer (for detailed composition see 3.1.7.2 
and Tab. 17-18) on ice for 30 min following centrifugation for 15 min at 4°C at 16,000 g. The 
supernatant (containing the nucleic protein fraction) was transferred to a 1.5 ml reaction tube. 
Finally, the cytosolic protein fraction was mixed with the same amount of nucleic protein 
extraction. The protein extracts were stored at -80°C until further use. 
3.2.7.4 Protein extraction of tumor samples 
Protein extracts of tumor samples were prepared to investigate the expression of various 
proteins by Western blotting. Depending on the weight of the tumors, the amount of RIPA 
buffer (for detailed composition see section 3.1.7.1 and Tab. 11-12) was determined: 20 µl 
RIPA buffer per 1 mg tumor. For lysis, the calculated amount of RIPA buffer was added 
together with one stainless steel bead to each sample. Tissues were lysed using a Tissuelyser 
(program: 3’ 50 Hz, 2’ 40 Hz). Thereafter, beads were removed, and the samples were 
incubated for 10 min on ice before they were sonicated (time: 10 sec., amplitude 42%, pulse 
000.5 s/000.5 s). After sonication, lysates were incubated on ice for 10 min following 
centrifugation for 20 min at 10.000 g. The supernatant was transferred into a new 1.5 ml 
reaction tube and was subsequently mixed with one fourth of 5x sample buffer (for detailed 
composition see Tab. 19) and boiled for 5 min at 95 °C. The samples were either stored at -
20°C or were directly used for SDS-PAGE. 
3.2.7.5 Protein concentration determination 
3.2.7.5.1 Protein determination according to Bradford 
The binding of the Bradford dye to proteins causes a shift in the absorption maximum of the 
dye from 465 to 595 nm. This increased absorption at 595 nm could be measured 
spectroscopically and used to determine the protein concentration of samples 177.  
First, a BSA standard series was prepared with concentrations ranging from 0 to100 μg/ml 
BSA. This series was used to quantify the amount of protein in each sample and to subtract 
any background. The protein samples were diluted 1:50 in ddH2O before measurement. 50 μl 
of each standard dilution and the dilution solutions of the samples were pipetted into a 96-well 
microtiter plate as technical replicates. Subsequently, 200 μl Roti®-Quant (2:5.5) was added 
to each well. After 5 min incubation at RT the optical density of the protein solution at an 
absorbance of 595 nm was measured using Victor™ X4 Multilabel Plate Reader. The Protein 
concentrations of the unknown samples were calculated using the slope of the regression line. 
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3.2.7.5.2 Protein determination according to the Bicinchoninic acid assay 
The Bicinchonic acid assay (BCA) was developed by Paul K. Smith (Measurement of 
Protein Using Bicinchoninic Acid, 1985). It is based on the conversion of Cu2+ to Cu+ under 
alkaline conditions. The Cu+ is then detected by reaction with BCA (The Bicinchoninic Acid 
(BCA) Assay for Protein Quantitation John M. Walker). By adding bicinchoninic acid it chelates 
with the Cu+ ion, forming a purple-coloured product that strongly absorbs light at a wavelength 
of 562 nm, which is proportional to the amount of protein in each sample. 
The assay is suitable to determine the protein concentration after RIPA buffer-based Protein 
lysis. The Pierce® Bicinchoninic Acid Assay (BSA) protein Assay Kit was used according to the 
manufacturer’s instructions. Briefly, a BCA standard series was prepared with concentrations 
ranging from 0 to 2,000 μg/ml BSA. This series was used to quantify the amount of protein in 
each sample and to subtract any background. The protein samples were diluted 1:20 in ddH2O 
before measurement. 25 μl of each standard dilution and the dilution solutions of the samples 
were pipetted into a 96-well microtiter plate as technical replicates. Subsequently, 200 μl of 
premixed working reagent (1:5) was added to each well. The plate was incubated for at least 
30 min, at 37°C in the dark. Afterward, the optical density of purple-coloured product at an 
absorbance of 562 nm was measured using Victor™ X4 Multilabel Plate Reader. The protein 
concentrations of the unknown samples were calculated using the slope of the regression line. 
3.2.7.6 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate denatured and reduced proteins according to their molecular weight due to a 
polyacrylamide gel. Large proteins move slower through the electric field than small proteins. 
Samples were loaded onto a (10% or 7.5%) polyacrylamide stacking gel and were afterwards 
separated in a 10% polyacrylamide resolving gel (preparation and composition of gels see 
Tab. 21). In addition, 2 µl of prestained protein ladder was added to each gel to estimate the 
size of each band. The separation was performed using gel chambers filled with 1 x SDS-
PAGE running buffer (for detailed composition see section 3.1.7.3) at 20 mA/gel for 
approximately 2 hrs. 
3.2.7.7 Semi-dry Western Blot 
For identification of proteins with specific antibodies, separated proteins were transferred 
onto a PVDF membrane using a semi-dry western blot system. The PVDF membrane was 
activated using 100% methanol. The membrane together with the gel and six Whatman paper 
were equilibrated in 1x Western blot transfer buffer (for detailed composition see section 
3.1.7.3). The membrane was placed on top of three Whatman papers. The gel was placed on 
the membrane and three Whatman paper were put on top of the gel. The transfer was 
conducted at 1 mA per cm2 of membrane for 1 h.  




Following protein transfer, membranes were incubated for 1 h in blocking solution (for 
composition see Tab. 19) to block unspecific protein binding sites for antibodies. Afterwards, 
membranes were washed three times (in total 15 min) with TBST buffer (for detailed 
composition see section Tab. 19) and incubated with the respective primary antibody (for 
details see Tab. 22) over night at 4 °C continuously shaking. 
On the next day, membranes were washed thrice in TBST buffer for 5 min each to eliminate 
any unbound antibodies. Afterwards, membranes were incubated with horse-radish 
peroxidase (HRP) conjugated secondary antibodies, that detect the constant region (Fc region) 
of the respective primary antibodies (for details see Tab. 23) for 2 h at RT. The antibody-tagged 
protein bands were detected by addition of 100 µl HRP Substrate (ECL solution), which was 
converted by HRP on secondary antibodies in proportion to the number of bound antibodies. 
The detection was performed by the CCD camera ImageQuant LAS4000 mini.  
3.2.8 Functional in vitro assays  
3.2.8.1 Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay (EMSA) was used to assess the DNA binding ability of 
STAT3 and was performed, as described in 178. Note that the EMSA experiment was performed 
in close cooperation with Prof. Dr. mult. Thomas Meier (Department of Psychosomatic 
Medicine and Psychotherapy, German Centre for Cardiovascular Research, Georg-August 
University, 37073 Goettingen, Germany). Briefly, SW837 cells grown on 10 cm dishes were 
either stimulated with 20 ng/ml Hy-IL-6 for 30 min or left untreated. Whole-cell extracts were 
prepared as described in section 3.2.7.3. Lysates of unstimulated or IFNγ stimulated HeLa 
cells were used as positive control for GAS binding (stimulated with 50 ng/ml for 30 min). For 
The sequences of the control probe M67, the native and the mutated RBPJ fragment were 
listed in Tab. 28. [33P]-labelled duplex oligonucleotide probes with 5 bp T overhangs at their 
5' end, were generated by an end-filling reaction catalyzed by the Klenow fragment. For the 
end-filling reaction the following substances were mixed and were incubated for 25 min at RT. 
 
Table 39 Composition of the end-filling reaction for EMSA 
Substances Concentration/amount 
Klenow fragment 5 units 
10 x Eco-Pol buffer 5 µl 
Annealed oligonucleotides  0.1 ng  
[33P]-labelled ATP 8 µl 
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After incubation, an excess of non-radioactive dNTPs (6.5 mM od each dNTP) was added, 
and the reaction mix was incubated for 5 min at RT. The reaction was stopped by addition of 
1 µl of 0.5 mM EDTA solution. Free nucleotides were removed by centrifugation at 700 xg for 
3 min at RT using an Illustra-MicroSpin-G-25 column. For competition experiments, a 750-fold 
molar excess of unlabeled native RBPJ was added to the reaction and incubated for 15 min at 
room temperature. 4 µl of cellular extracts were incubated with 8 µl of EMSA reaction buffer 
containing 1 ng of the 33P-labelled probes. Afterwards the samples were loaded onto 
equilibrated non-denaturing 8% TBE- acrylamide: bisacrylamide gels (29:1) which consists of: 
12% Rotiphorese, 2.4% TBE buffer, 2% APS and 0.2% TEMED. Electrophoretic separation 
was conducted at 400 V in 0.25x TBE buffer. Later, the DNA-binding activity was visualized on 
vacuum-dried gels (gel was pressed against Whatman paper and was than vacuum-dried) 
using a laser phosphoimaging system (Typhoon FLA 9500) including the TINA software. 
3.2.8.2 Colony Formation Assay 
The effect of diverse pathway perturbations on sensitivity to RT and/or CRT was tested 
using a colony formation assay (CFA), as standard in the field 147,179. The colony formation 
assay was specifically used to determine the capacity of cells to form colonies under different 
treatments. A colony is defined as an accumulation of at least 50 cells 179. In general, cells 
were seeded and allowed to adhere for approximately 8 hrs. For CRT experiments, cells were 
pre-incubated with 3 μM of 5-FU overnight and subsequently irradiated at 1, 2, 4, 6, and 8 Gy 
of X-rays. For RT, cells were subsequently irradiated (0, 1, 2, 4, 6, 8 Gy) 24 h after seeding. 
For pre-treatments Napabucasin was administered for 1 h, Hy-IL-6, Tocilizumab or 
Ruxolitinib for 16 h and DAPT for 24-72 h (Figure 3.2 A) prior irradiation. For RNA Interference 
studies the cells were transfected with either control siRNA or siRNA targeting the respective 
protein. After cell line specific incubation time (Tab. 35) cells were treated with or without 5-FU 
prior to irradiation (Figure 3.2 B). In combination experiments, the cells are first transfected 
with respective siRNA and then treated with the appropriate inhibitor (Figure 3.2 C). 
Followed irradiation, the medium was replaced with fresh medium to eliminate 5-FU, and 
all other substances. After cell line-specific incubation times (12-19 days), colonies were 
stained with Mayer’s hemalum solution, counted, and analyzed according to Franken et al. 179. 
Only colonies consisting of at least 50 cells were included into the evaluation. For 
determinationthe colony forming capacity, all fractions were normalized to the plating efficiency 
(PE) of the 0 Gy control plate. The PE is the ratio of number of counted colonies to the number 
of seeded cells 179. 
𝑃𝐸 [%] =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑓𝑜𝑟𝑚𝑒𝑑 (0 𝐺𝑦)
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑒𝑒𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 (0 𝐺𝑦)
∗  100 % 
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After determination of the plating efficiency, surviving fractions (SF) were calculated by 
using following equation 179: 
𝑆𝐹 [%] =  
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑎𝑓𝑡𝑒𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 (𝑥 𝐺𝑦)
𝑠𝑒𝑒𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 (𝑥 𝐺𝑦) ∗ 𝑃𝐸
 
For analysis, SF data were viewed dependent on the irradiation dose and additionally fit by 
linear regression 179. Confidence intervals and R2 change are included in the regression.  
Figure 3.2 Experimental flow for CFA experiments after different treatments. 
A| - C| Schematic treatment protocol for CFAs with indicated substances and incubation times either for 
stimulants and inhibitors (A), siRNAs (B) or a combination of both (C). 
 
Details for transfection are listed in Tab. 36 and described in section 3.2.4. In addition, detailed 
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Table 40 Detailed conditions for CFA experiments 
Cell line Treatment Incubation time Cell number 
   0, 1, 2 
Gy 
4 Gy 6 Gy 8 Gy 
LS411N 
siCtrl. / siSTAT3 72 h* 500 1,000 1,500 2,000 
DMSO / Napa 1 h 500 1,000 1,500 2,000 
Hy-IL-6 16 h 500 1,000 1,500 2,000 
Toci 16 h 500 1,000 1,500 2,000 
DMSO/ Ruxo 16 h 500 1,000 1,500 2,000 
STAT3-WT 24 h* 500 1,000 1,500 2,000 
STAT3-Y705F 24 h* 500 1,000 1,500 2,000 
STAT3-S705A 24 h* 500 1,000 1,500 2,000 
STAT3-
Y705F/S727A 
24 h* 500 1,000 1,500 2,000 
siRBP + DMSO 48 h* 500 1,000 1,500 2,000 
siCtrl. + DAPT 48 h* 500 1,000 1,500 2,000 
DMSO / DAPT 48 h* 500 1,000 1,500 2,000 
siRBPJ + DAPT 48 h* 500 1,000 1,500 2,000 
SW837 
siCtrl. / siSTAT3 96 h* 750 1,500 2,250 3,000 
siCtrl. / siRBPJ 72 h* 750 1,500 2,250 3,000 
siCtrl. / siSTAT3 + 
siRBPJ 
96 h* 750 1,500 2,250 3,000 








siCtrl. + DMSO 96 h* / 1 h* 750 1,500 2,250 3,000 
siSTAT3+ DMSO 96 h* / 1 h* 750 1,500 2,250 3,000 
siCtrl. + Napa 96 h / 1 h 1,500 3,000 4,500 6,000 
siSTAT3 + Napa 96 h / 1 h 1,500 3,000 4,500 6,000 
Hy-IL-6 16 h 750 1,500 2,250 3,000 
Toci 16 h 750 1,500 2,250 3,000 
DMSO / Ruxo 16 h +750 1,500 2,250 3,000 
DMSO / DAPT 72 h 750 1,500 2,250 3,000 
siRBPJ + DMSO 72 h* 750 1,500 2,250 3,000 
siCtrl. + DAPT 72 h* 750 1,500 2,250 3,000 
siRBPJ + DAPT 72 h* 750 1,500 2,250 3,000 
SW1463 
siCtrl. / siSTAT3 72 h† 750 1,500 2,250 3,000 








Hy-IL-6 16 h 750 1,500 2,250 3,000 
Toci 16 h 750 1,500 2,250 3,000 
DMSO / Ruxo 16 h 750 1,500 2,250 3,000 
siCtrl. / DMSO 72 h† 750 1,500 2,250 3,000 
siRBPJ + DMSO 72 h† 750 1,500 2,250 3,000 
siCtrl. + DAPT 72 h† 750 1,500 2,250 3,000 
siRBPJ + DAPT 72 h† 750 1,500 2,250 3,000 
STAT3-WT = expression vector for wild-type STAT3, STAT3-Y705F = expression vector for mutated STAT3 
(mutated at tyrosine 705), STAT3-S727A = expression vector for mutated STAT3 (mutated at serine 727), STAT3-
Y705F/S727A = expression vector for mutated STAT3 (mutated at tyrosine 705 and serine 727), * = Nucleofection, 
† = lipid-based transfection 
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3.2.8.3 Using Dual luciferase reporter assay to determine STAT3 transcriptional activity 
after different treatments. 
For determination of the STAT3 transcription factor activity under different pathway 
perturbation, a dual luciferase reporter assay (DLR) was performed. Therefore, the Cignal 
Reporter Assay Kit (used for SW837 cells) and the Dual-LuciferaseVR Reporter Assay System 
(used for LS411N and SW1463 cells) were used according to the manufacturers’ instructions 
and as described in 147. 
In the DLR assay, the activities of Firefly and Renilla luciferase were measured. The used 
DLR system contains two reporter plasmids each coding for a luciferase to measure 
transcriptional activity. One of those plasmids’ drives the expression of Renilla luciferase (Ren-
Luc), fused to a constitutive active promoter (Fig. 3.3 A, left panel), which cause Renilla 
luciferase to be expressed in all cells unregulated. Moreover, the expression of Renilla 
luciferase served as a transfection efficiency control and for normalization (Farr and Roman, 
1992). The other plasmids allow for the expression of Firefly-luciferase driven in the presence 
(Fig. 3.3 A, middle panel) or absence (Fig. 3.3 A, right panel) of the STAT3 transcriptional 
response element (Ctrl. -Luc or STAT3-Luc, respectively). Ctrl. -Luc allows for further 
normalization of STAT3-regulated expression of Firefly-luciferase. Ren-Luc was co-
transfected with either Ctrl. -Luc or STAT3-Luc into untreated or previously treated STAT3-
wild-type (WT) cells (Fig. 3.3 B). 
Figure 3.3 Principle of DLR assays. 
A| DLR assays based on two different luciferase reporter plasmids. One of those plasmids’ codes for 
Renilla luciferase (Ren-Luc), fused to a constitutive active promotor (left panel). Whereas the other 
plasmid codes for Firefly luciferase either under the control of an STAT3 binding domain (STAT3-Luc) 
or as a control without expression regulating binding domain (Ctrl. -Luc). B| Cells were co-transfected 
with Ren-Luc reporter plasmid together with either STAT3-Luc (left panel) or Ctrl. -Luc (right panel). 
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The standard DLR protocol was adapted individually for each CRC cell line (LS411N, 
SW1463 and SW837) (Figure 3.4). All details including inhibitor incubation times, individual 
cell numbers per well, transfection methods and amount of transfected DNA were listed in Tab. 
41. A detailed description of the different transfection methods is provided in section 3.2.4.  
To determine the impact of different treatments on STAT3 transcriptional activity, WT LS411N 
was washed with PBS, detached using 0.5% Trypsin-EDTA solution, counted, and seeded into 
12-well plates. After serum starvation, cells were co-transfected with the reporter plasmids 
(Ren-Luc + STAT3-Luc or Ren-Luc + Ctrl. -Luc, respectively). 24 h after lipid-based 
transfection cells were stimulated with indicated substances (Tab. 35) (Figure 3.4 A, upper 
panel). SW837 cells were co-transfected with reporter plasmids using nucleofection and 
seeded into 12-well plates. 24 h after transfection medium was exchanged. After additional 48 
h, cells were treated with indicated substances (Tab. 35) (Figure 3.4 A, middle panel). 
SW1463 WT cells were seeded into 12-well plates. 24 h after seeding, cells were transfected 
with reporter plasmids. After additional 24 h cells were treated as indicated (Tab. 35) (Figure 
3.4 A, lower panel). 
For Ruxolitinib, Tocilizumab and Napabucasin studies cells were additionally stimulated with 
rhIL-6 for 16 h before lysis. 
To analyze the STAT3 transcriptional activity after siRNA treatment, LS411N cells were 
firstly transfected with the indicated siRNAs. After 24 h of serum starvation, cells were co-
transfected with reporter plasmids (Figure 3.3 B, upper panel). SW837 cells were co-
transfected with respective siRNAs and reporter plasmids (Figure 3.3 B, middle panel). 24 h 
after transfection, the medium was changed. SW1463 cells were transfected with the indicated 
siRNAs using a lipid-based transfection system (Figure 3.3 B, lower panel). 24 h after first 
lipid-based transfection, cells are transfected again with the reporter plasmids. 
24 h after transfection, all cells were stimulated with rhIL-6 for 16 h before lysis. 
Afterwards, cell lysis was performed using a passive lysis buffer. Samples were frozen in 
nitrogen and subsequently stored at -80°C until further use. The light units of firefly luciferase 
reporter were first measured by adding 100 µl Luciferase Assay Substrat (LARII) to each well 
(96-well plate) with 20 µl of each sample. After the firefly luminescence was quantified, the 
reaction was quenched, and at the same time the Renilla luciferase reaction was 
simultaneously initiated by adding 100 µl Stop&Glo Reagent (1:50, included in the kit) to each 
well. 
Since each sample was measured in technical triplicates, mean values were calculated, 
and the blank value (only medium) was deducted from all measured samples to eliminate any 
background. For normalization, the ration of the Firefly light units to Renilla light units was 
calculated for each sample (“Firefly- light units / Renilla- light units”). Based on these 
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normalized values, the Hyper-IL-6-induced STAT3 activity of otherwise untreated cells was 
calculated as the ratio of STAT3-Luc to Ctrl. -Luc ("Ratio STAT3-Luc/Ctrl. -Luc"). The specific 
STAT3 transcriptional reporter activities of siRNA-treated cells or cells treated with Ruxolitinib, 
Tocilizumab and Napabucasin were calculated by further normalization to Ctrl. -Luc values of 
untreated and treated cells resulting in the ratio termed "normalized STAT3 activity“. 
Figure 3.4 Experimental flow for DLR experiments after different treatment. 
A| and B| Schematic treatment protocol for DLR assays with indicated substances and incubation times 
either for LS411N cells (upper panels), SW837 cells (middle panels) and SW1463 cells (lower panels) 
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Table 41 Detailed conditions for DLR assay 
Cell line Treatment Incubation time Cell number  Reporter DNA 
LS411N 
siCtrl. vs. siSTAT3 * 96 h 
200,000 1 µg / 1 µg / 0.1 ng 
DMSO vs. Napa 1 h 
Hy-IL-6 16 h 
Toci 16 h 
DMSO vs. Rux0 16 h 
SW837 
siCtrl. vs. siSTAT3 † 
DMSO vs. Napa 
Hy-IL-6 
Toci 







0.5 µg / 0.5 µg / 12.5 ng 
0.25 µg / 0.25 µg / 6.25 ng 
0.5 µg / 0.5 µg / 12.5 ng 
0.25 µg / 0.25 µg / 6.25 ng 
0.25 µg / 0.25 µg / 6.25 ng 
SW1463 
siCtrl. vs. siSTAT3 
DMSO vs. Napa 
Hy-IL-6 
Toci 






100,000 0.5 µg / 0.5 µl / 5 ng 
Reporter DNA: Ctrl. -firefly luciferase / STAT-firefly luciferase / Renilla luciferase; * Transfection with X-
tremeGENE HP, 2 µl lipid; † Transfection with Nucleofection (Amaxa), V-Kit, T-30; § Transfection with X-
tremeGENE HP, 0.5 µl lipid. 
 
3.2.8.4 Cellular viability assay 
Cellular viability was determined using CellTiter-Blue® (CTB) assay. This assay is based on 
the ability of living cells to reduce resazurin (redox dye) to resorufin (fluorescent end product). 
Resazurin is a redox indicator used to monitor viable cells with active metabolism. Non-viable 
cells lose their metabolic capacity and do not reduce resazurin into resorufin. The amount of 
resorufin is proportional to the number of viable cells 180. 
For details (experiment, treatment, incubation time, cell number, transfection reagent and 
amount of lipid) see Tab. 42. In this study the cellular viability of CRC cells following inhibitor 
treatment or genetic modification using siRNAs was measured. For inhibitor treatment, cells 
were cultivated in their respective medium and were seeded as triplicates into 96-well plates. 
24 h after seeding cells were treated with respective inhibitors. For RNA interference studies 
cells were transfected with siCtrl. or siSTAT3 (detailed description of lipid-based transfection 
is provided in section 3.2.4.2) and were seeded afterward as triplicate into 96-well plates. After 
specific incubation times 11 µl of resazurin (1:10) was added to each well. The 96-well plate 
was covered and incubated for 1 h at 37°C prior measurement. The reduction of resazurin to 
resorufin was measured at 595 nm emission wavelength using a plate reader according to the 
manufacturer’s instructions. The signal intensity of treated cells was calculated relative to the 
untreated control cells. A viability of at least 80% was required to continue working with the 
tested substances. 
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Table 42 Detailed conditions for CTB assay 
Cell line Treatment Incubation time Cell number 
LS411N 
siCtrl. vs. siSTAT3* 24 h / 48 h / 72 h / 96 h 5,000 
DMSO vs. Napa 1 h / 8 h / 24 h / 48 h 5,000 
Toci 1 h / 24 h / 48 h / 72 h 5,000 
DMSO vs. Ruxo 1 h / 24 h / 48 h / 72 h 5,000 
DMSO vs. DAPT 24 h / 48 h / 72 h 5,000 
SW837 
siCtrl. vs. siSTAT3† 24 h / 48 h / 72 h / 96 h 6,000 
DMSO vs. Napa 1 h / 8 h / 24 h / 48 h 6,000 
Toci 1 h / 24 h / 48 h / 72 h 6,000 
DMSO vs. Ruxo 1 h / 24 h / 48 h / 72 h 6,000 
DMSO vs. DAPT 1 h / 24 h / 48 h / 72 h 6,000 
DMSO vs. DAPT 24 h / 48 h / 72 h 6,000 
SW1463 
siCtrl. vs. siSTAT3§ 24 h / 48 h / 72 h / 96 h 5,000 
DMSO vs. Napa 1 h / 8 h / 24 h / 48 h 5,000 
Toci 1 h / 24 h / 48 h / 72 h 5,000 
DMSO vs. Ruxo 1 h / 24 h / 48 h / 72 h 5,000 
DMSO vs. DAPT 24 h / 48 h / 72 h 5,000 
* Transfection with BioRad SiLentFect, 0.2 µl lipid; † Transfection with RNAiMAX, 0.2 µl lipid; § 
Transfection with RNAiMAX, 0.1 µl lipid 
 
3.2.9 Statistics 
P-values and FRD-values < 0.05 were considered significant. The significance was 
depicted as: n.s.; *P < 0.05; **P < 0.01; ***P < 0.001. Statistical analysis was performed using 
Microsoft Excel software Add-in “Data Analysis” and GraphPad Prism software. For data 
analysis of CFA experiments, analysis of variance (ANOVA) was used to calculate significant 
differences between control and treatment groups with the use of ANOVA: Two-Factor with 
Replication. For visualization, data were presented as mean and standard error of the mean 
(s.e.m.) from at least three independent experiments using the software KaleidaGraph. 
Statistical analyses of DLR activity and CTB measurements were performed using an unpaired 
two-tailed Student's t-test in Microsoft Excel and visualized in Grapher. For qPCR analysis the 
medians of the resulting cycle threshold (Ct) values were normalized to the housekeeping gene 
HPRT1 and relative gene expression changes were calculated according to the 2-ΔΔCT 
algorithm. P-values were calculated using an unpaired two-tailed Student's t-test in Microsoft 
Excel and visualized in Grapher. Pearson's correlation was used to calculate P-values for 
correlation of qPCR and RNA-Seq data. Statistical tests of tumor volume were performed in 
GraphPad Prism (version 8), mixed-effects analysis using Tukey's multiple comparisons test. 
A Log-rank (Mantel-Cox) test was performed to generate P-values of Kaplan-Meier curves. 
 




This study is focused on the molecular mechanisms of STAT3-controlled CRT resistance 
of CRC cells to obtain a better understanding of the intrinsic therapy resistance. 
One of the major obstacles for a successful treatment response is due to the appearance of 
tumor cell resistance to CRT. This resistance is a fundamental problem because affected 
patients do not benefit from this treatment but nonetheless are afflicted with adverse side 
effects of cytotoxic therapies and irradiation. Therefore, from a clinical perspective, one goal is 
to improve sensitivity to CRT and thereby reduce unnecessary side effects. Unfortunately, the 
molecular mechanisms underlying CRT resistance remain complex and have not yet been 
sufficiently clarified. In recent studies, my host research group suggested a potential role of 
STAT3 in mediating CRT resistance in CRC cell lines. They described variable sensitivity of 
CRC cells treated with 5-FU-based CRT and 2 Gy irradiation as well as a positive correlation 
between CRC cell-intrinsic expression of STAT3 and CRT unresponsiveness 162. 
4.1 CRT resistance is controlled by active gp130 signalling and susceptible to 
pathway perturbations 
In order to check if STAT3 protein levels are functionally relevant for mediating CRT 
resistance, we have subsequently inhibited or activated STAT3 itself or STAT3 pathway 
components. Direct inhibition of STAT3 was induced by genetic inhibition using RNAi or by 
using direct STAT3 inhibitors. Indirect inhibition was achieved on STAT3 pathway components 
using various inhibitors, some of which are already in clinical application. In addition, 
experiments were performed in which STAT3 activity was either induced by using a fusion 
protein or reconstituted in STAT3-deficient cells. 
The experiments were conducted in collaboration with Melanie Spitzner (CALL, University 
Medical Center Göttingen) assisted by Florian Krause and Gigi Ton (CALL, University Medical 
Center Göttingen). Since we were most interested in the role of STAT3 in mediating CRT 
resistance we choose three MSS (Cancer genome atlas 2020) cell lines based on their STAT3 
expression as appropriate model cell lines. We used LS411N cells as negative control because 
of their STAT3-deficiency and their described sensitivity to CRT 162. Furthermore, SW1463 and 
SW837 cells were used as rectal cancer cell lines with STAT3 expression and high resistance 
to CRT 162. 
4.1.1 Transcriptionally active STAT3 drives CRT resistance 
To achieve a temporal STAT3 KD in LS411N, SW837 and SW1463 cells, we used siRNAs 
targeting STAT3. To determine the optimal STAT3 KD time points after RNAi treatment, we 
performed time series in the range of 24 - 96 hours. The assessment of whether the 
transfection and STAT3 KD was successful was performed by Western blot comparing the 
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expression levels of STAT3 and pSTAT3Y705 in the siRNA-treated cells with a control (siCtrl.) 
(Appendix, Fig 8.1). In addition, alteration of the cellular viability of the cells after RNAi 
treatment were excluded using CTB assay (Appendix, Fig 8.3). 
To test whether STAT3 protein levels are functionally relevant for CRT-resistance, STAT3 
was silenced in LS411N, SW837 and SW1463 cell lines using RNAi for 96 h, and 72 h, 
respectively. RNAi-mediated silencing of STAT3 was analyzed using Western blot analysis 
with antibodies detecting STAT3, pSTAT3Y705 and Actin as loading control (Fig. 4.1, upper left 
panels). Reduced STAT3 reporter activity was measured using DLR assay (Fig. 4.1, upper 
right panels). Additionally, cells were CFA-cultured to measure their survival following 
irradiation in the presence of 5-FU. Silencing of STAT3 significantly increased the sensitivity 
of SW1463 and SW837 cells to CRT whereas the sensitivity of LS411N was not changed (Fig. 
4.1, lower panels).  
Figure 4.1 siRNA-mediated silencing of STAT3 results in a sensitization to CRT in STAT3 
expressing cells. 
Indicated cells treated with siRNA against STAT3 or control siRNA (siCtrl.) were analyzed for inducible 
phosphorylation or expression of STAT3 by immunoblotting (upper left)71 or monitored for inducible 
STAT3 transcriptional activity (upper right) or were colony formation assay (CFA)-cultured to measure 
their survival following irradiation in the presence of 5-FU (lower graph) 71. Data presented as mean ± 
s.e.m. from at least n=3 independent biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired 
two-sample Student's t-test or two-way analysis of variance (ANOVA).  
 
Next, we tested whether the gain of STAT3 activity converts CRT-sensitive LS411N cells 
into CRT-resistant cells. LS411N cells were reconstituted with either WT STAT3, or signalling-
inactive versions of STAT3 in which critical tyrosine and/or serine phosphorylation sites were 
inactivated by replacement with phenylalanine or alanine, respectively (S727A, Y705F, 
Y705F/S727A). The exchange with alanine and phenylalanine mimicked a constitutive 
dephosphorylation 181 of the STAT3 protein and allows to study the necessity of individual 
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phosphorylation sites. The expression of the different STAT3 versions was analyzed via 
immunoblotting (Fig. 4.2, upper left panel). Expression of WT and S727A-STAT3 version, but 
not Y705F- and Y705F/S727A-STAT3 variants, restored STAT3 transcriptional activity 
measured using DLR assay (Fig. 4.2, upper middle panel). Importantly, the presence of WT 
STAT3 increased clonogenic survival after 5-FU-based CRT (Fig. 4.2, upper right panel), while 
expression of all signalling-inactive mutants did not (Fig. 4.2, lower panels).  
Figure 4.2 Expression of wild-type STAT3 increases the CRT resistance in STAT3-negative 
LS411N cells. 
LS411N cells were transfected with empty control vector (Ctrl.) or constructs encoding HA-tagged 
versions of wild-type STAT3 or STAT3 variants harboring indicated amino acid exchanges. Expression 
and phosphorylation of STAT3 proteins (upper left), their transcriptional activity (upper middle), or CFA 
survival of wild-type-reconstituted cells (upper left) as well as CFA survival of STAT3 variants (lower 
panels) compared to control cells were monitored after irradiation with the indicated doses (Gy) in the 
presence of 5-FU (CRT) 71. Data presented as mean ± s.e.m. from at least n=3 independent biological 
replicates. Experiments were performed by Florian Krause (medical student), CALL, under permanent 
supervision. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-sample Student's t-test or two-way 
analysis of variance (ANOVA).  
 
These data revealed a direct contribution of signalling active STAT3 to CRT resistance and 
underlines the necessity of a functional Y705 phosphorylation site. In order to elucidate the 
impact of STAT3 in the resistance of CRC cells, Spitzner et al. initially examined the expression 
of STAT3 and pSTAT3Y705 in human CRC cell lines. However, there was no phosphorylation 
of STAT3 at the activating tyrosine residue 705 in 10 out of 12 CRC cell lines. Hence, STAT3 
was not constitutively active in vitro 147. This strongly indicated an input of upstream regulatory 
signals that activated the JAK/STAT signalling pathway. 
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In the next section we focused on potent activators of STAT3, like inflammatory cytokine 
receptors such as the receptor for IL-6. Elevated levels of serum IL-6 and sIL-6R were detected 
in patients with i.e., CRC 125 that coincide with surgery, chemo- and radiotherapy 127. Moreover, 
IL-6 is known to play various roles in cancer including metastasis of CRC 124. IL-6 binds to 
membrane bound IL-6R or to soluble sIL-6R. Subsequently, the non-signalling IL-6/IL-6R or 
IL6/sIL-6R complexes bind to the ubiquitously expressed gp130 domain (Fig. 4.3 A) (Fig. 2.4 
B), leading to gp130-homodimer formation and finally to the signal initiation 129. Signal initiation 
leads to the activation of JAK that phosphorylates STAT3 119,127,135,149-151.  
Expanding on this, we aimed to explore the possible effect of gp130/JAK/STAT3 axis 
activation on CRT resistance. To this end, we used the designer fusion protein Hy-IL-6 which 
consisting of IL-6 and the soluble IL-6 receptor chain and therefore mimics IL-6 trans-signalling 
130,182,183. To assess the influence of the Hy-IL-6 induced gp130 signalling cascade on CRT 
resistance, SW837, SW1463 cells as well as LS411N cells were treated with Hy-IL-6. 
Stimulation resulted in a strong inducible phosphorylation of STAT3 at the critical tyrosine 
phosphorylation sites (Y705) in SW837 and SW1463 cells but not in STAT3-deficient LS411N 
cells, compared to unstimulated cells (Fig. 4.3 B, upper right, middle, and left panel). In 
addition, total STAT3 levels remain unaffected. Furthermore, the stimulation of SW837 and 
SW1463 increased STAT3 transcriptional activity measured using DLR assay (Fig. 4.3 B, 
upper left panels) that translates into increased CFA survival in the presence of 5-FU and 
irradiation (Fig. 4.3 B, lower panels). The stimulation of LS411N cells had no impact on CRT 
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Figure 4.3 Transcriptionally active STAT3 drives CRT resistance. 
A| Expression analysis of gp130 by immunoblotting in unstimulated CRC cells. B| Hy-IL-6-induced 
STAT3 phosphorylation and transcriptional activity were analyzed in STAT3-negative LS411N cells 
(upper left panel) and STAT3-positive SW837 or SW1463 cells (upper middle and right panel), and the 
impact of that stimulation on sensitivity to CRT was assessed (lower panels) 71. Data presented as mean 
± s.e.m. from at least n=3 independent biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired 
two-sample Student's t-test or two-way analysis of variance (ANOVA).  
 
In summary, RNAi against STAT3 resulted in a clear sensitization against CRT in STAT3 
expressing cells (SW1463 and SW837) whereas CFA survival of STAT3 non-expressing 
LS411N cells are not impaired by RNAi mediated silencing of STAT3. Expression of different 
STAT3 variants in LS411N cells showed increasing resistance to CRT only after expression of 
the signalling active wild-type STAT3 version, in which the important phosphorylation sites 
(Y705 and S727) are active. Further, stimulation with the fusion protein Hy-IL-6 induced strong 
STAT3 phosphorylation that is associated with increased resistance to CRT. In conclusion, 
experiments proofed that activated/phosphorylated STAT3, which is transcriptionally active, 
drives CRT resistance in CRC cells. 
4.1.2 Gp130/STAT3 pathway inhibitor mediated perturbation modulates CRT 
resistance 
To further explore the role of IL-6/gp130/STAT3 signalling in mediating CRT resistance, we 
employed established inhibitors of the gp130/IL-6 receptor signalling cascade to analyze their 
ability to change the CRT resistance in CRC cells. 
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4.1.2.1 Treatment with Tocilizumab alter IL-6 signalling in CRC cells 
Tocilizumab is a clinically used monoclonal antibody that binds to the IL-6 receptor (sIL-6R 
and IL-6R) and thereby inhibits the IL-6 classical as well as the trans-signalling pathway and 
in turn their signal output 119,127,135. It was previously shown that short time incubation with 
Tocilizumab dampened the STAT3 phosphorylation of Y705, as well as the transcriptional 
activity in SW1463 cells 167. In this present work we used LS411N, SW837 and SW1463 cells 
and treated them with previous established Tocilizumab concentrations (Tab. 35). To ensure 
that the cells were still viable we measured the cellular viability for LS411N, SW837 and 
SW1463 cells after incubation with Tocilizumab (Appendix, Fig 8.4). Treatment of SW837 and 
SW1463 cells with Tocilizumab dampened STAT3 tyrosine phosphorylation, while total STAT3 
levels remained unchanged (Fig 4.4, middle and right panel). In addition, treatment with 
Tocilizumab reduced STAT3 transcriptional activity compared to the untreated samples as well 
as it rendered both cell lines more sensitive to CRT, as revealed by their decreased CFA 
survival rates (Fig. 4.4, left and right panel). Importantly, Tocilizumab treatment had no impact 
on CFA survival of STAT3-deficient LS411N cells. 
Figure 4.4 Treatment with Tocilizumab render STAT3 expression cells more sensitive against 
CRT. 
Indicated cells were treated with Tocilizumab (Toci) and were analyzed for inducible phosphorylation or 
expression of STAT3 by immunoblotting (upper left) or monitored for inducible STAT3 transcriptional 
activity (upper right) or were colony formation assay (CFA)-cultured to measure their survival following 
irradiation in the presence of 5-FU (lower graph)71. Data presented as mean ± s.e.m. from at least n=3 
independent biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-sample Student's t-
test or two-way analysis of variance (ANOVA).  
 
4.1.2.2 Treatment with the JAK inhibitor Ruxolitinib  
Ruxolitinib is a clinically used small-molecule inhibitor of JAK1 and JAK2 119, that is not 
selective for the IL-6/gp130 axis but targets the JAK/STAT axis on an intracellular level. In 
inactive form STAT3 is predominantly located in the cytoplasm where it gets activated in 
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response to i.e., cytokine stimulation via tyrosine phosphorylation by JAK proteins 141. The 
inhibitory effect of Ruxolitinib is based on its selectivity for JAK1 and JAK2 and therefore on 
the inhibition of STAT3 activation 184.  
To test a potential effect of Ruxolitinib on inhibition of STAT3 phosphorylation we first 
treated the CRC cell lines SW837 and SW1463 with different Ruxolitinib concentrations 
(ranging from 10, 50,100, 250 to 500 nM) for 1 and for 24 h to identify reasonable 
concentrations and time-points (Fig. 4.5 A). The inhibitory effect on phosphorylated STAT3 at 
tyrosine 705 (pSTAT3Y705) was analyzed by Western blotting (Fig. 4.5 A). pSTAT3Y705 levels 
were reduced in SW837 samples treated with a minimum of 100 nM Ruxolitinib for 1 h and 24 
h (Fig. 4.5 A, left panels) and in SW1463 samples treated with 1000 nM Ruxolitinib for 1 h and 
a minimum of 50 nM Ruxolitinib for 24 h in comparison to the corresponding control samples. 
While total STAT3 levels remain stable and are not affected by Ruxolitinib treatment (Fig. 4.5 
A, right panels). The cellular viability of LS411N, SW837, and SW1463 was not affected even 
using the highest Ruxolitinib concentrations (5000 nM). All cellular viability curves resulted in 
> 80% viability, meaning that Ruxolitinib did not induce a viability loss, confirming that all 
concentrations were suitable for further experiments (Fig.4.5 B). Note that additional time 
points for Ruxolitinib treatment are shown in Appendix, Fig 8.5. 
Figure 4.5 Treatment of CRC cells with Ruxolitinib reduces pSTAT3Y705 expression in a dose 
dependent manner. 
A| Western Blot analysis was performed to determine the most effective Ruxolitinib (Ruxo) concentration 
and treatment timepoint for SW837 and SW1463. For this pSTAT3Y705 expression levels were measured 
using Western Blot after treating the cells for 1 h or 24 h with Ruxolitinib concentrations ranging from 0 
to 500 nM. B| To test if Ruxolitinib reduce cellular viability LS411N, SW837 and SW1463 were incubated 
with different concentrations Ruxolitinib ranging from 0 to 5000 nM for 24,48 and 72 h. Cellular viability 
was measured using a cell titer blue assay and the data are presented as mean ± s.e.m. from at least 
n=3 independent biological replicates.  
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To test if the Ruxolitinib-dependent inhibition of STAT3 phosphorylation influences CRT 
resistance, LS411N, SW837 and SW1463 cells were treated with the previous established 
concentrations Ruxolitinib for 16 h (Tab. 35), incubated with 3 μM 5-FU overnight, followed by 
irradiation. For the STAT3 negative cell line LS411N the highest possible Ruxolitinib 
concentration was used (1000 nM). Successful inhibition of STAT3 phosphorylation was 
confirmed using anti-pSTAT3Y705 immunoblotting (Fig. 4.6, upper left panels), and decreased 
STAT3 activity was verified using DLR assay (Fig. 4.6, upper right panels). Treatment of 
SW837 and SW1463 cells with Ruxolitinib rendered both cell lines more sensitive to CRT, as 
revealed by their decreased CFA survival rates (Fig. 4.6, lower panels). Importantly, Ruxolitinib 
treatment has no impact on CFA survival of STAT3-deficient LS411N cells. 
Figure 4.6 Manipulating the JAK/STAT pathway using Ruxolitinib alters STAT3 activation and 
renders cells more sensitive against CRT. 
Indicated cells treated with Ruxolitinib (Ruxo) were analyzed for inducible phosphorylation or expression 
of STAT3 by immunoblotting (upper left) or monitored for inducible STAT3 transcriptional activity (upper 
right) or were colony formation assay (CFA)-cultured to measure their survival following irradiation in 
the presence of 5-FU (lower graph) 71. Data presented as mean ± s.e.m. from at least n=3 independent 
biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-sample Student's t-test or two-
way analysis of variance (ANOVA).  
 
Using Tocilizumab and Ruxolitinib we demonstrated that manipulation of gp130/JAK/STAT 
pathway components at both extracellular and intracellular levels alters STAT3 activation and 
renders STAT3 expressing cells more sensitive against a 5-FU based CRT. Next, we wanted 
to analyze the impact of direct STAT3 inhibition. 
4.1.2.3 Treatment with the pSTAT3 inhibitor Napabucasin  
A promising direct inhibitor of STAT3 is the small-molecule inhibitor Napabucasin (BBI-608) 
185. Napabucasin is less toxic, highly effective in low molecular ranges, orally bioavailable and 
has already been tested in a phase-III clinical trial for highly advanced, chemotherapy-
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refractory CRC 186. This study resulted in the suggestion that STAT3 might be an important 
target for the treatment of CRC patients with elevated pSTAT3 expression 186.  
To identify reasonable concentrations and time points, we first treated SW837 and SW1463 
cells with different Napabucasin concentrations (ranging from 100 to 1000 nM) for 1h (Fig. 
4.7A). The inhibitory effect on pSTAT3 at tyrosine 705 was analyzed by Western blotting (Fig. 
4.7 A). pSTAT3Y705 levels were reduced in SW837 samples treated with a minimum of 500 nM 
Napabucasin for 1 h (Fig, 4.7 A, left panels) and in SW1463 samples treated with 750 nM 
Ruxolitinib for 1 h in comparison to the corresponding control sample. While total STAT3 levels 
remain stable and are not affected by Napabucasin treatment (Fig. 4.7 A, right panels). 
Furthermore, we tested whether the treatment with Napabucasin affects the cellular viability. 
The cellular viability decreased from minimal drug concentration to the highest one in all the 
cases of 24,48 and 72 h of incubation with Napabucasin (Fig. 4.7 C). This indicates that all 
three cell lines were relatively susceptible to Napabucasin-mediated reduction of cellular 
viability when treating them with high concentrations over a longer period. Based on these 
results we decided to perform the following experiments with a Napabucasin incubation time 
of 1 h. 
Figure 4.7 Treatment of CRC cells with Napabucasin reduces pSTAT3Y705 expression in a dose 
dependent manner. 
A| Western blot analysis was performed to determine the most effective Napabucasin (Napa) 
concentration after 1 h of treatment for SW837 and SW1463. STAT3 and pSTAT3Y705 expression levels 
were measured using Western Blot after treating the cells for 1 h with Napabucasin concentrations 
ranging from 0 to 100 nM. B| To test if Napabucasin reduces cellular viability LS411N, SW837 and 
SW1463 were incubated with different Napabucasin concentrations ranging from 0 to 5000 nM for 24,48 
and 72 h. Cellular viability was measured using a cell titer blue assay and the data are presented as 
mean ± s.e.m. from at least n=3 independent biological replicates. 
 
To analyze the effect of direct STAT3 inhibition on the CRT sensitivity of CRC cells, 
LS411N, SW837 and SW1463 cells were incubated for 1 h with the respective concentrations 
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of Napabucasin (Tab. 35). The treatment with Napabucasin prevented the phosphorylation of 
the key activator site, Y705, in STAT3 expressing SW837 and SW1463 cells (Fig. 4.8, upper 
right, middle and left panels) as well as it strongly reduced reporter activity of STAT3 (Fig. 4.8, 
upper right, middle and left panels). Resulting from this it sensitized both cell lines to CRT (Fig. 
4.8, lower panels) without influencing the amount of STAT3 expression (Fig. 4.8, upper right, 
middle and left panels). The CFA survival of LS411N cells remained unaffected following 
treatment with Napabucasin.  
Figure 4.8 Treatment of CRC cells with Napabucasin reduces pSTAT3Y705 expression and 
renders cells more sensitive to CRT. 
LS411N, SW837 or SW1463 cells were left untreated or treated with Napabucasin (Napa) (left and 
middle panel) and analyzed for STAT3 functionality (upper graphs) or were monitored for CFA survival 
after CRT (lower graphs) 71. Data presented as mean ± s.e.m. from at least n=3 independent biological 
replicates. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-sample Student's t-test or two-way analysis 
of variance (ANOVA).  
 
To evaluate whether treatment with Napabucasin triggers other STAT3 independent 
mechanisms that lead to a sensitization of CRC cells to CRT, we combined treatment with 
Napabucasin and RNAi against STAT3 in SW1463 cells. Successful RNAi mediated STAT3 
KD as well as the inhibitory effect of Napabucasin on pSTAT3Y705 levels were confirmed using 
immunoblotting (Fig. 4.9, right panel). As observed in Fig. 4.1 and Fig. 4.8, both approaches 
individually affect CRT sensitivity significantly (Fig. 4.9, left panel). However, when the two 
treatments are combined, no synergistic effect can be observed in terms of a change in CRT 
sensitivity (Fig. 4.9, left panel). Thus, the effect of Napabucasin in our assays can be 
predominantly ascribed to inhibition of STAT3 tyrosine phosphorylation. 
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Figure 4.9 Combined treatment of Napabucasin and RNAi targeting STAT3 has no additive effect 
on CRT resistance. 
Following siRNA- mediated STAT3 silencing and treatment with Napabucasin (Napa), SW1463 cells or 
untreated control cells were subjected to STAT3 immunoblot analysis (right panel) or CFA survival after 
CRT (left panel) 71. Data presented as mean ± s.e.m. from at least n=3 independent biological replicates. 
*P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-sample Student's t-test or two-way analysis of variance 
(ANOVA).  
 
In summary, the extent of CRT resistance could be tuned in both directions by manipulating 
the performance of STAT3 even directly or indirectly through modification of upstream 
effectors. 
4.2 Targeting gp130/STAT3 signalling in vivo 
The data prompted us to test whether the inhibition of the gp130/STAT3 signalling axis can 
suppress the growth of tumor transplants under 5-FU based CRT in vivo. To assess the effect 
of STAT3 inhibition on CRT-sensitivity in vivo my host research group established a 
subcutaneous rectal cancer xenograft nude mice model that mirrors clinical conditions i.e., 
fractionated doses of both radiation and chemotherapy 147. In previous studies they used the 
small-molecule inhibitor STATTIC, which inhibits the function of the SH2 domain of STAT3, 
preventing phosphorylation at Y705 and, subsequently, dimerization and nuclear translocation 
187. In the absence of STATTIC, the tumor volume remained stable during the administration 
of 5-FU and irradiation whereas the tumor volume of STATTIC-treated mice decreased over 
time. Therefore, there was a statistically significant effect of the STATTIC treatment on the 
reduction of tumor volume during the CRT treatment, associated with a significantly delayed 
tumor re-growth in STATTIC-treated mice compared with control animals as well as a survival 
benefit for STATTIC- treated mice 147. These results are limited by the fact that STATTIC was 
administered locally into the tumor, as STATTIC is not orally bioavailable 187. Following 
experiments were performed in collaboration with Melanie Spitzner. 
 
Results | Kristin Kördel 
67 
 
4.2.1 Testing Napabucasin in vivo 
Accordingly, as STATTIC is not a favorable inhibitor we tested the very promising STAT3 
inhibitor Napabucasin because it had a striking impact on CRT re-sensitization in our cell 
culture models (Fig. 4.7 and 4.8). 
To assess the effect of a Napabucasin mediated pSTAT3Y705 inhibition on CRT-sensitivity 
in vivo we used the subcutaneous rectal cancer xenograft nude mice model that was previously 
established 147 (see section 3.2.1. and Fig. 3.1 A and B for details). In a pre-test the 
effectiveness of two different concentrations Napabucasin (maximum dose:20 mg/kg and 
reduced dose: 5 mg/kg) were tested 185. We used the rectal cancer cell line SW1463, which is 
STAT3 expressing and showed a sensitization against CRT after treatment with Napabucasin 
(Fig. 4.8, right panel). Therefore, 2 million SW1463 cells were injected into 8 to 10 weeks old 
female NMRI-Foxn1nu/Foxn1nu mice under sevoflurane inhalation. Once the tumors reached 
about 150 mm³ in size, mice were randomized into three treatment groups: DMSO (n=2), 5 
mg/kg Napabucasin (n=3) and 20 mg/kg Napabucasin (n=2). The mice were treated like 
indicated in Fig. 3.1 A.  
We did not notice any obvious sign of toxic side effects or extreme body weight drop of 
Napabucasin treated mice compared with DMSO treated mice (Fig. 4.10 A). Regardless of the 
treatment the tumor volume of all treatment groups continues to increase (Fig. 4.10 B). After 
14 days of treatment either with DMSO or with Napabucasin the mice were sacrificed and 
tumors as well as major organs including stomach, spleen, liver, kidneys, and heart were 
collected. The appearance as well as the morphology of dissected organs were comparable 
with those of untreated animals (Fig. 4.10 C). These observations indicated that Napabucasin 
treatment did not lead to visible alterations. The expression of pSTAT3Y705 was higher in tumors 
of DMSO treated mice, as compared to tumors of Napabucasin treated mice indicating a clear 
Napabucasin effect in SW1463 forming tumors in a dose independent manner (Fig. 4.10 D). 
At the same time, the STAT3 expression level remained unchanged. Therefore, we choose 5 
mg/kg Napabucasin for the following experiments. 
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Figure 4.10 Establishment of effective Napabucasin concentrations for further in vivo 
experiments. 
A| Body weight curves of SW1463 bearing mice treated with either DMSO (n=2), 5 mg/kg Napabucasin 
(n=3) or 20 mg/kg Napabucasin (n=2) for 14 days. B| Tumor volumes of mice starting at the first day 
after tumor cell inoculation. C| After three weeks of treatment, tumor-bearing mice were sacrificed 1 hour 
after oral application of either DMSO or Napabucasin, pictures of different organs were taken to compare 
treated mice with non-treated mice and D| Western blot analysis was performed to confirm inhibition of 
STAT3 phosphorylation 71. 
 
In analogy to the dose-finding experiments, tumors were induced by subcutaneous injection 
of 2 million SW1463 in the right flank of 8 to 10 weeks old NMRI-Foxn1nu/Foxn1nu mice. The 
treatment was started when the tumor volume had reached about 150 mm³ in size. All nude 
mice were randomly assigned into five different treatment groups: DMSO (n=15), Napabucasin 
(n=15), Napabucasin + RT (n=15), Napabucasin + CRT (n=13) and DMSO + CRT 
groups(n=14). The mice are treated like indicated in Fig. 3.1 B with 5 mg/kg Napabucasin or 
DMSO orally. For the CRT experiments, 50 mg/kg 5-FU was administered intraperitoneal and 
5 mg/kg Napabucasin or DMSO, given orally one hour before irradiation. Irradiation is 
performed under sevoflurane inhalation narcosis. Nontumor parts were shielded with a lead 
shield for vital organ protection, and tumors were irradiated daily with 1.8 Gy for 14 days using 
an X-ray operating at 70 kV, 25 mA and with 0.5-mm Al filtration. To document the tumor 
development during the treatment period pictures at day 1, 5, 9 and 14 after treatment start 
were taken. The Tumor and the body weight were measured thrice weekly. The treatment 
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period is followed by an observational period to investigate the tumor regrowth. We defined 
the tumor regrowth as a tripling in tumor volume (450 mm3). 
4.2.1.1 Treatment with Napabucasin alone or in combination has no impact on body 
weight of tumor bearing mice 
The body weight of mice remained stable, regardless of the treatment even during the hole 
administration period (Fig. 4.11 A) as well as at the end of treatment (Fig.4.11 B). 
Figure 4.11 Different treatments have no impact on the body weight of the mice. 
A|-B| Body weight of mice treated 14 days with either DMSO (n=15), Napabucasin (n=15), DMSO + 
CRT (n=14), Napabucasin + CRT (n=13) or Napabucasin + RT (n=15) (left panel) (A) and at the end of 
treatment (right panel) (B) 71. Data points consisted of at least seven mice. 
 
4.2.1.2 Treatment with Napabucasin alone did not affect the tumor volume  
Both control groups (DMSO and Napabucasin) show a dramatically increasing tumor 
volume after treatment start (Fig 4.12 A and Fig 4.10 B). Treatment with Napabucasin alone 
did not noticeably suppress the growth of tumor transplants compared to treatment with DMSO 
alone (Fig 4.12 A-C).  
Importantly, mice in both control groups showed average time to tumor regrowth and life 
span (Fig 4.12 D-F). The time to tumor regrowth was defined as a tripling in tumor size (450 
mm3) and is an important clinical aspect after the end of medical treatment. DMSO treated 
mice showed 11 days to tumor tripling in comparison to 13 days in Napabucasin treated mice 
(Fig. 4.12 E). All mice included in these treatment groups died within 45 days (Fig. 4.12 F). 
However, tumors in both control groups showed similar growth speed, suggesting that 
Napabucasin alone without 5-FU and irradiation did not affect tumor development. 
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Figure 4.12 Napabucasin alone did not affect the tumor volume. 
A| and B| Tumor volumes of mice during treatment only with DMSO and Napabucasin without CRT (A), 
and at the end of treatment (B) 71. C| Pictures of tumors under treatment with DMSO and Napabucasin. 
Pictures were taken 1 day, 5 days, 9 days, and 14 days after treatment start. D| Kaplan-Meier curves 
were calculated to analyze the time to tumor tripling in the respective groups 71. E| The median tumor 
tripling time of DMSO treated mice was 11 days, compared to 13 days of Napabucasin treated mice 71. 
F| Kaplan-Meier curves comparing the survival of DMSO treated mice with Napabucasin treated mice, 
respectively. Data points (A) consisted of at least seven mice. The significance was verified by unpaired 
two-sample Student's t-test (B and E) or were calculated by Log-rank (Mantel-Cox) test (A, D and F).  
 
4.2.1.3 Napabucasin reduces tumor volume only in combination with RT and CRT 
treatment 
The use of Napabucasin as monotherapy did not show any effect on tumor volume 
development (Fig. 4.12). Therefore, we treated mice additionally with RT and CRT (for details 
see section 3.2.1. and Fig. 3.1 B). The tumor volume during Napabucasin + RT and 
Napabucasin + CRT treatment was significantly reduced in both groups compared to the 
control group. The CRT treatment even more abolished the tumor volume compared to the RT 
group (Fig. 4.13 A and B). At the end of treatment, the Napabucasin + CRT treated tumors 
are the smallest in terms of appearance and calculation. The additional RT reduces the tumor 
volume compared to Napabucasin monotherapy but not as much as the additional CRT (Fig. 
4.13 A - C). In the Napabucasin + RT treated but more pronounced in the Napabucasin + CRT 
treated group the tumor regrowth was time-delayed compared to the Napabucasin only group 
(Fig. 4.13 D). While in the group exposed to Napabucasin + CRT, the mice demonstrated 
significantly longer median time to tumor tripling (53 days) compared to 27 days in 
 
Results | Kristin Kördel 
71 
 
Napabucasin + RT groups and 13 days in only Napabucasin treated animals (Fig. 4.13 E). 
This resulted in a survival advantage for RT and CRT treated mice. Napabucasin + CRT 
treated mice also have a survival advantage compared to Napabucasin + RT and Napabucasin 
only treated animals (Fig. 4.13 F). 
Figure 4.13 Influence of irradiation and chemoradiotherapy on tumor volume. 
A| - B| Tumor volumes of mice during treatment only with Napabucasin, with RT or with CRT (A), and 
at the end of treatment (B.) C| Respective pictures of tumors under different treatments during the 14 
days treatment period. Pictures were taken 1 day, 5 days, 9 days, and 14 days after treatment start. D| 
Kaplan-Meier curves were calculated to analyze the time to tumor tripling in the respective groups. E| 
The median tumor tripling time of Napabucasin treated mice was 13 days, compared to 27 days of 
Napabucasin + RT and 54 days of Napabucasin + CRT treated mice. F| Kaplan-Meier curves comparing 
the survival of the three Napabucasin treated groups, respectively. P-values were calculated by mixed-
effects analysis using Tukey’s multiple comparisons test (A), unpaired two-sample Student's t-test (B 
and E) or Log-rank (Mantel-Cox) test (D and F). Data points consisted of at least seven mice (A).  
 
4.2.1.4 Treatment with Napabucasin in combination with CRT completely abrogated 
tumor growth during treatment period 
To determine whether CRT alone induces the suppression of the tumor volume we 
compared DMSO + CRT treated mice with Napabucasin + CRT treated mice. However, when 
combined with CRT, Napabucasin treatment completely abrogated tumor growth (Fig. 4.14 A- 
C). 
In addition, Kapla- Meier curves were calculated to compare the tumor regrowth between 
Napabucasin + CRT and DMSO + CRT groups (Fig. 4.14 D). The additional administration of 
Napabucasin increased the median tumor tripling time from 43 days to 53 days (Fig. 4.14 E). 
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No survival advantage was seen when treating mice with Napabucasin + CRT compared to 
DMSO + CRT (Fig. 4.14 F). 
Figure 4.14 The treatment with Napabucasin and CRT diminishes tumor volume. 
A| and B| Tumor volumes of mice during treatment only with DMSO and Napabucasin with CRT (***P 
< 0.0001) (A), and at the end of treatment (B) 71, ***P = 6.668E-05. C| Respective pictures of tumors 
under different treatments during the 14 days treatment period. Pictures were taken 1 day, 5 days, 9 
days, and 14 days after treatment start. D| Kaplan-Meier curves were calculated to analyze the time to 
tumor tripling in the respective groups 71. E| The median tumor tripling time of DMSO + CRT treated 
mice was 43 days, compared to 54 days of Napabucasin + CRT treated mice 71, **P = 1.13E-02. F| 
Kaplan-Meier curves comparing the survival of DMSO + CRT treated mice with Napabucasin + CRT 
treated mice, respectively (n.s). P-values were calculated by mixed-effects analysis using Tukey’s 
multiple comparisons test (A), unpaired two-sample Student's t-test (B and E) or Log-rank (Mantel-Cox) 
test (D and F). Data points consisted of at least seven mice (A). 
 
So far, the results in human CRC cells as well as in xenograft nude mice model led to the 
conclusion that transcriptionally active STAT3 controls CRT sensitivity in vitro and in vivo. This 
CRT sensitivity can be modified by manipulating the gp130/JAK/STAT pathway specifically by 
manipulating activated STAT3. Alteration of STAT3 activity by direct (RNAi, Napabucasin, or 
mutation of the phosphorylation site Y705) and indirect (Tocilizumab and Ruxolitinib) inhibition 
increased CRT sensitivity, whereas activation of STAT3 by gp130/JAK axis-activating Hy-IL-6 
decreased CRT sensitivity. The use of Napabucasin demonstrated, both from cell culture data 
and in the xenograft nude mice model, that inhibition of STAT3 leads to CRT sensitization, an 
abrogated tumor growth as well as a significant advantage in time of tumor regrowth.  
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4.3 Target genes of the gp130/STAT3 axis 
To gain insights into the STAT3-controlled CRT resistance, I analyzed the consequences 
of STAT3 perturbation on a global transcriptome level. Therefore, I used RNA-Seq technology 
to identify respective STAT3 downstream targets that functionally mediate the resistance 
phenotype. I have demonstrated that siRNA mediated STAT3 knock down resulted in 
decreased clonogenic survival in CRC cells (Fig. 4.1). Likewise, I have demonstrated that 
stimulation with Hy-IL-6 resulted in remarkably increased clonogenic survival of STAT3-
expressing CRC cells (Fig. 4.3). 
Based on these results, SW837 cells were either transfected with siRNA targeting STAT3 
or with a negative control siRNA (siCtrl.). 80 h after transfection, cells were stimulated with Hy-
IL-6 for 16 h or were left untreated. After stimulation cells were harvested for further protein or 
RNA analysis (Fig. 4.15 A). RNA-Seq data and abundance measurement files have been 
submitted to the GEO under the accession number GSE139455. Western blot validation using 
antibodies against STAT3 and pSTAT3Y705 showed a clear STAT3 knock down and a Hy-IL-6 
induced phosphorylation of STAT3 in the corresponding samples (Fig. 4.15 B).  
Figure 4.15 Schematic overview of the RNA-Sequencing workflow and expression validation. 
A| RNA-Sequencing-based detection of STAT3 target genes in SW837 cells with basic or silenced 
STAT3 expression in the presence or absence of Hyper-IL-6. B| Immunoblot analysis of siRNA-treated 
SW837 cells with the indicated antibodies for three experimental conditions: (a) cellular stimulation with 
Hyper-IL-6 either in the presence of STAT3, or (b) upon siRNA-mediated STAT3 silencing, and (c) 
targeted STAT3 expression without further stimulation 71. 
 
Next, I determined differential gene expression profiles of SW837 cells under three 
experimental conditions: (a) cellular stimulation with Hy-IL-6 either in the presence of STAT3 
(black), or (b) upon siRNA-mediated STAT3 silencing (blue), and (c) targeted STAT3 
expression without further cell stimulation (orange). At a FDR cut-off 5% (FDR < 0.05), the 
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analysis of individual settings revealed 231 (188 up-regulated and 43 down-regulated, Fig. 
4.16 A, left panel), 2,969 (979 up-regulated and 1,990 down-regulated, Fig. 4.16 A, middle 
panel), and 3,738 (1,628 up-regulated and 2,110 down-regulated, Fig. 4.16 A, right panel) 
differentially expressed (DE) genes, respectively. Further analysis revealed 71 genes that were 
significantly deregulated in all three settings, suggesting that their altered transcriptional 
activity is dually affected by STAT3 expression and cellular stimulation (Fig. 4.16 B, yellow).  
Figure 4.16 Differentially expressed genes after STAT3 pathway alterations. 
A| Volcano plots depicting the number and distribution of differentially up- and down-regulated genes. 
The x-axis shows the log2 fold changes in expression and the y-axis the P-value of a differentially 
expressed genes. The red dots mark the genes that a significantly deregulated with an FDR cut off 5% 
71. B| Venn diagram of differentially expressed genes under indicated conditions (n=3). RNA-Seq 
revealed 231 (siCtrl. vs. siCtrl. + Hy-IL-6 left panel), 2,969 (siCtrl. + Hy-IL-6 vs. siSTAT3 + Hy-IL-6, 
middle panel), and 3,738 (siCtrl. vs. siSTAT3, right panel) significant genes (FDR < 0.05), respectively 
71.  
 
4.3.1 Opposite Direction Analysis uncovered dual influenced STAT3 target 
genes 
To filter the genes more stringently, I considered only genes that were upregulated or 
downregulated after pathway stimulation, and simultaneously but inversely, regulated after 
STAT3 inhibition, for the next experiments. Such Opposite Direction Analysis (ODA) ensured 
that I only work with genes that were dually influenced by pathway inhibition and activation. 
The ODA revealed 55 candidate genes probably playing an influential role in STAT3-mediated 
CRT-resistance (Fig. 4.17). Interestingly, 53 of the 55 genes are upregulated after stimulation 
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and downregulated after STAT3 silencing and even more downregulated after STAT3 silencing 
along with Hy-IL-6 stimulation.  
Figure 4.17 Opposite Direction Analysis reveal 55 genes. 
A| Expression profiles of genes fulfilling the Opposite Direction Analysis criteria of being upregulated on 
stimulation with Hy-IL-6, and downregulated on STAT3 inhibition, and vice versa 71.  
 
In order to technically validate the results generated so far, I quantified the mRNA 
expression levels of 12 selected ODA genes for all three conditions using qRT-PCR analysis. 
Data obtained by RNA-Seq tightly and significantly correlated with those generated by PCR, 
demonstrating the accuracy of the screening approach (Fig. 4.18). 
Figure 4.18 qRT-PCR validation of 12 chosen ODA genes. 
Linear model analysis correlating mRNA fold changes elucidated by RNA-Seq with qPCR values of 12 
chosen ODA genes. P-values were calculated using Pearson's correlation 71. 
To identify potential STAT3 target genes, that may impact the CRT resistance, I classified 
the 55 ODA genes into 4 functional categories, respectively (Fig. 4.19). Category 1 includes 
genes that are predominantly related to regulation and functionality of the immune system (Fig. 
4.19, upper right), category 2 includes genes that primarily contribute to signalling transduction 
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processes (Fig. 4.19, upper left), category 3 includes genes important in metabolic processes 
(Fig. 4.19, lower left) and category 4 includes genes that have functions outside the previous 
3 categories (Fig. 4.19, lower right). However, the function of some genes cannot be assigned 
to only one category, so affected genes are listed in the crossover areas between categories.  
Figure 4.19 ODA genes were classified according to their function. 
The 55 ODA genes were filtered according to information found in the human gene database 
(GeneCards).  
The representation in Figure 4.19 illustrated the wide range of genes that are dually 
influenced by Hy-IL-6 stimulation and STAT3 silencing. The analysis revealed genes involved 
in many signalling pathways and regulatory processes. Some of these pathways and 
processes have been previously linked to CRC and therapy resistance.  
To narrow this gene list down, I conducted a literature search that included information’s of 
the genes regarding their importance in CRC. I additionally searched for possible associations 
between the expression of the genes and a therapy-radio resistance. Based on these results, 
I selected the following 12 most interesting genes. The WNT/β-catenin signalling represents a 
key oncogenic pathway previously linked to CRT resistance 33. E74-like ETS transcription 
factor 3 (ELF3) is a transcription factor which is overexpressed in CRC and promotes CRC 
proliferation and invasion by enhancing WNT/β-catenin signalling 188. Furthermore, it was 
previously reported that ELF3 expression was associated with disease recurrence of stage II 
CRC 189. Hypoxia-inducible factor 1 (HIF1A), is an established target of JAK-STAT signalling 
and previously reported as a potential determinant of tumor radiosensitivity 190. In addition, 
HIF1A overexpression was significantly associated with higher CRC-specific mortality 191. 
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DPYD, encodes a key 5-FU-metabolizing enzyme dihydropyrimidine dehydrogenase 192. 
DPYD is the rate-limiting enzyme, degrading over 80% of 5-FU to its inactive metabolite 193. 
Different studies confirmed the predictive value of DPYD expression levels to predict the 
efficacy of 5-FU based therapy in CRC patients 194,195. Hexokinase 1 (HK1), an enzyme that 
catalyzed the first step of glycolysis, has been identified to affect tumorigenesis of CRC and 
melanoma. shRNA-mediated attenuation of HK1 and HK2 led to decreased cell viability in CRC 
cells 196. The transmembrane glycoprotein Mucin 1 (MUC1) impacts the response to 
radiotherapy in pancreatic cancer 197 and has been demonstrated to participate in 
maintenance, tumorigenicity, glycosylation and metastasis of colorectal cancer stem cells 198. 
Evidence exist that MUC1 has an impact on chemo- and drug resistance in different types of 
cancer. For example, it mediated chemo-resistance in lung cancer cells 199 as well as it showed 
to induce drug resistance in pancreatic cancer 200. The Nicotinamide 
Phosphoribosyltransferase (NAMPT) is a rate-limiting protein in the NAD salvage pathway 201. 
High expression of NAMPT in tumors is associated with decreased patient survival and in 
mediating the radiation resistance in human glioblastoma stem-like cells 202. It has also been 
shown that NAMPT is a potent oncogene in colon cancer progression 203. B-Cell Lymphoma 6 
Protein Transcript (BCL6) is highly expressed in colorectal cancer 204 and its methylation is a 
prognostic and chemo-sensitive marker in CRC 205. In addition, I choose the key transcriptional 
regulator of the NOTCH pathway, Recombination Signal Binding Protein for Immunoglobulin k 
J-region (RBPJ) 206,207 . In previous studies, inhibition of the NOTCH pathway has been linked 
to sensitization of glioblastoma or breast cancer cells to radiation 208. The dual oxidase 2 
(DUOX2) may affect the therapeutic effect of gastrointestinal cancer 209,210 and was shown to 
exhibit a significant higher expression in CRC tumor samples and facilitated the invasion and 
metastasis ability of CRC cells 211. Zhou et al. found that serum levels of the S100 calcium-
binding protein A9 (S100A9) were significantly lower after surgery than before surgery in CRC 
patients and that S100A9 serum levels served as a diagnostic biomarker in CRC 212 and gastric 
cancer patients 213. The upregulation of Serpin Family B Member 3 (SERPINB3) and Serpin 
Family B Member 4 (SERPINB4) has previously been described as protective in cells exposed 
to radiation and the suppression of these proteins has been shown to suppress tumor growth 
214. Tribbles pseudokinases 2 (TRIB2) disrupted the p53/MDM2 regulatory axis, which led to 
resistance to various chemotherapeutic agents 215. Furthermore, TRIB2 expression was 
elevated in CRC tissue compared to normal tissues and indicated a poor prognosis of CRC 
patients 216. 
4.3.2 Influence of preselected STAT3 downstream targets on RT resistance 
Next, I tested whether the depletion of the 12 preselected ODA genes (BCL6, DPYD, 
DUOX2, ELF3, HIF1A, MUC1, NAMPT, RBPJ, S100A9, SERPINB3, SERPINB4, TRIB2) had 
an impact on RT resistance (Fig. 4.20 A). Towards this, SW837 cells were transfected with 
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either siRNAs targeting one of the 12 genes or with a control siRNA (siCtrl.). As a control, 
SW837 cells were additionally transfected with siRNA targeting STAT3, since it has already 
been shown that a STAT3 KD led to a sensitization of the cells to CRT (Fig. 4.1, middle panel). 
For further analysis, cells were stimulated with Hy-IL-6 (Fig. 4.20 A) and were subsequently 
irradiated with 4 or 6 Gy or were left without any further irradiation. The CFA survival of all 
samples after 4 Gy irradiation was determined (Fig. 4.20 B, left panel). The calculated SF of 
the control samples (black columns) were set to 100% survival. The blue columns represent 
samples with SF below 100% meaning that a depletion of the respective target gene sensitize 
SW837 cells against RT. KD of STAT3 as well as BCL6, DPYD, DUOX2, HIF1A, MUC1, 
NAMPT, RBPJ, S100A9, and SERPINB3 resulted in sensitization of the cells to irradiation with 
4 Gy. The SF of these genes were subsequently analyzed after 6 Gy irradiation (Fig. 4.20 B, 
right panel). In addition to the KD of STAT3, the depletion of BCL6, DPYD, HIF1A, MUC1, 
NAMPT and RBPJ also showed a sensitizing effect against irradiation. Based on this screening 
experiment as well as the literature research, I selected the four most interesting genes (RBPJ, 
MUC1, BCL6 and NAMPT), with which I will conduct further experiments regarding resistance 
towards RT in SW837 cells. 
Figure 4.20 Pre-screening of STAT3 target genes in SW837 cells. 
A| Schematic overview of the screening experiment. SW837 cells were transfected with control siRNA 
(siCtrl.) or 12 different siRNA targeting the indicated genes. After cell plating and 16 h stimulation with 
Hy-IL-6 cells were irradiated with 4 or 6 Gy or were left without irradiation. For CFA analysis the medium 
was exchanged, and the cells could form colonies for 19 d. B| CFA survival of all samples after 4 Gy 
irradiation (left panel). The SF of the control sample (black column) was set to 100% survival. The blue 
columns represent samples that SF is below 100% and the grey columns represent samples that 
survival is above 100%. The samples with SF below 100% after 4 Gy irradiation were analyzed for SF 
after 6 Gy irradiation (right panel). Data presented as mean from n=2 independent biological replicates. 
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To further investigate the selected genes for their ability to modulate RT resistance, MUC1, 
BCL6 and NAMPT were silenced in SW837 cells using RNAi (72 h - BCL6, NAMPT and RBPJ; 
96 h- MUC1; Appendix, Fig. 8.1, and Fig. 8.2) and additionally stimulated with Hy-IL-6. 
Successful KD of each gene was determined using qRT-PCR (Fig. 4.21 A, left panel) or 
immunoblotting (Fig. 4.21 B -D, left panels). Additionally, cells were CFA-cultured to measure 
their survival following irradiation. Silencing of BCL6, NAMPT and RBPJ significantly increased 
the sensitivity of SW837 cells towards irradiation (Fig. 4.21 A and C, right panels) whereas the 
sensitivity of SW837 was not changed after MUC1 KD (Fig. 4.21 B, right panel). 
Figure 4.21 siRNA-mediated silencing of BCL6, NAMPT and RBPJ results in a sensitization of 
SW837 cells to RT. 
A| - D| SW837 cells were treated with Hy-IL-6 and siRNA targeting BCL6 (A, 72 h RNAi treatment), 
MUC1 (B, 96 h RNAi treatment), NAMPT (C, 72 h RNAi treatment), RBPJ (D,72 h RNAi treatment) or 
with a control siRNA (siCtrl.)71. Cells were colony formation assay (CFA)-cultured to measure their 
survival following irradiation (RT) (right panels). Representative RT-qPCR analysis (A) or Western blot 
analysis with the indicated antibodies (B, C and D) (left panels). Data presented as mean ± s.e.m. from 
at least n=3 independent biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-sample 
Student's t-test or two-way analysis of variance (ANOVA).  
 
These results indicate that STAT3-mediated CRT resistance in SW837 cells may not be 
controlled by a single target gene but rather is an interplay of many different proteins and 
signalling cascades. In order to further elucidate the exact molecular mechanism of STAT3-
mediated CRT resistance, further experiments are needed to possibly uncover the network of 
STAT3 target genes that jointly control CRT resistance. Due to the clear sensitizing effect after 
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RBPJ KD, I decided in the following section of the thesis to investigate the STAT3 target gene 
RBPJ in more detail regarding its ability to sensitize CRC cells to CRT. 
 
4.4 RBPJ - a promising STAT3 target gene 
I first analyzed whether RBPJ is a direct target of STAT3 using EMSA. An in-silico search 
revealed the presence of a canonical docking site for STAT family members, called GAS 
sequence 217, in the first intron of the RBPJ gene approximately 300 bp 3' of the known 
promotor region and 75 bp downstream of the first exon (Fig. 4.22 A). 
For identification of STAT1 binding, cellular extracts from unstimulated and IFNγ stimulated 
HeLa cells 141 were incubated with the 33P-labelled high-affinity control GAS probe M67. The 
autoradiograms showed a specific signal that was interpreted to represent binding of STAT1 
protein to the M67 probe after IFNγ stimulation (line 2), whereas I could not detect a binding in 
unstimulated extracts (line 1). Using cellular extracts from Hy-IL-6-stimulated SW837 cells in 
gel-shift assays, I found that STAT3, which has a slightly slower electrophoretic migration than 
STAT1 218, bound to 33P-labelled duplex oligonucleotides of the native sequence 5´-
TTCCGGGAT-´3 (nat) (line 5), but not to a mutated sequence thereof (5´-CCTTGGTAG-´3) 
(mut) (line 3). In addition, competition experiments using cell lysates incubated with the 33P-
labelled native sequence and subsequently challenged by a 750-fold molar excess of 
unlabeled DNA of the same sequence resulted in a complete loss of DNA binding activity (line 
4) (Fig. 4.22 B). These observations demonstrated that STAT proteins are sequence-
specifically recruited to the RBPJ promoter in SW837 cells.  
Figure 4.22 EMSA showing STAT protein binding to GAS elements in the human RBPJ promoter. 
A| Cut out of the promotor region sequence of RBPJ. Exons 1 and 2 are highlighted in grey, the gamma-
interferon-activation sequence (GAS) in turquoise and a GAS-like element in blue 71. The shown gene 
sequence was obtained from www.ensembl.org. B| Binding of STAT proteins to 33P-labelled 
oligonucleotides encompassing prototypic GAS (M67), a mutated GAS (mut) or the native GAS element 
(nat) from the RBPJ promotor, was analyzed by EMSA using unstimulated or IFN-γ-stimulated HeLa 
cells, or Hy-IL-6-stimulated SW837 cells. As control, the labelled M67 probe was outcompeted (com) by 
incubating lysates with an excess of unlabeled M67 probe 71.  
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The EMSA experiment demonstrates that the expression of RBPJ can most likely be directly 
controlled by STAT3. Upon activation STAT3 can bind to the GAS binding site present in the 
RBPJ promoter region and thus regulate RBPJ as one of its direct target genes. 
4.4.1 The gp130/STAT3 axis connects with the RBPJ-dependent NOTCH 
signalling pathway 
The NOTCH signalling has been known for decades and was originally found during cell 
fate determination from Drosophila to humans 219-223. It is a conserved ligand-receptor 
signalling pathway which can regulate cell differentiation, proliferation, survival, apoptosis, 
stem cell maintenance as well as the self-renewal of progenitor and stem cells in both adult 
and embryonic organs 224,225. At present, four NOTCH receptors have been identified in 
humans, such as NOTCH 1-4 224. Mature NOTCH receptors are heterodimeric proteins 
consisting of a transmembrane subunit (NTM) and an extracellular subunit (NEC) derived from 
proteolytic processing of large single-chain precursors by a furin-like protease in the trans-
Golgi network (Fig. 5.1, left) 220,224,226. NOTCH receptors are activated by interacting with cell 
membrane-associated ligands designated as either Delta-like (DLL1, DLL3, DLL4) or Serrate-
like ligands (JAG1 and JAG2) 223,227. The ligation of NOTCH receptors to their ligands is 
followed by a receptor subunit separation and two strictly controlled proteolytic cleavage steps. 
The first cleavage step is mediated by ADAM/TACE metalloproteases, that cleave the receptor 
at S2, which initiates a S3 cleavage mediated by the γ-secretase complex (composed of 
presenilin 1 and 2, nicastrin, presenilin enhancer 2, and anterior pharynx-defective 1) 206,207,225. 
This series of cleavages release the active form of NOTCH called NOTCH intracellular domain 
(NICD), which translocate into the nucleus where it assembles with the conserved DNA-
binding protein, RBPJ to drive the expression of NOTCH target genes 206,207. The initially 
inactive RBPJ complex binds to a corepressor complex (CoR) which gets exchange after 
binding of NICD by recruitment of a coactivation complex (CoA) (Fig. 5.1, right) 207.  
4.4.1.1 The NOTCH expression profile in CRC  
First, I tested for the presence of NICD as an indicator for constitutive NOTCH signalling as 
well as for other important NOTCH signalling components. Immunoblot against NICD revealed 
a strongt NICD expression in unstimulated CRT-resistant SW837 and SW1463 cells (Fig. 4.23 
A, left panel), that, in marked contrast, was almost absent in CRT-sensitive LS411N cells. In 
accordance, expression of the transcription factor HES1, a main target of active NOTCH 
signalling 228 was weak in LS411N cells but easily detectable in SW837 and SW1463 cells. 
Moreover, the signal intensities of HES1 expression are proportional to the NICD positivity and 
CRT sensitivity of the three cell lines (Fig. 4.23 A, middle panel). Furthermore, the presence 
of NICD in the tested cell lines directly correlated with their STAT3 transcriptional activity (Fig. 
4.23 A, right panel).  
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The cause of constitutive NICD generation in CRT-resistant cells was evaluated by a 
detailed expression analysis of proteins involved in regulating the NOTCH processing (Fig. 
4.23 B). SW837, SW1463 and LS411N cells were tested positive for three different NOTCH 
receptors (NOTCH 1,2,3) (Fig. 4.23 B, left panel), different patterns of NOTCH ligands (Jagged 
1/2 and DELTA-like) (Fig. 4.23 B, middle panel) and NOTCH cleaving components such as 
ADAM proteases or γ-secretases complex subunits (presenilin 1, presenilin 2, Nicastrin, 
PEN2) (Fig. 4.23 B, right panel). However, a combination of elements capable of NOTCH 
processing was found only in CRT-resistant SW837 and SW1463 cells, but not in LS411N 
cells. This uncovered a cell-intrinsic tonic NOTCH signalling activity that is moreover critically 
relevant for CRT-resistant cells than for CRT-sensitive cells. 
Figure 4.23 NOTCH expression profile in unstimulated CRC cells. 
A| Expression analysis of NOTCH pathway components (upper panel) and correlation of NICD 
expression with STAT3 transcriptional activity (lower panel) 71. B| Expression analysis NOTCH receptors 
(left panel) and ligands (middle panel) as well as γ-secretase complex and additional NOTCH pathway 
processing proteins (right panel) 71.  
 
To investigate the effect of Hy-IL-6 stimulation on the NOTCH expression profile of CRC 
cells, I stimulated LS411N, SW837 and SW1463 cells with Hy-IL-6 or I left the cells untreated. 
Western Blot analysis revealed an increased expression of RBPJ in all cell lines (Fig. 4.24 A). 
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Furthermore, I detected increased expression levels of NICD, NOTCH2, NOTCH3 indicating a 
stronger activation of NOTCH signalling compared to untreated cells in SW837 cells (Fig. 4.24 
A, middle panel). NICD expression was not influenced by stimulation in SW1463 and NOTCH2, 
NOTCH3 expression is decreased after stimulation (Fig. 4.24 A, right panel). In stimulated 
LS411N cells the NICD expression is strongly decreased suggesting a weakened NOTCH1 
signalling whereas the NOTCH2 expression is unchanged and the NOTCH3 expression is 
increased (Fig. 4.24 A, left panel). 
At present, CRT plays an integral part in treatment concepts for various tumor entities 68-70. 
Therefore, I analyzed whether irradiation had an impact on the expression of NOTCH signalling 
components in CRC cells. LS411N, SW837 and SW1463 cells were irradiated with different 
doses ranging from 0 Gy to 8 Gy, respectively. Increased expression of NICD and NOTCH2 
can be detected in irradiated SW837 and SW1463 cells compared to unirradiated cells. In 
addition, the RBPJ expression in SW1463 cells was increased while it remained unchanged in 
SW837 (Fig. 4.24 B, middle and right panel). Surprisingly, the protein level of NICD, RBPJ and 
NOTCH2 decreased following irradiation in LS411N cells (Fig. 4.24 B, left panel).  
Figure 4.24 The influence of Hy-IL-6 or irradiation on the NOTCH expression profile. 
A| CRC cells were stimulated with Hy-IL-6 (20 ng/ml, 16 h) and isolated proteins were analyzed using 
immunoblot with the indicated antibodies. Data presented as mean ± s.e.m. from at least n=3 
independent biological replicates. B| CRC cells were irradiated (0-8 Gy) and isolated proteins were 
analyzed using immunoblot with indicated antibodies 71. 
In this section, I demonstrated that SW837, SW1463, and LS411N express selected NOTCH 
signalling components. I discovered that the CRT-sensitive LS411N cells expressed the 
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NOTCH components, including NICD, less than the CRT-resistant SW837 and SW1463 cells. 
Furthermore, I could show that the expression of NOTCH pathway components is a cell line 
specific, dynamic process and is dependent on stimulation or irradiation. This again reflects 
the enormous heterogeneity of the individual cell lines. 
4.4.2 Perturbations of the NOTCH signalling pathway modulates CRT resistance 
Up to this point, I demonstrated that inhibition of RBPJ by RNAi rendered SW837 cells more 
sensitive to RT (Fig 4.21 D) and that LS411N, SW837 and SW1463 cells express important 
NOTCH signalling components depending on various stimuli (Fig 4.23 and 4.24). 
Furthermore, I tested to what extent RBPJ contributes to STAT3-mediated CRT resistance by 
silencing the expression of the two proteins either alone or in combination. Successful RNAi 
mediated STAT3 and RBPJ KD as well as the inhibitory effect of the STAT3 KD on pSTAT3Y705 
levels and the RBPJ KD on NICD levels were confirmed using immunoblotting (Fig. 4.25, right 
panel). Western Blot analysis of SW837 cells treated with siRNA targeting RBPJ show a 
decreased expression of the NOTCH intracellular domain NICD compared to the negative 
control (Fig 4.25, right panel). In our study NICD serves as a marker for active NOTCH 
Signalling. Proofing that a depletion of RBPJ damped the NICD expression and at the same 
time the NOTCH signalling. As observed in Fig. 4.1 and Fig. 4.21, both approaches individually 
affect CRT sensitivity significantly (Fig. 4.25, left panel). However, when the two treatments 
are combined, no synergistic effect can be observed in terms of a change in CRT sensitivity 
(Fig. 4.25, left panel). Moreover, RBPJ silencing phenocopied STAT3 silencing as targeting 
RBPJ alone was as effective as inhibition of STAT3 itself. Indeed, the CFA survival curves of 
all three experimental settings were nearly identical (Fig. 4.25), indicating that RBPJ, similar 
to STAT3, is a key determinant of CRT resistance. 
Figure 4.25 Combined silencing of STAT3 and RBPJ has no additive effect on CRT resistance. 
SW837 cells were treated with siRNA against STAT3 and RBPJ, either alone or in combination and 
were cultured in colony formation assays (CFA) to measure their survival following irradiation in the 
presence of 5-FU (CRT) (left panel) 71. Representative Western blot analysis with the indicated 
antibodies. Data presented as mean ± s.e.m. from at least n=3 independent biological replicates. *P < 
0.05, **P < 0.01, ***P < 0.001, unpaired two-sample Student's t-test or two-way analysis of variance 
(ANOVA).  
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Since I observed a correlation between RBPJ-dependent NOTCH signalling and CRC 
resistance, as well as a cell-intrinsic tonic NOTCH processing activity, I wanted to test the 
impact of pharmacological NOTCH pathway inhibition on CRT resistance. 
The γ-secretase complex catalyzed the cleavages of a variety of transmembrane proteins 
by untethering the cytoplasmic domain from the membrane, that allow the cytoplasmic 
domains to transduce signals to the nucleus 229,230. Thus, this enzyme complex is a potent 
target for many anti-NOTCH therapies because its inhibition abolished further NOTCH activity 
completely. In recent years, a significant number of clinical trials have also been conducted in 
which GSI were used as anticancer agents 231. The chemical compound N-[N-(3,5-
difluorophenacetyl)-L-alanyl] -(S)-phenylglycine t-butyl ester (DAPT) 232 is a GSI which showed 
to re-sensitize platinum resistant A2780/CP70 and OV2008/C13 cells to cisplatin treatment 233. 
Furthermore, treating human head and neck squamosa cell carcinoma with DAPT increased 
the sensitivity to cisplatin in vitro 234. 
LS411N, SW837 and SW1463 cells were incubated with different DAPT concentrations 
ranging from 0.1 to 5 µM and for different time points (24, 48 and 72 h) to identify reasonable 
DAPT concentrations and timepoints (Appendix, Fig 8.5 C). To verify DAPT-induced NOTCH 
activity, I analyzed the expression of NICD and HES1 using Western blotting. NICD and HES1 
expression was almost absent in LS411N cells treated for 24 h with 5 µM DAPT and SW163 
and SW837 cells treated with 5 µM DAPT for 72 h (Appendix, Fig 8.5 C). To determine a 
possible DAPT-induced loss of cellular viability, I checked the cellular viability of the cells using 
CTB assay after 24,48 and 72 h treatment with different DAPT concentrations ranging from 
0.1 to 100 µm. Even after treatment with the highest DAPT concentration, no loss of viability 
was observed in LS411N, SW1463 and SW837 cells (Appendix, Fig 8.4 B). 
To test the hypothesis, that cell-intrinsic tonic NOTCH signalling might be relevant for CRT 
resistance, I treated CRT-resistant SW837 and SW1463 as well as CRT-sensitive LS411N 
cells either with DAPT alone or in combination with RNAi targeting RBPJ (Fig. 4.26). In each 
cell line the successful RNAi mediated silencing of RBPJ was determined using 
immunoblotting. Treatment with DAPT resulted in a reduction of NICD expression in all three 
CRC cell lines, which is more pronounced than the reduction of NICD expression after RBPJ 
silencing (Fig. 4.26, upper panels). Moreover, treatment with DAPT resulted in a sensitization 
to CRT similar to the sensitization after RBPJ silencing in SW837 and SW1463 cells, while the 
combined blockade of the γ-secretases complex and RBPJ had no additive effect (Fig. 4.26, 
lower panels). The CRT-sensitive LS411N cells are not influenced by either RBPJ silencing or 
treatment with DAPT. 
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Figure 4.26 Modulation of CRT resistance after RBPJ silencing and treatment with γ-secretases 
inhibitor DAPT in CRC cells. 
A| LS411N (left panel), SW837 (middle panel)71, and SW1463 (right panel) cells were treated with RNAi 
against RBPJ and after treatment with the γ-secretases inhibitor DAPT, either alone or in combination 
were analyzed for expression of NICD and RBPJ by immunoblotting (upper panels) or were colony 
formation assay (CFA)-cultured to measure their survival following irradiation in the presence of 5-FU 
(lower graphs). Data presented as mean ± s.e.m. from at least n=3 independent biological replicates. 
*P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-sample Student's t-test or two-way analysis of variance 
(ANOVA).  
 
4.4.3 High expression of NOTCH receptors impairs DFS in rectal cancer patients 
Finally, to investigate if the RBPJ/NOTCH axis has any prognostic relevance in CRC 
patients, I analyzed pretherapeutic gene expression profiles obtained from 207 patients with 
locally advanced rectal cancer who were treated with preoperative CRT. Kaplan-Meier curves 
were estimated to visualize correlation of gene expression data with clinical parameters. These 
curves display the DFS which was defined as the time from surgery until detection of 
locoregional or distant recurrence (Fig. 4.27, left panels). These curves uncover that high 
expression of NOTCH2, NOTCH3, and NOTCH4 is associated with impaired DFS, while there 
was no difference for NOTCH1 (Fig. 4.27). Additionally, the number of patients included for 
the correlation of gene expression (NOTCH1-4) with disease-free survival for each time point 
(months) and the two groups (high expression vs. low expression) was demonstrated (Fig. 
4.27, right panel).  
Furthermore, I examined the expression distribution of the four NOTCH receptors and 
analyzed in which tissues they are predominantly expressed (tumor or mucosa) (Fig. 4.28). 
NOTCH1 and NOTCH2 do not show clearly distinguishable expression in tumor and mucosa 
samples (Fig. 4.28, left panels) while NOTCH3 and NOTCH4 show a clear increased 
expression in tumor samples (Fig. 4.28, right panels).  
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Figure 4.27 High expression of NOTCH2,3 and 4 impairs DFS in rectal cancer patients treated 
with preoperative CRT. 
A| Survival curves of 207 rectal cancer patients who were treated with preoperative CRT. Survival data 
were plotted against pretherapeutic gene expression levels of NOTCH1-4, respectively 71. B| Number 
of patients included for the correlation of gene expression (NOTCH1-4) with disease-free survival for 
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Figure 4.28 NOTCH receptor expression in tumor and mucosa samples from rectal cancer 
patients treated with preoperative CRT. 
A| Box plot shows the expression analysis of NOTCH1-4 in tumor and mucosa samples of 207 rectal 
cancer patients who were treated with preoperative CRT (upper panels). Distribution of respective gene 
expression in tumor samples (red dots) or mucosa samples (black dots) (lower panels) Each dot 
represents one patient.  
 
Summarized, I identified RBPJ as a direct target gene of Hy-IL-6 activated STAT3 
signalling. The RBPJ-dependent NOTCH Signalling was modified by STAT3 via regulation of 
the RBPJ expression. Stimulation of the IL-6/STAT3 pathway via Hy-IL-6 increases the amount 
of RBPJ, in contrast siRNA mediated silencing of STAT3 resulted in a reduced RBPJ 
expression. The silencing of RBPJ, the most important binding partner of NICD, provoked in a 
reduced NOTCH activity and a re- sensitization to irradiation of CRC cells to CRT. Expression 
analysis of essential NOTCH pathway components showed cell line specific expression 
patterns that can be related to the respective CRT resistance of the cells. While CRT-sensitive 
LS411N cells express many NOTCH processing enzymes little or not at all, these are clearly 
expressed in the CRT-resistant cells. Furthermore, genetic and/or chemical inhibition of the 
NOTCH pathway shows that CRT-resistant cell lines are re-sensitized after NOTCH inhibition 
whereas there are no changes in CRT resistance of LS411N cells. Importantly, irradiation 
further increased the constitutive presence of NICD in CRT-resistant SW837 and SW1463 
cells, indicating an alliance between tumor cell-intrinsic and treatment-induced signal 
responses. Moreover, genetic profiling of rectal cancer patients revealed the importance of the 
STAT3/NOTCH axis as expression of NOTCH pathway components correlated with clinical 
outcome. In further experiments we can try to specify the exact NOTCH receptor / ligand 
combinations that are accountable for the resistance of the cells against CRT.
 




Despite ever-improving anti-cancer therapy and screening, CRC remains a major cause of 
cancer-related deaths globally 1-3,8-10. Currently, the combined treatment of 5-FU-based 
chemotherapy, together with radiation followed by radical surgical resection of the tumor is a 
principal treatment modality for patients with locally advanced rectal cancers 68-70. However, 
about one third of patients will have no or only little response to this preoperative CRT 68,70,90. 
Thus, the efficiency of cancer treatment is usually limited by acquired and intrinsic resistance, 
leading to tumor recurrence and consequently poor prognosis 79,235. Unfortunately, the 
mechanisms of treatment resistance, both intrinsic and extrinsic, are very complex and were 
actively debated 236. The role of STAT3 in mediating CRT resistance in CRC cells was 
previously presumed 147,162. This work demonstrated that activated STAT3 mediates the CRT 
resistance in CRC cells. We showed, that blocking inflammatory gp130/ STAT3 signalling re-
sensitized CRT resistant CRC cells. Furthermore, treating SW1463-tumor bearing mice with 
Napabucasin in combination with CRT abolished tumor growth and serves as a potential 
clinical treatment strategy. Moreover, we identified STAT3 target genes that were susceptible 
to STAT3 pathway perturbations. In the context of this, we identified RBPJ as a direct STAT3 
target gene that modulates CRT resistance and ensures a tumor cell-intrinsic NOTCH 
signalling. Finally, we uncovered a disastrous crosstalk between inflammatory STAT3 
signalling and the RBPJ-dependent NOTCH signalling in regulating CRC resistance towards 
CRT. All these findings expand our understanding of the complex processes controlling the 
CRT resistance in CRC cells and thus may help to improve the therapy of CRC patients in the 
future 71. 
5.1 Inflammation promotes CRT resistance 
5.1.1 Activated STAT3 controls CRT resistance 
In this study, we explored the role of STAT3 in mediating CRT resistance in CRC cells. We 
found that the “tonic” activity of STAT3 in CRC cells is the key to their CRT resistance.  
In the STAT3-expressing and CRT-resistant cell lines SW837 and SW1463, strong STAT3 
phosphorylation at Y705 was detected after IL-6 stimulation, whereas in STAT3-negative and 
CRT-sensitive LS411N cells, both STAT3 and phosphorylated STAT3 (pSTAT3) were not 
detected regardless of stimulation. In accordance with this, LS411N cells showed no STAT3-
dependent transcriptional activity, whereas SW837 and SW1463 possessed robust basal 
STAT3 transcriptional activity. Loss of STAT3 expression and concomitant reduced 
transcriptional activity rendered SW837 and SW1463 cells sensitive to CRT. This effect was 
not observed in LS411N cells, indicating the importance of STAT3 in mediating CRT 
resistance. These results confirmed the suggestion of my host research group that attributes 
STAT3 a primary role in mediating CRC resistance in CRC cells 147. Furthermore, these results 
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demonstrate that LS411N cells are a suitable negative control for STAT3-dependent CRT 
trials. Interestingly, LS411N cells harbor a deletion mutation (pT178fs) in the STAT3 gene, 
which leads to a frameshift in this protein and may explain the lack of expression 237. 
In response to stimuli, STAT3 signalling is activated by phosphorylation of the main 
phosphorylation site at T705 119,127,135,149-151. Following activation, phosphorylated STAT3 
dimerize and subsequently translocate from the cytosol into the nucleus, where it regulated 
the transcription of its target genes 141,144,152. Furthermore, an additional phosphorylation site 
S727, maximizes transcriptional activity of STAT3 153. Therefore, the phosphorylation of S727 
act as a booster that fully activates STAT3. Interestingly, expression of the STAT3 gene is 
increased strongly in response to IL-6, and the resulting high levels of unphosphorylated 
STAT3 (U-STAT3) drive oncogene expression by a mechanism distinct from that used by 
STAT3 dimers 238,239. U-STAT3 functions as a transcription factor, binding to unphosphorylated 
NFκB in competition with inhibitor of NFκB (IκB), driving expression of a small subset of genes 
that also respond to activated NFκB, such as, IL6, and IL8 238,240. However, the U-STAT3 
mechanism is not as well characterized as the classical mechanism induced by pSTAT3. 
Nevertheless, it is important to know whether the CRT resistance of our cells depends on 
pSTAT3 and/or U-STAT3. 
Since LS411N cells do not express STAT3, these cells provide an optimal molecular 
background for experiments in which both wild-type STAT3 and mutated STAT3 variants were 
studied. While all STAT3 variants were expressed, they differed in their functionality. 
Expression of wild-type STAT3, in which both phosphorylation sites are intact, resulted in a 
huge increase of STAT3 dependent transcriptional activity and thus, to an increased resistance 
of the cells to CRT. Mutation of the phosphorylation site S727 alone, also led to greatly 
increased activity, but not to the same extent as in the wild-type variant. Notably, mutation of 
the major phosphorylation site Y705 showed a loss of function on transcription factor activity 
level. Furthermore, no increased resistance of the cells to CRT was observed once either of 
the two phosphorylation sites were mutated. These results clearly demonstrated that the amino 
acid residues Y705 and S727 are essential for mediating STAT3 induced CRT resistance and 
that phosphorylation of S727 maximizes the activity of STAT3. 
By knocking down STAT3, it was possible to sensitize CRC cells to CRT. We additionally 
found that phosphorylated and thus transcriptionally active STAT3 can induce CRT resistance. 
This strongly suggests that CRT resistance is primarily mediated by active STAT3 and not by 
the alternative U-STAT3 mechanisms. In accordance with that, it has recently been shown that 
pSTAT3 is present in exosomes from 5-FU resistant CRC cells and to enhance 5-FU 
resistance in sensitive cells through caspase cleavage cascade 236. 
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5.1.2 IL-6 trans-signalling promotes CRT resistance  
Aberrant activation of STAT3 in cancers is associated with the presence of constitutive 
activating mutations in upstream tyrosine kinases or tumor-associated oversupply of ligands 
including cytokines, chemokines, and growth factors that are either expressed by tumor cells 
themselves or by the surrounding cells of the TME 140. The TME consists of cancer-associated 
fibroblasts (CAFs), vascular cells and infiltrating immune cells which plays a crucial role in the 
mediation of chemoresistance 45. Cancer-associated fibroblasts (CAFs) are able to reduce 
drug uptake in tumors and cause resistance during chemotherapy 236,241. Furthermore, it was 
shown that Tumor-associated macrophages (TAMs) protected CRC cells from 5-FU based 
chemotherapy via putrescine 242. Inflammation affects key cytokine-mediated signalling 
pathways that control tumor-initiating and tumor promoting processes such as IL-6/gp130- 
mediated STAT3 signalling 45. Over the past decades, there is increasing evidence of IL-6 
playing a main role in the progression of cancer, particularly CRC 110,114. 
Cells lacking expression of IL-6R do not respond to IL-6, but can be stimulated by IL-6, 
bound to a soluble form of IL-6R 243. This signalling pathway, termed IL-6 trans-signalling 244, 
is important for inflammatory diseases and cancer especially within the TME 131. Leading to 
the assumption, that the CRT resistance development can be enhanced by components 
present in a pro-tumorigenic TME. To this end, we stimulated CRC cells with the designed 
fusion protein Hy-IL-6 which consists of IL-6 and the soluble IL-6 receptor chain and therefore 
mimics IL-6 trans-signalling 6,130,183. The aim of the Hy-IL-6 stimulation experiments was first to 
demonstrate that IL-6 trans-signalling can induce STAT3 activation in CRC cells and second 
to confirm the CRT resistance-promoting effect of increased STAT3 activity. Treatment with 
Hy-IL-6 induced STAT3 activation and thus, rendered cells more resistant to CRT. 
Interestingly, already resistant CRC cell lines even gained an increase in CRT resistance after 
Hy-IL-6 stimulation, whereas STAT3 negative and CRT-sensitive cells did not. Thereby, the 
increase in CRT resistance is accompanied by increased transcriptional activity of STAT3 
underlining our suggestion that active STAT3 is the driver of CRC resistance.  
Patients suffering from colon cancer have been found to produce high levels of IL-6 whereas 
low levels of IL-6R in inflamed colon and colon cancer have been found 126. Leading to the 
suggestion that IL-6 may preferentially activate through trans-signalling rather than via the 
classical receptor pathway 126. Additionally, sIL-6R was shown to drive most of the pro-
inflammatory activities of IL-6 137. Moreover, Schmidt et al. demonstrated that IL-6 trans-
signalling is required for efficient tumor growth of CRC 243. These findings underline the 
importance of the use of Hy-IL-6 in cell culture models because it mimics the IL-6 trans-
signalling. To further approve the suggestion that IL-6 trans-signalling is the mediator of CRT 
resistance in CRC cells the use of the trans-signalling inhibitory protein sgp130Fc 245 would be 
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a good approach for classic cell culture experiments and in vivo studies. Sgp130FC is a 
recombinant version of soluble gp130, which is generated by the fusion of two soluble gp130 
molecules to the Fc region of human IgG1, that differentially inhibits the pro-inflammatory 
activities of IL-6 without affecting the protective activities of this cytokine 137. 
5.1.3 Inhibition of the gp130 /STAT3 axis decreases CRT resistance  
Previous results indicate that signalling activity of STAT3 associated with partial CRT 
resistance can be further potentiated by triggering cytokine receptors of the gp130 family, 
which may happen in a pro-tumorigenic TME found in solid tumors 45,246. To further emphasize 
the importance of the gp130/STAT3 axis in mediating CRT resistance, we inhibited this 
signalling axis at different molecular levels. We did this by either treating CRC cells with 
Tocilizumab or Ruxolitinib that block STAT3 upstream components, or by treating cells with 
the direct STAT3 inhibitor Napabucasin. Tocilizumab is a humanized monoclonal anti- IL-6R 
antibody, that is FDA approved for the treatment of rheumatic arthritis and Crohn`s disease 
247,248. It competitively binds to both soluble and membrane bound IL-6R and blocks both, the 
intracellular IL-6 trans-signalling and the classic signalling pathway 247,248. Ruxolitinib, is a 
potent and selective oral inhibitor of JAK1 and JAK2 inhibitor and has been approved for 
treating myelofibrosis and polycythemia vera 249. It blocks JAK activity by competing with ATP 
in the catalytic site of the JAK tyrosine kinases 250. Additionally, the activity of STAT3 was 
inhibited using the promising small-molecule inhibitor Napabucasin that is less toxic, highly 
effective in low molecular ranges, and orally bioavailable in vivo 185,251. The use of these 
inhibitors would suggest that CRC cells, whose CRT resistance mechanisms are particularly 
dependent on the activity of the gp130/JAK/STAT3 pathway, would respond with sensitization 
to CRT. Indeed, all three substances inhibited the activation of STAT3, which in turn leads to 
reduced transcriptional activity of STAT3 as well as a re-sensitization of CRT-resistant cells to 
5-FU based CRT. This is the case for both, by blocking STAT3 upstream events and direct 
STAT3 inhibition. Besides, the basal STAT3 amount was not affected by any treatment which 
ensures that only STAT3 activation is prevented by the inhibitors. Importantly, our negative 
control cell line LS411N was not influenced by treatment with these pharmacological inhibitors, 
underlining that they are not particularly dependent of neither the IL-6 induced gp130 
signalling, nor STAT3 signalling itself.  
In gastric cancer cells co-cultivated with CAF cells, Ham et al. showed that treatment with 
Tocilizumab with 5-FU resulted in a significant decrease of CAF-mediated chemotherapy 
resistance 252. Moreover, Tocilizumab has been tested to sensitize oral squamous cell 
carcinoma (OSCC) towards radiation, demonstrating that Tocilizumab decreases surviving 
fractions compared to the control and thus reduced radiation resistance in OSCC 253. 
Nevertheless, since monoclonal antibodies can be harmful due to adverse effects such as 
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immunosuppression, blocking anti-inflammatory activities of IL-6 in general and not specific in 
tumor cells, its clinical application should be considered more carefully 254,255. Ruxolitinib is 
under active clinical investigation for treatment of inflammatory-driven solid tumors 249,256. In 
metastatic triple-negative breast cancer, a non-randomized phase II study evaluated the 
efficacy of Ruxolitinib treatment in patients with pSTAT3-positive tumors 256. Disappointingly, 
no objective responses were observed, and the median PFS was only 1.2 months 256. 
Therefore, they analyzed patients’ biopsies regarding STAT3 signatures. They found, that 
Ruxolitinib treatment suppressed the JAK/STAT3 pathway in the tumor tissue 256. Stover et al. 
postulated that the limited anti-tumor activity either occur via incomplete JAK/STAT inhibition 
or acquired resistance mechanisms that developed after Ruxolitinib treatment 256. Moreover, 
the treatment of patients with relapsed/refractory metastatic CRC with Ruxolitinib combined 
with regorafenib was analyzed in a randomized, double-blind, phase two study 257. Again, the 
treatment with regorafenib and Ruxolitinib did not show an increase in PFS/OS compared to 
regorafenib combined with placebo treatment 257. Although our results showed that treatment 
of CRC with Tocilizumab and Ruxolitinib along with a 5-FU based CRT might have a beneficial 
effect on CRT resistance, their actual use for treating of CRC patients is rather questionable. 
Additionally, the lack of specificity and the potential side effects are also major disadvantages 
of indirect STAT3 inhibition 157. Nevertheless, their use allowed us to further investigate STAT3-
mediated resistance mechanisms in our cell culture model and to define the gp130/STAT3 
pathway as one of the major signalling pathways in mediating therapy resistance. 
To put the focus more on potential clinical treatment strategies, we decided to use the direct 
STAT3 inhibitor Napabucasin. Napabucasin has already been tested in a phase-III clinical trial 
for highly advanced, chemotherapy-refractory CRC 186 as well as in studies treating tumor cells 
from different cancer entities as well as cancer stem cells 185,258,259. Interestingly, our 
experiments resulted in a loss of cellular viability after treating STAT3-expressing cells with 
Napabucasin concentrations above 500 nM. This effect may indicate that due to the massive 
inhibition of STAT3, the cells are no longer viable. In our negative control cell line LS411N, 
which has been shown not to "rely" on the STAT3 pathway, the Napabucasin-mediated loss of 
viability was not observed. Furthermore, we demonstrated that Napabucasin reduced STAT3 
activation and thus the transcriptional activity as well as it rendered cells more sensitive to 
CRT. Our results are consistent with those of Zhang et al. They found that treatment with 
Napabucasin inhibited cell proliferation, cell motility, cell survival, as well as it sensitized 
prostate cancer cells to docetaxel 259. Since the exact mechanism of action of Napabucasin is 
not yet clear, we performed experiments to assess potential molecular off-site effects. Thus, 
we combined RNAi targeting STAT3 together with Napabucasin. As observed before, both 
approaches individually re-sensitize CRC cells to CRT and their combination did not have 
synergistic effects. Thus, the effect of Napabucasin can specifically be ascribed to inhibit the 
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STAT3 pathway. Of note, an advantage over RNAi mediated STAT3 KD is that the basal 
STAT3 level is not reduced after Napabucasin treatment. This ensures that only active STAT3 
is inhibited, but U-STAT3 is still present in the cellular system. Underlining again the hypothesis 
that the pSTAT3 mediated STAT3 pathway, and less the U-STAT3 mediated pathway, are the 
key to CRT resistance. We showed that Napabucasin prevented the activation of STAT3, but 
not through which mechanisms this inhibition occurs. Froeling et al. found that Napabucasin 
can bind to NAD(P)H Quinone Dehydrogenase 1 (NQO1) leading to the formation of reactive 
oxygen species (ROS) 260. ROS causes DNA damage and some other intracellular changes 
such as the reduction of active STAT3 260. We can neither confirm nor deny whether this 
mechanism of action also takes effect in our cells. Experiments would have to be performed 
to measure ROS production before and after Napabucasin treatment. In addition, we would 
have to test our cells for Napabucasin-induced DNA damage, like the upregulation of the stress 
response genes (ATF3 and ATF4), as well as other members of the AP1 transcription complex 
(FOS, JUN) and early response genes that are involved in cell cycle arrest in response to DNA 
damage (CDKN1A, BTG1, BTG2) 260.  
Summarized, our data suggest that there is a “tonic” or “chronic” activation of the IL-
6/gp130/STAT3 signalling axis in CRT-resistant CRC cells, which in turn mediates CRT 
resistance. However, we were not able to detect pSTAT3 in unstimulated cells using both, 
Western blot, and flow cytometry approaches (data not shown). In addition, we tested whether 
SW1463 cells secrete IL-6, which then activates the STAT3 signalling pathway via an autocrine 
loop. However, the use of an Enzyme-linked Immunosorbent Assay (ELISA) showed no IL-6 
secretion in cell culture supernatant collected at 0 h, 1 h, 3 h, 6 h, 24 h, 48 h and 72 h intervals 
(data not shown). Irradiation of the cells with 6 Gy and 15 Gy also did not result in increased 
IL-6 secretion (data not shown). This could be due to the assay itself, as the sensitivity may 
not have been sufficient, or the timing of the experiment may have been poor. These results 
indicated that this “tonic” STAT3 activation may be mediated by signaling events independent 
of gp130. What points against this suggestion is that the use of Tocilizumab sensitizes CRC 
cells to CRT. Since Tocilizumab prevents the binding of IL-6 to the gp130 receptor subunit 248, 
it can be assumed that constant low-level IL-6/gp130 signalling must exist in CRC cells. 
However, the question remains: Where does this “tonic” STAT3 activation come from? The 
term “tonic signalling” has already been known in the 1990s, describing a low-level, constitutive 
signalling in the basal state of B and T lymphocytes 261. Tonic signalling describes that even in 
the absence of robust and activating antigen triggers, low-level phosphorylation of signaling 
intermediates can be observed in resting lymphocytes 261. It is possible that the amount of 
pSTAT3 as well as IL-6, in our cells is below a certain detection limit. Zhu et al., found that 
CRC cell lines SW480 and HCT116 secreted IL-6 (SW480= approx. 63.2 pg/ml; HCT116= 
approx. 57.7 pg/ml) and that LPS stimulations increased IL-6 mRNA transcription as well as 
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an increase IL-6 secretion (SW480= approx. 247.4 pg/ml; HCT116= approx. 267.2 pg/ml) 262. 
Indicating, that CRC cells are capable of secreting IL-6 in general. 
Summarized, these effects occurred in the absence of an external pathway activation, 
suggesting that there is some kind of “tonic” or “chronic” IL-6/gp130/STAT3 signalling in our 
CRC cells. Nevertheless, we cannot resolve the discrepancy between undetectable STAT3 
activity and simultaneous STAT3-mediated CRT resistance. However, we showed really 
clearly that active STAT3 is critical for mediating CRT resistance in CRC cells. 
5.2 Targeting the gp130/STAT3 axis in vivo 
Altogether, our findings so far prompted us to test whether the inhibition of the gp130/STAT3 
signalling axis can suppress the growth of tumor transplants under CRT in vivo. Therefore, we 
choose the STAT3 inhibitor Napabucasin because treatment of CRC cells resulted in a re-
sensitization of the cells to CRT in vitro. In addition, Napabucasin is gaining increasing 
importance in clinical trials for CRC patients 186. The combination of Napabucasin and CRT 
significantly slows SW1463 xenograft growth compared with the DMSO, and CRT treated 
group and thus provides a significant advantage in time to tumor regrowth. Hence, we could 
recapitulate the previously generated results of Napabucasin treatment in vitro. Furthermore, 
we demonstrated that treatment with Napabucasin as a monotherapy did not affect tumor 
outgrowth, whereas the combination with RT or CRT prevented the tumor growth. In contrast, 
Zhang et al. demonstrated that treatment with Napabucasin alone suppressed tumor growth 
in a prostate cancer mouse xenograft model 259. Based on our results, we hypothesized that 
Napabucasin may act as a RT/CRT sensitizer in CRC cells. This hypothesis is supported by 
the observation of Nagaraju et al, who showed that Napabucasin serves as a CRT sensitizer 
in HCT116 colon cancer cells, both in vitro and in vivo 163. What distinguishes our two studies 
is that Nagaraju et al. used MSI cell lines 163 representing only 13%-15% of the total sporadic 
CRC tumors 40, whereas we used MSS cells, that represent the majority of sporadic tumors 23. 
Additionally, we assessed full tumor regrowth (defined as tripling in tumor size) to measure 
treatment response, which more closely mirrors the clinical situation as well as the procedure 
for clinical studies 71.  
Currently, there are several in vivo models available to study CRC. Besides "classical" 
methods like AOM-based models and genetically engineered models, there are applications 
for xenotransplant models and models in which organoids are transplanted into mice 45. The 
choice of the appropriate mouse model should be made concerning the intended research 
question. Our aim was to investigate the tumor intrinsic effect of Napabucasin along with CRT 
in an immunosuppressed background. However, we used an established mouse model, which 
is defined as the standard in the field for preclinical xenograft studies investigating inhibitor 
effects following CRT 263. This mouse model has the advantages that it mirrors the clinical 
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setting of fractionated doses of both irradiation and chemotherapy 147. Noteworthy, for studying 
tumor-extrinsic factors and the impact of the TME on CRT resistance, other approaches would 
be to use available techniques like patient-derived xenograft (PDX), tumor organoids or co-
cultures of tumor cells with TME associated cells 45,249. 
5.3 The STAT3-NOTCH alliance mediating CRT resistance 
5.3.1 The STAT3 target gene RBPJ as a new radiosensitizer of CRC cells 
The mechanism by which STAT3 mediates CRT resistance is not yet clear. Since STAT3 
is a transcription factor, the effect is probably mediated by one or more of its target genes. 
Therefore, I analyzed the global consequences of STAT3 pathway perturbations on the 
transcriptome of CRT-resistant SW837 cells. A total number of 71 genes was dually influenced 
by STAT3 expression and cellular stimulation with Hy-IL-6. According to the self- defined ODA 
criteria, I identified 55 genes that were upregulated after pathway stimulation, and 
simultaneously but inversely, downregulated after STAT3 inhibition, and vice versa 71. These 
genes are involved in many signalling pathways and regulatory processes, that have been 
partially linked to CRC and therapy resistance before (for details see section 4.3.1 and Figure 
4.19). In this discussion, however, I will not go further into detail regarding the other 54 target 
genes. The ODA uncovered the key transcriptional regulator of the canonical NOTCH pathway, 
RBPJ 206,207. Closer examination showed that the RBPJ promoter comprised a STAT3 GAS 
binding site. This suggests that STAT3 can directly regulate RBPJ transcription. Using EMSA, 
the binding of STAT3 to the GAS sequence of the RBPJ promoter was detected after Hy-IL-6 
stimulation. As positive control for GAS-binding, lysates of IFN-γ- stimulated HeLa cells were 
used. Note, HeLa cells co-express STAT1 and STAT3, which possess distinct electrophoretic 
mobility, and hence, can distinguish between both STAT proteins when simultaneously 
detected by EMSA 71. Therefore, the slower and faster migrated band represents STAT3 and 
STAT1, respectively 218. Moreover, RNAi-mediated silencing of RBPJ led to a pronounced re-
sensitization of CRC cells to RT, which thereby identifies RBPJ as a new resistance-mediating 
STAT3 target gene in CRC. 
5.3.2 NOTCH expression profile correlates with STAT3 activity  
Since RBPJ is the main transcription factor of the NOTCH signalling 206,207, it is obvious that 
I subsequently focused on the NOTCH signalling in CRC cells and the possible influence of 
this signalling axis on CRT resistance. The NOTCH signalling has been known for decades 
and was originally found during cell fate determination from Drosophila to humans 219-223. 
NOTCH signalling is a conserved ligand-receptor signalling pathway, which can regulate cell 
differentiation, proliferation, survival, apoptosis, stem cell maintenance as well as the self-
renewal of progenitor and stem cells in both adult and embryonic organs 224,225. Dysregulated 
activation of NOTCH signalling in human cancers was first implicated through studies in T cell 
acute lymphoblastic leukemia (T-All) that uncovered a constitutively active form of NOTCH1 
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which was detected in more than 50% of patients with T-ALL 264,265. In recent decades, more 
evidence has accumulated on the oncogenic activity of NOTCH signalling in a broad spectrum 
of human cancers, including breast, lung, pancreatic, prostate cancer, glioblastoma, as well as 
CRC 225. However, due to its pleiotropic functions, NOTCH signalling was shown to influence 
both, promoting or suppressing tumor development, dependent on the cellular context 207,266-
269. At present, four NOTCH receptors (NOTCH 1-4) have been identified in humans 224 that 
derived from proteolytic processing of large single-chain precursors by a furin-like protease in 
the trans-Golgi network (Fig. 5.1, left) 220,224,226. The canonical NOTCH signalling is activated 
after ligation of NOTCH receptors and ligands (DLL1, DLL3, DLL4, JAG1 and JAG2) (Figure 
5.1) 220,223,224,226,227 followed by two strictly controlled proteolytic cleavage steps that are 
necessary to fully activate the NOTCH pathway. The first cleavage step is mediated by 
ADAM/TACE metalloproteases, which initiates the second cleavage by the γ-secretase 
complex 206,207,225. This series of cleavages release the active form NICD, which translocate 
into the nucleus where it assembles with RBPJ to drive the expression of NOTCH target genes 
(Figure 5.1, right) 206,207. 
NOTCH signalling components have been shown to be expressed in the normal 
gastrointestinal tract where they play a critical role in the maintenance of the intestinal epithelia 
270,271. In the human colon, NOTCH1,2 and 3 are expressed at the basal crypt, while JAG1 is 
present at the top of the crypts 272. Moreover, NOTCH1,2,3, and the NOTCH target gene HES1 
are expressed in the gastric mucosa 272.The expression of NOTCH ligands, receptors and 
downstream genes has been studied in CRC tissue samples. A study discovered that levels 
of JAG, NOTCH1 and HES1 are comparable to or partially greater than those found in 
proliferative intestinal crypts, indicating that the NOTCH pathway is activated in colorectal 
adenocarcinomas 273,274. Moreover, numerous gain gain-of-function mutations in NOTCH1 and 
NOTCH2 were found in solid cancers and B/T cell lymphomas, which allow for constitutive 
proteolytic NICD cleavage or increased stability of NICD, increase the expression of NOTCH 
target genes 275. In accordance with this, I observed constitutive NOTCH activity in 
unstimulated CRC cells. Robust expression of NICD was found in CRT-resistant SW837 and 
SW1463 cells that was almost absent in CRT-sensitive LS411N cells. The presence of NICD 
directly correlated with STAT3 transcriptional activity. In accordance, the expression of HES1 
was weak in LS411N cells but easily detected in SW837 and SW1463 cells. The signal 
intensities of HES1 expression are proportional to the NICD positivity and CRT sensitivity of 
these cells. Additionally, CRC cells were tested positive for three NOTCH receptors (NOTCH 
1,2,3), patterns of NOTCH ligands (Jagged 1/2 and DELTA-like) and NOTCH cleaving 
components (ADAM proteases or γ-secretases complex subunits: presenilin 1, presenilin 2, 
Nicastrin, PEN2. However, a combination of elements capable of NOTCH processing was 
found only in CRT-resistant SW837 and SW1463 cells, but not in LS411N cells 71. This 
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uncovered a cell-intrinsic tonic NOTCH signalling activity that is moreover relevant for CRT-
resistant CRC cells than for CRT-sensitive cells.  
Figure 5. 1 The NOTCH signalling pathway 
Mature NOTCH receptors are heterodimeric proteins consisting of a transmembrane subunit (NTM) and 
an extracellular subunit (NEC) derived from proteolytic processing of large single-chain precursors by a 
furin-like protease in the trans-Golgi network 220,224,226. Following ligation of NOTCH receptors on the cell 
surface by DELTA/Jagged ligands, NICD becomes proteolytically cleaved. The first cleavage step is 
mediated by ADAM/TACE metalloproteases, that cleave the receptor at S2, which initiates a S3 
cleavage mediated by the γ-secretase complex 71,206,207,225. NICD translocate in the nucleus where it 
assembles with the transcription factor RBPJ to drive NOTCH target genes expression 206,207. 
 
Stimulation of CRC cells with Hy-IL-6 showed a clear upregulation of NICD in CRT resistant 
cell lines, while the sensitive cell line showed a downregulation of NICD. RBPJ, on the other 
hand, was expressed in a higher amount by all three cell lines after Hy-IL-6 stimulation. In the 
SW837 cells, it is also striking that Hy-IL-6 stimulation increased the expression of the 
receptors NOTCH2 and 3, which was not the case in the other two cell lines. I have already 
observed that STAT3 is activated by stimulation with Hy-IL-6 and that CRC cells become more 
resistant to CRT treatment through STAT3 pathway stimulation. Using genome wide studies, 
I have identified RBPJ as a STAT3 target, which found to be a direct STAT3 target using 
EMSA. Here I was able to show that the RBPJ protein is increasingly expressed in CRT-
resistant CRC cells after Hy-IL-6 stimulation. Irradiation gradient experiments uncovered that 
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NICD, RBPJ and NOTCH2 were upregulated in irradiated cells with an increase of irradiation 
dose compared to non-irradiated CRC cells. Thus, upregulation was observed only in CRT-
resistant CRC cells, whereas protein levels of all tested proteins decreased in the CRT-
sensitive cell line LS411N. This observation indicates that the irradiation of already CRT-
resistant rectal cancer cells even further promotes their radio resistance by inducing the 
generation of NICD and RBPJ. In Accordance with this, Zhang et al., demonstrated an 
upregulation of NOTCH1 and HES1 after irradiation of HT-29 and LoVo cells 235. Furthermore, 
it was demonstrated that radiation therapy promotes inflammatory responses in the tumor 
tissues, and the upregulation of cytokines such as IL-6 is not only a crucial mediator of 
inflammation but also conferred a survival advantage to tumor cells 253,276.  
RBPJ inhibition re-sensitized CRT-resistant cells to CRT. However, the combination of 
RBPJ KD and STAT3 KD did not lead to a synergistic effect on CRT resistance. This could be 
due to the fact that the cells may already be at their maximum sensitization threshold and 
further inhibition would only lead to cell death. Moreover, RBPJ silencing phenocopied STAT3 
silencing as targeting RBPJ alone was as effective as inhibition of STAT3 itself, indicating that 
RBPJ, similar to STAT3, is a key determinant of CRT resistance. 
5.3.3 RBPJ-dependent NOTCH signalling in mediating CRT resistance 
In addition to NOTCH- mediated carcinogenic effects, it was reported that NOTCH signalling 
mediated radio resistance and chemoresistance of several tumors, such as gastric carcinoma 
and esophageal adenocarcinoma 208,277. The inhibition of the NOTCH pathway has been linked 
to sensitize of glioblastoma or breast cancer cells to radiation 208. However, the NOTCH 
pathway has not yet been directly linked to CRT responsiveness in CRC. The canonical 
NOTCH pathway depends on two strictly controlled proteolytic cleavage steps, mediated by 
ADAM/TACE metalloproteases and the γ-secretase complex 206,207,225.This multitude of 
activation steps enables the inhibition of the NOTCH pathway at different points. I 
demonstrated that pharmacological inhibition of the γ-secretase complex as well as RNAi-
mediated KD of RBPJ resulted in the sensitization of CRC cells to 5-FU-based CRT. 
DAPT belongs to the class of nonspecific γ-secretase inhibitors (GSIs). The γ-secretase 
complex catalyzed the cleavage of various transmembrane proteins by untethering the 
cytoplasmic domain from the membrane. This allows the cytoplasmic domains to transduce 
signals to the nucleus 229,230. Originally, the γ-secretase was found to be the protease 
responsible for generating of Amyloid β (Aβ), and thus GSIs were initially developed for 
treatment of Alzheimer`s disease 278-281. Recently, a significant number of clinical trials have 
also been conducted in which GSI were used as anticancer agents 231. The use of these agents 
has shown therapeutic activity in numerous preclinical models, but with a few exceptions they 
have not yet produced satisfactory results in early clinical trials 231,275. The first trial of a γ-
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secretase inhibitor in CRC was conducted by Strosberg and colleagues. In this phase II clinical 
trial, the γ-secretase inhibitor RO4929097 displayed only little effect in patients with metastatic, 
refractory CRC 273.  
In the performed experiments, the expression of NICD was considered a marker for active 
NOTCH signalling. Interestingly, the reduction of NICD was more pronounced after DAPT 
treatment than after RBPJ KD. DAPT treatment completely inhibited canonical NOTCH 
signalling 231, but GSIs are not completely effective in blocking all tumor-related NOTCH 
functions 282. Indeed, besides the more common canonical NOTCH signalling that depends on 
the proteolytic cleavage steps as well as on binding to RBPJ, NOTCH can signal via a non-
canonical pathway that proceeds without RBPJ 283. For example, NOTCH4 canonical signalling 
is required for developing of mammary glands, but NOTCH4 non-canonical signalling is related 
to mammary tumorigenesis 283. Nevertheless, both approaches individually, as well as in 
combination re-sensitized CRT resistant cells to CRT without any synergistic effect. Leading 
to the suggestion that the RBPJ-dependent NOTCH signalling is important in mediating CRT 
resistance. Alternative RBPJ-independent mechanisms seemed to be not necessary for the 
maintenance of CRT resistance. Notably, the CRT- sensitive cell line LS411N, was not 
influenced by neither RBPJ KD nor DAPT treatment. This suggests that the NOTCH pathway, 
as well as the STAT3 pathway, may not be involved in CRT resistance in these cells. 
In addition to DAPT, other GSIs were tested for their potential effect in CRC cells. Meng 
and colleagues reported about a chemotherapy induced NOTCH1 upregulation in colon cancer 
cells, which could be reversed by adding a GSI (GSI34) to the cells. Additionally, 
downregulation of NOTCH1 resulted in enhanced chemo sensitization whereas an 
overexpression of NICD increased chemoresistance 284. Meng et al. hypothesized that colon 
cancer cells may upregulate NOTCH1 as a protective mechanism in response to 
chemotherapy 284. Recently, a novel ADAM17 inhibitor (ZLDI-8) was described, which 
sensitized CRC cells to 5-FU or irinotecan by inhibiting NOTCH and reversing EMT in vivo and 
in vitro 225,285. A disadvantage of GSIs is that they block the processing of more than 90 different 
substrates and are not strictly NOTCH-specific 275,286. This non-specific inhibition makes it 
impossible to discriminate between individual NOTCH receptors 287 in order to study their 
individual impact on CRT resistance. Furthermore, treating patients with GSI caused partially 
severe side effects like gastrointestinal toxicity including, diarrhea, vomiting, and nausea 275. 
Therefore, various research groups focused on direct inhibition of the NOTCH signalling by 
modulating the expression of single NOTCH components. The direct inhibition allowed specific 
members of the NOTCH pathway to be targeted, potentially minimizing side effects caused by 
global inhibition of the pathway 288. Liu et al., observed that the miR-195-5p mediated inhibition 
of NOTCH1 promoted the chemotherapeutic effects of 5-FU by increasing apoptosis in CRC 
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cells 289. Additionally, inhibition of NOTCH2 and RBPJ via miR-195-5p inhibited CRC stemness 
and 5-FU resistance in human CRC tissue and CRC cells 290. RNAi mediated inhibition of 
NOTCH1 in regorafenib-resistant SW480 colon cancer cells partially restored sensitivity to 
regorafenib treatment in vitro 291. KD of JAG2 sensitized CRC cells to chemotherapy via 
downregulation of p21 292. There have also been attempts to target the NOTCH pathway 
downstream of the γ-secretase-mediated activation 275. Moellering et al., designed a peptide 
named SAHM1 (stabled α-helical peptide derived from MAML1) that mimic a dominant 
negative form of MAML1 by competitively binding to the NICD-RBPJ complex in T-ALL 286. 
However, the development of such agents as therapeutic drugs remains challenging due to 
manufacturing, stability, and other pharmacokinetic issues 275. As an important downstream 
target of the NOTCH signalling pathway, HES1 was shown to promote chemoresistance to 5-
FU in CRC in vitro and in vivo 293. Therefore, the clinical significance of chemo response of 
HES1 in stage II and II CRC patients was investigated using a tissue microarray293. Stage II 
CRC patients with higher HES1 expression showed a higher recurrence rate after 
chemotherapy 293. Additionally, colon cancer cell lines that overexpressed HES1 were more 
resistant to 5-FU treatment in vitro 293.  
To investigate the exact mechanisms of NOTCH-mediated CRT resistance, further 
experiments need to be conducted. Since there are different NOTCH receptors as well as 
ligands, a future question would be whether there is a specific receptor/ligand combination in 
CRC cells that mediates CRT resistance. This finding could allow for protein-specific inhibition 
of these proteins without disrupting the complete NOTCH signalling. 
5.4 What do our data implicate for future clinical strategies? 
In this work, I identified a novel crosstalk between IL-6/gp130/STAT3 signalling and the 
RBPJ/NOTCH pathway mediating the CRT resistance in CRC cells. Blocking the tumor cell-
intrinsic gp130/STAT3 axis or the RBPJ/NOTCH axis enhanced the responsiveness to CRT in 
CRC-resistant cells as well as in an in vivo xenograft mouse model. But how can these results 
now be integrated into a clinical treatment strategy for CRC patients? 
5.4.1 Potential use of pSTAT3 and NOTCH receptor expression as prognostic 
markers in rectal cancer patients 
Napabucasin has already been tested in a phase-III clinical trial for highly advanced, 
chemotherapy-refractory CRC. In this trial Jonker et al. demonstrated the first time that 
pSTAT3 is a poor prognostic factor in patients with metastatic CRC. 22% of the studied patients 
had pSTAT3 positive tumors, which were associated with a shortened OS 186. Additionally, 
patients with pSTAT3-positive disease treated with Napabucasin showed a longer OS than in 
the placebo group 186. In contrast, Napabucasin treatment of patients with pSTAT3 negative 
tumors resulted in negatively impaired OS compared to the placebo group 186 . Based on our 
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findings and keeping the clinical trial of Jonker et al., in mind, I propose a potential model for a 
personalized treatment strategy for CRC patients with pSTAT3-positive tumors (Figure 5.2 A). 
This treatment strategy includes screening of pre-therapeutic tumor biopsies for the presence 
of phosphorylated STAT3, followed by a combined treatment with CRT and Napabucasin in 
case of phospho-STAT3 positivity.  
Figure 5. 2 Proposed model for personalized treatment of CRC patients. 
A| Pre-therapeutic biopsies of CRC patients were tested for phosphor-STAT3 using 
immunohistochemistry (IHC). Patients with pSTAT3 negative tumors will be treated with standard CRT, 
whereas patients with pSTAT3 positive tumors will be treated with standard CRT in combination with 
Napabucasin 71 . B| Based on (A), the phsopho-STAT3 status of the tumours could be determined and 
then a distinction made between NOTCH positive and NOTCH negative tumours. Based on this, 
phospho-STAT3 and NOTCH positive tumours could be treated with napabucasin + CRT, while only 
STAT3 positive tumours would be treated with standardised CRT. 
 
Considering the crosstalk of STAT3 and NOTCH signalling, the model in Figure 5.2 A could 
be further specified. Identical to Figure 5.2 A, pSTAT3-positive tumors must be identified. 
Furthermore, we can determine the NOTCH status of the tumors using markers such as 
NOTCH receptors (Figure 5.2 B). 
The common feature of all cancers associated with a dysregulated NOTCH activity is the 
overexpression of NOTCH receptors and their ligands. In the gastrointestinal tract, NOTCH 
signalling is critical in cell proliferation control and tumorigenesis 235. In pretherapeutic gene 
expression profiles obtained from 207 patients with locally advanced rectal cancer, I uncovered 
that high expression of NOTCH2, NOTCH3, and NOTCH4 is associated with impaired DFS, 
while there was no difference for NOTCH1. Indicating that rectal patients with lower NOTCH 
2,3 and 4 expression had a better outcome. For NOTCH ligands as well as other pathway 
components such as cleavage proteins, no expression advantage or disadvantage could be 
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found. Many studies exist that investigated NOTCH components as possible biomarkers for 
gastrointestinal cancers. Chu et al., showed that NOTCH1 expression was significantly higher 
in colorectal tumors than that of normal colorectal epithelial cells 294. Furthermore, the overall 
survival rate for patients with NOTCH1-positive tumors was significantly lower than for those 
with NOTCH1- negative tumors 294. Additionally, NOTCH3 was associated with poor clinical 
outcomes in multiple gastric datasets. Inhibiting NOTCH3 expression by RNAi sensitizes 
gastric cancer cells to cisplatin and 5-FU 295. It was shown that NOTCH1 and its target gene, 
HES1 are expressed more in advanced colon tumors than in low-grade tumors 284,296. All four 
NOTCH receptors were correlated to worsen OS for all gastric cancer patients 297. Additionally, 
overexpression of the NOTCH target gene HEY1 in malignant colorectal tissue from stage II 
and stage III CRC patients correlates with poor outcome 298. Considering all these results, it is 
initially surprising that no effect of NOTCH1 expression was detected in the rectal cancer 
samples I examined. However, precisely this finding reflects the heterogeneity of cancer in 
general and reinforces the current efforts to develop a therapy strategy that is individually 
adapted to each patient. 
Defining the pSTAT3 as well as the NOTCH status of the tumors can ensure that only 
patients in whom both signalling pathways are active are treated with Napabucasin (Figure 
5.2 B). Nevertheless, further studies of Napabucasin in combination with CRT must be made 
proofing that our suggested concept could be adapted into clinical treatment settings. 
Currently, a phase 3 trial including patients with previously treated metastatic CRC treated with 
Napabucasin in combination with FOLFIRI (5-FU, Leucovorin and Irinotecan) is ongoing 
(NCT02753127 299). This study hopefully gives new insights regarding the clinical importance 
of Napabucasin in the treatment of CRC. In addition, it would have to be investigated whether 
pSTAT3-positive tumors, which are NOTCH negative, would also respond to treatment with 
Napabucasin. This would require preliminary experiments with cell lines that are active in 
pSTAT3 but lack NOTCH activity. Another consideration would be the use of Napabucasin 
together with a NOTCH inhibitor. However, I showed that inhibition of both STAT3 and NOTCH 
resulted in no synergistic effect regarding the CRT re-sensitization. In addition, there is still no 
applicable NOTCH inhibitor that has been able to show success in clinical trials. However, the 
overall results provide a basis for future experiments addressing the issue of CRT resistance 
in CRC cells, which may contribute to an optimized treatment of CRC patients. 
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6. Conclusion  
In this project, I studied the role of STAT3 in the context of CRT resistance in CRC. Here, I 
identified IL-6/gp130/STAT3 signalling crosstalk’s with RBPJ/NOTCH pathway as a CRT 
resistance mechanism in CRC cells. Blocking the tumor cell-intrinsic gp130/STAT3 axis or the 
RBPJ/NOTCH axis enhanced the responsiveness to CRT in CRC-resistant cells (Figure 6.1). 
Furthermore, I showed that STAT3 executed treatment resistance by triggering the expression 
of RBPJ (Figure 6.1). Moreover, genetic profiling of rectal cancer patients revealed the 
importance of the NOTCH receptor expression because it correlated with clinical outcome.  
Treatment resistance is associated with many complicated processes, including aberrant 
activation of multiple signalling pathways. Therefore, it is implausible that only one signalling 
pathway is responsible for controlling treatment resistance. It is more likely to be a network of 
many different factors and signalling pathways that are regulated by tumor intrinsic 
mechanisms (like interaction with other tumor cells) as well as by tumor extrinsic mechanisms 
(such as the interaction with the TME). There are studies describing the crosstalk of NOTCH 
and STAT3 in gastrointestinal cancer, but not in the context of tumor-intrinsic CRT resistance 
development in CRC cells. Both the NOTCH and the JAK/STAT3 pathway exhibit pleiotropic 
effects on many common processes regulating cell fate 228. In neuroepithelia cells the 
suppression of HES1 reduced the induction of STAT3 phosphorylation 228. In gastric cancer 
patients, NOTCH1 and JAG1 expression was significantly associated with pSTAT3 300. In 
addition, another group proved that the expression of HES1 correlates with the expression of 
Matrix Metallopeptidase 14 (MMP14) 301. Furthermore, they showed that STAT3 
overexpression increased expression of MMP14. HES1 depletion decreased STAT3 
phosphorylation but did not change the basal expression level of STAT3 in Caco2 and SW480 
cells 301. Ectopic overexpression of HES1 increased MMP14 expression as well as STAT3 
phosphorylation in HCT116 cells 301. This result led to the suggestion that up-regulation of 
MMP14 by HES1 in colon cells depends on the STAT3 pathway and regulates the invasion 
ability 301. Inhibiting the endogenous NOTCH pathway by GSI inhibitor DAPT reduced the IL-6 
expression 302. Simultaneous inhibition of the STAT3 and NOTCH pathway greatly inhibited 
the malignant behavior of gastric cells and significantly restored sensitivity of the resistant cells 
to trastuzumab 302. These findings suggested that sustained activation of JAG1/NOTCH 
signalling in gastric cancer cells elicits an aberrant release of IL-6, leading to resistance to 
trastuzumab 302.  
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Figure 6. 1 Crosstalk between the gp130/JAK/STAT3 signalling and the RBPJ/NOTCH pathway 
in mediating CRT resistance in CRC cells. 
Schematic overview of inflammatory gp130/STAT3 signalling and the RBPJ/NOTCH axis as well as the 
identified crosstalk between both pathways 71. Pharmaceutical inhibitors used in this study are depicted 
in red. Hyper-IL-6 represents a chimeric fusion protein encompassing IL-6 and the soluble IL-6 receptor 
chain and therefore mimics IL-6 trans-signalling 182. Both signalling pathways act together to block the 
responsiveness to CRT in CRC cells. In response to stimuli, cytokine receptors of the gp130 family 
activate Janus tyrosine kinases (JAKs) that in turn activate STAT3 via tyrosine phosphorylate. Activated 
STAT3 dimerizes and translocate into the nucleus to regulate expression of its target genes 119,127,135,149-
151, including RBPJ. Following ligation of NOTCH receptors on the cell surface by DLL4/JAG ligands, 
NICD becomes proteolytically cleaved by ADAM family members translocate in the nucleus where it 
assembles with the transcription factor RBPJ to drive NOTCH target genes expression 206,207.  
In this work, only tumor cell-intrinsic resistance mechanisms were investigated. However, 
as repeatedly emphasized, tumor extrinsic factors are also of crucial importance in the 
mediation of CRT resistance. Extrinsic NOTCH activity for example of tumor surrounding cells, 
showed high importance in CRC. Activated NOTCH1 signalling was observed in CRC and 
other cancers. This activation could either occur via NOTCH1 ligands on the surface of tumor 
cells (tumor intrinsic mechanisms) or by NOTCH ligands and components of the TME (tumor 
extrinsic mechanisms) 303,304. It was nicely shown that the activation of NOTCH1 signalling in 
the murine intestinal epithelium led to highly penetrant metastasis in CRC 303. Interaction 
between a tumor and its microenvironment is important for tumor initiation and progression. 
Moreover, extrinsic factors released by TME associated cells can promote treatment 
resistance. In colorectal tumors, it was shown that myofibroblasts secreted IL-6 and IL-8 have 
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a critical role in the maintenance and spread of CSCs via the NOTCH/HES1 and STAT3 
signalling pathway 305. These data suggest IL6/IL8 mediated NOTCH/HES1 signalling pathway 
as a potential target in drug development 305. 
In summary, blocking the tumor cell-intrinsic gp130/NOTCH signalling axis could improve 
responsiveness to CRT. Overall, the discovery of a gp130/NOTCH alliance as the basis of 
CRT resistance offers a novel treatment concept for patients with rectal cancer. Appropriate 
clinical trials are needed to validate the suitability of our concepts to reverse CRT resistance 
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KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog 
LIF Leukemia inhibitory factor 
Linker Linker domain 
MAPK Mitogen-activated protein kinases 
MDSC Myeloid derived suppressor cell 
MgCl Magnesium chloride 
MM Multiple melanoma 
MMP-1,2 Matrix Metallopeptidase 1,2 
MMP14 Matrix Metallopeptidase 14 
MMR Mismatch repair 
mRNA Messenger ribonuclein acid 
MSI Microsatellite instability 
MSS Microsatellite stable 
MUC1 Mucin 1 
n.a. not applicable 
Na3VO4 Sodium orthovanadate 
NaCl Sodium chloride 
NAMPT Nicotinamide Phosphoribosyltransferase 
NaOH Sodium Hydroxide 
Napa Napabucasin 
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NEC Extracellular subunit 
NES Normalized Enrichment Score 
NF-κB Nuclear factor-κB  
NICD NOTCH intracellular domain 
NIG NGS-Integrative Genomics Core Unit 
NMRI Naval Medical Research Institute 
NP-40 Nonident P-40 
NQO1 NAD(P)H Quinone Dehydrogenase 1 
NTD Amino-terminal domain 
NTM Transmembrane subunit 
ODA Opposite Direction Analysis 
OS Overall survival 
OS Overall survival 
OSCC Oral squamous cell carcinoma 
OSM Oncostatin 
p35 Tumor protein p35 
P53 Tumor protein 53 
PBS Phosphate-buffered saline 
PCA Principle Component Analysis 
pCR Pathological complete response 
PCR Polymerase chain reaction 
PDGF Platelet derived growth factor 
PDX Patient-derived xenograft 
PE Plating efficiency 
PEN2 Presenilin enhancer 2 
PFS Progression free survival 
PIAS Protein inhibitors of activated STATs 
PLB Passive lysis buffer 
p-STAT Phosphorylated STAT protein 
pSTAT3 phosphorylated STAT3 
PVDF Polyvinylidene fluoride 
qPCR Quantitative polymerase chain reaction 
RBPJ Recombination Signal Binding Protein for Immunoglobulin k J-region 
RIPA Radioimmunoprecipitation assay 
RNA Ribonuclein acid 
RNAi RNA-Interference 
RNase Ribonuclease 
RNA-Seq RNA Sequencing 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
RT Radiotherapy 
Ruxo Ruxolitinib 
S100A9 S100 calcium-binding protein A9 
SCNA Somatic copy number alterations 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SERPINB3 Serpin Family B Member 3 
SERPINB4 Serpin Family B Member 4 
SF Surviving fraction 
SH2 Src-homology 
sIL-6R Soluble IL-6 receptor 
SMAD4 SMAD family member 4 
SOCS Suppressor of cytokine signalling 
STAT Signal transducer and activator of transcription 
STR Short tandem repeat 
TAD Transactivation domain 
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T-All T cell acute lymphoblastic leukemia 
TAM Tumor-associated macrophages 
TBS(T) Tris buffered saline (supplemented with Tween-20) 
TEMED Tetramethylethylenediamine 
TF Transcription factor 
TGFβ Transforming growth factor-beta 
TME Tumor microenvironment 
TNE Tumor-node-metastatic 
Toci Tocilizumab 
TRIB2 Tribbles pseudokinases 2 
TS Thymidylate synthase 
TYK2 Non-receptor tyrosine-protein kinase 2 
UICC Union Internationale Conte le Cancer 
U-STAT3 unphosphorylated STAT3 
WT Wild-type 
Units   
% Percent 









rpm Rounds per minute 
RT Room temperature 
sec Second 
x g Times gravity 
Amino Acid  Three letter code One letter code 
Alanine  A Ala 
Arginine  R Arg 
Asparagine  N Asn 
Aspartic acid  D Asp 
Cysteine  C Cys 
Glutamic acid  E Glu 
Glutamine  Q Gln 
Glycine  G Gly 
Histidine  H His 
Isoleucine  I Ile 
Leucine  L Leu 
Lysine  K Lys 
Methionine  M Met 
Phenylalanine  F Phe 
Proline  P Pro 
Serine  S Ser 
Threonine  T Thr 
Tryptophan  W Trp 
Tyrosine  Y Tyr 
Valine  V Val 
Alanine  A Ala 
 




Figure 8. 1 siRNA time series to establish the optimal knockdown time point. 
A| SW837 cells were treated with RNAi targeting STAT3, RBPJ, NAMPT and MUC1 or corresponding 
control siRNA (siCtrl.) for 24,48,72 and 96 h. expression of the B| SW1463 cells were treated with RNAi 
targeting STAT3 and RBPJ or corresponding control siRNA (siCtrl.) for 24, 48 ,72 and 96 h, respectively. 
C| SW1463 cells were treated with RNAi targeting RBPJ or corresponding control siRNA (siCtrl.) for 24, 
48 ,72 and 96 h. A-C| The expression of the respective proteins was analyzed by immunoblotting using 
the indicated antibodies. Note that for immunoblot analysis after RNAi against STAT3 the cells are 
stimulated with rhIL-6 bevor lysis (Tab. 35). 
Figure 8. 2 siRNA time series to establish the optimal knockdown time point for BCL6. 
SW837 cells were treated with RNAi targeting BCL6 or corresponding control siRNA (siCtrl.) for 24,48,72 
and 96 h, respectively. The mRNA expression of BCL6 was analyzed by qRT-PCR using BCL6 specific 
primes. The BCL6 expression in the control approach was set to 1. The optimal knockdown is defined 
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Figure 8. 3 Influence of RNAi induced STAT3 depletion on the cellular viability of CRC cells. 
A-C| To test if the depletion of STAT3 using RNAi reduce cellular viability LS411N 8(A), SW837 (B) and 
SW1463 (C) cells were treated with RNAi targeting STAT3, the corresponding negative control (siCtrl.) 
or the assay intern controls (PLK and Mega) for 24,48,72 and 96 h, respectively. The cellular viability 
was measure using a cell titer blue assay and the data are presented as mean ± s.e.m. from at least 
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Figure 8. 4 Influence of Tocilizumab and DAPT treatment on the cellular viability of CRC cells. 
A| and B| LS411N, SW837 and SW1463 cells were treated with different Tocilizumab (A) or DAPT (B) 
concentrations for 24,48 and 72 h, respectively. The cellular viability was measure using a cell titer blue 
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Figure 8. 5 Treatment of CRC cells with Napabucasin, Ruxolitinib and DAPT. 
A| pSTAT3Y705 expression levels were measured using Western Blot after treating the SW837 and 
SW1463 cells for 8 h or 16 h with Napa concentrations ranging from 0 to 1000 nM. B| To further evaluate 
the most effective Ruxo concentrations SW837 and SW1463 cells were incubate for 3 h or 6 h with 
indicated Ruxo concentrations or were left untreated. Proteins were isolated analysed regarding 
pSTAT3Y705 and STAT3 expression. C| To test if treatment with DAPT reduce NICD protein levels 
LS411N, SW837 and SW1463 cells, they were incubated with different DAPT concentrations ranging 
from 0 to 5000 nM for 24,48 and 72 h.   
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